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Summary
The release-controlling action of hydrophilic matrix tablets based on 
heterodisperse polysaccharides (HP) was investigated in relation to the initial physical 
characteristics of the tablets. Mercury intrusion porosimetry, surface area analysis by 
nitrogen adsorption, scanning electron microscopy and liquid penetration studies were 
used to characterise physical characteristics. Mercury porosimetry was selected as the 
primary source of physical data since reproducible and representative quantitative data 
were obtained.
HP-based granules were prepared and subsequently compacted into tablets under 
carefully controlled conditions. Quantification of porous structure showed that the 
tablets had different pore volumes and pore size distributions. The release of a highly 
water-soluble model drug from HP-based matrix tablets was found to be independent of 
initial dry matrix structure. A second model drug, having low water-solubility, was 
found to be released from HP-based tablets at a rate that was independent of the shape of 
the tablet and the force at which the tablet was compacted.
A theory of porosity-independent release was postulated and tested. The 
implications of this hypothesis are potentially far-reaching in relation to clinically and/or 
pharmaceutically equivalent controlled drug delivery systems. HP-based formulations 
were contained within hard gelatin capsules in the form of loose, uncompacted granules. 
This gave a very porous matrix system. The in vitro release profiles of slightly water- 
soluble and freely water-soluble model drugs from matrix capsules were similar to the 
release profiles obtained when the same materials were compacted into matrix tablets. 
Since capsule and tablet matrices had equivalent release profiles they were considered 
functionally interchangeable under the in vitro testing conditions employed. The dosage 
forms were also pharmaceutically equivalent since they contained the same formulation, 
processed in the same way. Such flexibility in oral controlled release systems has not 
been hither to described.
A gamma scintigraphy on pharmaceutically equivalent tablet and capsule 
matrices showed that capsule matrices fragmented earlier than tablets matrices but that 
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1. Introduction
1.1 Concepts of controlled release, hydrophilic matrices, functional 
interchangeability and pharmaceutical equivalence.
The majority of pharmaceutically active therapeutic agents are administered as 
solid oral dosage forms produced by the formulation and processing of powdered solids
(1). For some drugs, delivery as an oral controlled release dosage form can provide 
greater safety and efficacy in therapeutics than conventional dosage forms. The purpose 
of controlled release systems is to optimise drug input rate into the systemic circulation 
in order to achieve a desirable and predictable pharmacodynamic response as well as to 
improve patient compliance, minimise side effects and maximise drug product efficacy. 
Controlled release dosage forms can have pharmacoeconomic value since they often lead 
to greater clinical effectiveness, fewer adverse side effects requiring treatment and 
economic benefits where increased patient compliance is associated with increased cure 
rates, reduced length of treatment and lower medical care costs (2). The majority of 
controlled release preparations are designed for prolonged release with prolonged 
therapeutic effect making them suitable for chronic administration.
The hydrophilic matrix (HM) is a popular and widely used strategy for achieving 
controlled release drug delivery. HM’s can be easily prepared by distributing a drug 
through a hydrophilic carrier, frequently a polysaccharide, and either compacting the 
material into tablets or containing it within a hard gelatin capsule. This principle has 
been successfully applied for several drugs as exemplified by the marketed controlled 
release tablets of felodipine (Plendil®, Astra), nifedipine (Nifelan®, Elan) and alprazolam 
(Xanax®XR, Pharmacia/Upjohn). Some of the perceived advantages of HM over 
alternative controlled release technologies, such as reservoir, hydrogel and osmotic 
systems, are listed in table 1.1 (3).
HM formulations are more commonly presented in tablet than capsule form. 
Controlled released capsule formulations are often complex and generally consist of the 
active ingredient formulated as multiple unit dosage forms contained within a hard 
gelatin capsule. The sub-units are usually based on microgranules, spheroids, beads or 
pellets and can be produced using a wide range of technologies. In a review of 
controlled release delivery of some water-soluble drugs, Khan (4) described some 
methods that have been used to formulate controlled release sub-units. This included 
spheroids produced by loading a drug onto a water-insoluble but swellable non-ionic 
polymer then coating with a slightly water permeable polymer; microgranules produced
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by granulating a drug with water-soluble polymers then coating the granules with wax 
like substances or with permeable hydrophobic polymers, and beads and pellets 
produced by attaching a drug to a solid inert carrier then coating with soluble film 
forming polymers such as polymethacrylates. Marketed controlled released capsule 
dosage forms based on multiple unit dosage forms contained within a hard gelatin 
capsule shell include Minocin MR® (minocycline HC1, Lederle) and Indomax 75 SR® 
(indomethacin, Ashbourne Pharmaceuticals Ltd.). Dilacor XR™, a proprietary 
formulation of diltiazem HC1, is more unusual in that it consists of 3 or 4 mini tablets 
contained within a capsule (5). Each tablet consists of three layers. The faster hydrating 
core layer contains 60mg of the active drug. Two external layers sandwiched around the 
core limit drug release from the lateral side of a cylindrical shaped tablet. The matrix is 
hydrophilic and releases through a swollen gel structure over 24hr (5).
In the U.K. it is common for drugs delivered as immediate release solid dosage 
forms to be formulated as capsule preparations at one drug strength and in tablet form at 
another drug strength. For example, the anti-depressant drug dothiepin, is marketed by 
Boots as Prothiaden® 25mg capsules and Prothiaden® 75mg tablets, while the anti- 
infammatory drug, mefenamic acid, is marketed by Parke-Davis as Ponstan® 250mg 
capsules and Ponstan® 500mg tablets. For controlled release products it is usual for any 
one company to manufacture a drug in either capsule or tablet form, but it is unusual for 
both controlled release tablets and capsules to be manufactured by the same company. 
This possibly reflects the high development and production costs involved in producing 
two controlled release dosage form technologies. However, for drugs that are no longer 
under patent protection, and have a high market share, it is common for one company to 
market the drug in capsule form and for another company to market the drug in tablet 
form. For example, the calcium-channel blocker diltiazem HC1 is marketed by Lorex 
Pharmaceuticals Ltd. as Tildiem Retard® 90mg and 120mg tablets and by Napp 
Laboratories Ltd. as Adizem-SR® 90mg, 120mg and 180mg capsules. Similarly, the 
coronary vasodilator, isosorbide dinitrate, is marketed by Zeneca Pharma as Sorbid SA® 
20mg capsules, and by Schwarz Pharma Ltd. as Isoket retard® 20mg tablets.
In the U.K, a pharmacist presented with a prescription for any generically written 
solid oral dosage form must dispense the dosage form presentation indicated on the 
prescription. This means that when a drug is prescribed the practitioner must specify 
whether a capsule or tablet dosage form presentation is required. Similarly, in the USA, 
a practitioner must specify the dosage form to be dispensed. However, in 1997 the 
standards division of the United States Pharmacoepia (USP) suggested that the concept
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of functional interchangablility of solid oral dosage forms should be adopted by the USP 
(174). The division of standards recommended that USP general notices and 
requirements include the following statement; ‘Unless otherwise stated in the individual 
monograph, tablets and capsules prepared with the same active substance and of the 
same release rate classification (e.g. prompt release) are considered to be functionally 
interchangeable’. This would mean that any specific official USP solid oral dosage form 
could be dispensed regardless of whether it was formulated as a tablet or a capsule. 
However, three criteria must be met:
(1) the articles contain the same active ingredients
(2) the articles contain the same amount of active ingredient
(3) the articles’ release characteristics are the same
The practical implication of functional interchangeability means that either a 
capsule or tablet form could be dispensed, depending on the patients needs and/or 
desires, as long as the two preparations contained the same drug in the same quantity and 
had equivalent release profiles. However, there would be no requirement for the tablets 
and capsules to contain the same excipients or for the formulations to be processed in the 
same way. Functional interchangeability could for example, exist between a hydrophilic 
matrix tablet and a capsule containing the drug formulated as controlled release pellets, 
even if the formulations contained different excipients and were processed in different 
ways.
A new direction in oral controlled release technology would be solid oral dosage 
forms that could be considered functionally interchangeable and yet remain 
pharmaceutically equivalent. This would mean that the articles would contain the same 
active ingredient, the same amount of active ingredient, have the same release 
characteristics and also contain the same excipients, processed in the same way. The 
potential advantage of such a system would be the possible reduction in research, 
development and manufacturing costs involved in producing two dosage form 
presentations of the same active ingredient since capsules and tablets would be 
composed of the same formulation, processed in the same way. The possibility of 
achieving functional interchangeability and pharmaceutical equivalence in oral 
controlled release tablets and capsules using heterodisperse polysaccharides has been 
investigated here.
13
Perceived advantages of hydrophilic matrices over other controlled 
release dosage systems
Simplicity of formulation
High drug loading: their capacity to incorporate active principles is
large, which makes them suitable for the delivery of large doses.
Economically efficient excipients
Wide range of carriers approved for oral use are available
Low capital equipment costs: the dosage forms may be manufactured
using standard powder processing and tabletting equipment
The possibility of dose ‘dumping’ is low
Bioerodable: HM systems erode as they pass down the GI tract avoiding 
the potential accumulation of ‘ghost’ dosage forms in the body.
The systems depend on both erosion and diffusion, and therefore drug 
release is not entirely dependent on GI motility
Versatility: systems formulations can be formulated as ‘mini-matrices’ 
or floating tablets
Table 1.1 Perceived advantages of HM over other controlled release dosage systems 
(3).
1.2 Hydration of and drug release from hydrophilic matrices
When a dry (or glassy) HM comes into contact with an aqueous medium, the 
solvent (usually water) penetrates the free spaces between the macromolecular chains. A 
relatively impermeable gelatinous surface barrier develops, which retards further ingress 
of water and acts as a rate-controlling barrier to drug release (6). As water penetrates 
into the dosage form the thickness of the gel-like layer increases and the outer layers 
become progressively more hydrated. Movement of drug from an erodible swollen HM 
into the surrounding medium occurs in two ways. Water-soluble drugs undergo 
dissolution as they are exposed to an aqueous solvent front and begin to diffuse through 
the tortuous network of the swollen gel (6). As the solvent front moves further into the 
matrix the distance that the dissolved molecules must travel to reach the solvent-matrix 
interface increases. In addition, the progressive swelling leads to an increase in the 
volume of the swollen network and therefore a further increase in the diffusional 
pathway. Release by diffusion shows time-dependent kinetics with a high rate of release
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observed at the beginning of the process, which decreases with time in an exponential 
way. Drug release can also occur via attrition of the outer surface of the swollen 
polymer (7). For poorly water-soluble drugs this is frequently the primary mechanism of 
release (6) although some degree of release by erosion will also exist for water-soluble 
drugs. The presence of a solvent front, the potential for unlimited swelling and the 
combined controlling mechanism of diffusion and erosion are the distinguishing features 
of HM’s. Such dosage forms differ from the swellable but effectively insoluble cross- 
linked polymers commonly known as hydrogels.
Studies using cryogenic SEM have provided evidence that the gel-like layer 
within hydrated hydroxypropylmethylcellulose (HPMC) matrices might not be 
homogenous and may have a complex internal microstructure (8). It has also been 
shown that gas bubbles form an important structural feature of the hydrated surface layer 
of HPMC matrices (9). Direct visual evidence suggests that air bubbles originate from 
void spaces within the core tablet (10). The internal structure of the hydrated layer 
formed by sodium alginate matrices in simulated gastric fluid has been shown to differ 
markedly from the structure formed in simulated intestinal fluid (11). It has been 
suggested that the structure of the gel-like layer of hydrated HM’s may be important in 
controlling drug release (10,11).
1.3 Kinetics of drug release from hydrophilic matrices
The overall rate of drug release rate from HM’s generally follows first-order 
kinetics, a potential drawback of matrix systems that have conventional geometry such as 
spheres, cylinders and slabs (12). However, zero-order release profiles have been 
achieved (13-15) and even bimodal release kinetics have been reported (16). The 
kinetics of drug release is thought to be determined by the relative movements of 
boundaries that exist within a hydrated matrix (17). Up to three boundaries have been 
defined in hydrating matrices. The boundary that separates the swollen matrix from the 
dissolution medium is commonly known as the erosion front, while the boundary that 
separates swollen polymer from dry (or glassy) polymer is known as the swelling front 
(17). Lee et al. (18) and Colombo et a l (17) have described the possibility of the 
presence of a third front; the boundary between undissolved and dissolved drug. This 
front has been termed the diffusion front and can occur under certain conditions of drug 
loading and drug solubility and will only be observed when it is not coincident with the 
swelling front. Movement of the swelling front, diffusion front and erosion fronts are
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thought to be associated with rate of water uptake, rate of dissolution and rate of matrix 
erosion, respectively (17). Colombo et al. (17) proposed that when a polymer is 
sufficiently soluble the erosion front can synchronise with the swelling front leading to 
zero-order release kinetics provided that the releasing area is constant. Drug release 
from such systems will be linear because the distance over which the drug molecules 
must diffuse to reach the tablet surface will remain roughly constant. Under certain 
conditions of drug solubility and loading the erosion and swelling fronts can move 
separately and the difference between the erosion and diffusion fronts is thought to be 
decisive for release kinetics (17). Zero-order dissolution profiles for water-soluble drugs 
are not generally obtained with gelling agents comprising non-ionic cellulose ethers 
alone. By mixing combinations of HPMC and the more water-soluble polymer, sodium 
carboxymethylcellulose, zero-order release kinetics have been achieved (13,14). This 
has been attributed to the rate of advancement of the swelling front being similar to the 
rate of erosion (19). However, after assaying tablet erosion Vazquez et al. (15) 
concluded that although erosion mechanism may contribute to the observed zero-order 
dissolution kinetics other factors are probably involved.
The apparent simplicity of the formulation and behaviour of HM devices belies 
the fact that the mechanism of drug release from matrices is probably a very complex 
phenomenon. Consequently, the process is difficult to model because so many different 
processes may be contributing. The mathematical analysis of release kinetics from HM’s 
is also complicated by the presence of a moving diffusional front and an eroding polymer 
front. The mathematical descriptions of such mass transfer problems involving moving 
boundaries are known as Stefan problems (20). Simple pseudo-steady state 
approximations have been used to analyse the kinetics of release of a dispersed solute 
from a polymer matrix, the most common one being Higuchi’s treatment for a non- 
erodible matrix under perfect sink conditions (21,22). This approach involves fitting 
cumulative release data to the square root of time, providing limited quantitative data. 
The pseudosteady state approach assumes a linear solute concentration profile, which is 
valid only when the solute loading is in excess of the solute solubility. However, in 
reality this is not always the case (20). Release data has also been analysed using the 
simple exponential equation developed by Ritger and Peppas (23), where the fraction 
released is proportional to tn, n being a diffusional coefficient indicative of the 
mechanism of drug release. Although the Higuchi and Ritger treatments are widely 
applied in the literature to swellable matrix systems they are only approximations to 
complex moving boundary problems.
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1.4 Hydrophilic m atrix carriers
Rapid hydration and swelling of individual polymer particles, and their 
coalescence to form a gel matrix is the key to the successful performance of a HM. An 
ideal HM carrier would also behave independently of pH and ionic strength, would be 
inexpensive, cost effective, regulatory authority-acceptable, inert, easily processed and 
versatile so that a wide range of release profiles could be obtained. At present, no HM 
carrier fulfils all of the foregoing desirable qualities. The most widely used and the most 
intensely studied HM carriers are the cellulose ethers, in particular 
hydroxypropylmethylcellulose (HPMC). Grades of hydroxypropylcellulose (HPC) and 
sodium carboxymethylcellulose (NaCMC) are actively promoted as HM carriers for 
controlled release tablet formulations by their manufacturers. The low cost of thermally 
modified starches has prompted renewed interest in their use as HM carriers (24). 
Sanchez et a l (25) reported the use of a thermally modified wheat starch by a 
gelatinisation/freeze-drying technique. Chitosan has been shown to act as an effective 
carrier in acid conditions. However, in water or simulated intestinal fluid, disintegration 
and rapid drug release occurs (26). The release controlling action of polyvinylalcohol 
has been investigated (17,27). Xanthan gum is a more recent HM carrier and its 
behaviour as a sustained release excipient has been investigated extensively by Talukdar 
et a l (28-30). Scleroglucan successfully forms HM tablets at physiological pH’s, and in 
many other aspects behaves as a nonionic polysaccharide carrier similar to the cellulose 
ethers (24). Te Wierik et al (31) have shown that amylodextrins possess the 
characteristics of a controlled release excipient. Carbopol is a cross-linked polymer of 
acrylic acid that has also been used as a HM carrier (32,33). Under acidic conditions the 
material is unionised however, as neutral pH’s the carboxylic acid groups ionise. This 
creates a low pH environment that has been used advantageously to control the release of 
a basic compound (33). A number of combinations of HM carriers have been studied in 
the literature. Combinations of HPMC/NaCMC have been used to optimise drug release 
profiles (14,19,34). A HM consisting of pectin and HPMC has been used to optimise the 
release of diltiazem HC1 from a simple tablet matrix (5). Combinations of locust bean 
gum and xanthan gum have been investigated (35) and the technological characteristics 
and release retarding action of xanthan gum and guar gum have also been considered 
(36). The wide range of materials that have been investigated as potential HM carriers 
reflects the extensive and continued interest in HM dosage forms.
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1.5 Structure and properties of heterodisperse polysaccharides
A controlled release tabletting excipient that utilises the synergistic interaction 
that occurs between the heteropolysaccharide, xanthan gum and the homopolysaccharide, 
locust bean gum in the presence of secondary and tertiary components has been 
developed by Penwest Pharmaceuticals Co., Patterson, NY, USA. The individual 
components are wet massed using a high shear mixer producing a heterodisperse (HP)- 
based material that is easily compacted into tablets (37). Some of the properties of this 
system (TIMERx™) have been described previously (38). A review of the 
characteristics of the individual components of the excipient and the possible nature of 
the synergistic interaction is given.
1.5.1 Xanthan gum: structure and properties
Xanthan gum (XG) is a water-soluble anionic polysaccharide produced on a 
commercial basis by viscous fermentation of the bacterium xanthomonas campestris 
(39). XG gained food approval in the United States in 1969 and is now widely used in 
the food industry because of its unique and useful properties (40). It also finds many 
applications in the textile and cosmetic industry (40).
The primary structure of xanthan, shown in figure 1.1, is a (3 (1—»4)-linked D- 
glucose mainchain with a trisaccharide side-chain attached to the 3 position of every 
second glucose giving a pentasaccharide repeating unit. The trisaccharide side chain is 
made up of a p -(l—>4) linked D-mannose, an a-(l-»2) linked glucuronic acid and an a- 
D-mannose. The a  and P linked mannose units are variably acetylated and pyruvylated 
respectively (41).
At temperatures greater than 60°C and at low ionic strength xanthan chains exist 
in aqueous solution in an essentially disordered state resulting in a solution that has a low 
viscosity (39). Reduction in temperature and/or the addition of salt induces a sharp 
transition to an ordered structure that has been identified by x-ray fibre diffraction 
analysis as a 5-fold helix (42). The negatively charged side chains align with the 
backbone and the overall structure is stabilised with hydrogen bonds (39).
XG molecules have a high hydrodynamic volume and even at low concentrations, 
XG exhibits weak gel features that are of considerable technological value in, for 
example, the suspension of solid particles or the stabilisation of emulsions (39). At low 
concentrations, solutions of XG exhibit high viscosity’s compared to those of most other 
polymers (39). As the concentration of gum is increased, a peak viscosity is reached
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owing to the high affinity of XG for water. The peak occurs at a relatively low 
concentration owing to XG having a high affinity for water (39). At all concentrations, 
solutions of XG are viscoelastic: they always have a degree of mobility and when the 
two are brought together, they coalesce (39). At rest, the molecules associate into 
complex aggregates stabilised by hydrogen bonding imparting a high elastic modulus to 
the material. When shear is applied, the aggregates are disrupted with a resultant 
decrease in viscosity. The process is reversible and when the shear is removed the 
system returns to its originally high viscosity (41). The degree of pseudoplasticity of XG 
is higher than that of any other FDA-approved gums (39).
The viscosity of solutions of XG have been shown to be almost independent of 
pH changes (43). The behaviour of XG solutions in the presence of salts has been shown 
to be complex and appears to depend on the concentration of the gum. Zatz and Knapp 
(44) reported that a 0.3% solution of XG exhibited negligible viscosity change when 
either calcium chloride, sodium citrate or sodium chloride was added. Solutions 
containing higher concentrations of XG showed increased viscosity while solutions 
containing lower concentrations of XG underwent a reduction in viscosity. As the 
quantity of salt added to solutions containing high concentrations of XG was increased, a 
limiting viscosity was observed. Each of the salts appeared to be equally effective in 
changing the viscosity, suggesting that intermolecular charge repulsion was not a 
primary factor in these salt effects on viscosity. These results confirmed the finding of 
Rocks (43) who reported that solutions containing greater than 0.5% XG increased in 









Figure 1.1 Primary structure of xanthan gum
19
1.5.2 Locust bean gum: structure and properties
Locust bean gum (LBG) is a galactomannan obtained from the species ceratonia 
siliqua, also known as the carob plant (45). The gum portion of carob pods is the 
endosperm, which is contained within the seeds of the pod. Specks of brown that may be 
seen in the gum are remains of the dark brown rusk that surrounds the endosperm. 
Galactomannans are polysaccharides that consist of a (3-(l—»4)-D-mannan backbone 
incompletely and irregularly substituted with single a - ( l—»6)-linked D-galactose side 
chains, (figure 1.2), with the galactose substituents occurring in cluster (‘hairy regions’) 
interspersed with unsubstituted mannan backbone (‘smooth regions’) (46). Locust bean 
gum has a molecular weight of approximately 2.6 x 106 and a mannose to galactose ratio 
in the region of 3.5:1 (47).
Solutions of LBG show characteristics of hyperentangled macromolecules (48). 
In contrast to XG, LBG is only slowly soluble and ungelled at low temperatures. 
Prolonged exposure to the dissolution media allows molecules to associate and undergo 
gelation as the result of intermolecular cross-linking in ‘smooth’ regions of the chain. 
Most of the gum will disperse in concentrations up to 5% but part remains as insoluble 
floes that settle on standing (45). Dispersions that are first heated to approximately 95°C 
have a much higher viscosity than dispersions made in cold water so to obtain the 
greatest efficiency as a thickener dispersions are made in hot water and then cooled (45). 
LBG solutions are pseudoplastic (49) and since LBG is a neutral polysaccharide pH has 
little influence on the viscosity of solutions in the range pH 3 to 11 (49).
LBG is widely used in the food, textile and cosmetic industry. Its binding and 
stabilising properties are utilised in ice cream and sausage making, its heat-shock 
resistance is utilised in ice-cream making, while its thickening action is utilised in 
lotions, creams and print pastes (45).
HO
OH
Figure 1.2 Primary structure of locust bean gum (x and y = 3 or 4)
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1.5.3 Xanthan gum/locust bean gum synergism
When aqueous solutions of XG and LBG are mixed together, an interaction 
between the two polysaccharides occurs that results in the formation of a firm, 
thermoreversible gel with synergistic effects (47). Gels can be formed at room 
temperature using 0.2% total polysaccharide concentration (50). Solutions of mixed 
gums are associated with a high elastic modulus (50). The dynamic modulus of mixed 
gum systems is nearly independent of pH between pH values of 5 to 10 but decreases 
rapidly below 5 (40). Dynamic modulus is decreased in the presence of urea suggesting 
that hydrogen bonding is involved (40). Mixed systems are characterised by sharp 
setting and melting behaviour consistent with co-operative transitions and cross-linking 
by ordered non-covalent associations (51). The Theological behaviour of XG and all 
LBG/XG mixed systems is typical of weak gels (48). Various XG/LBG ratios have been 
suggested as optimal ratios. Copetti et al. (48) found that in mixed systems the 
maximum viscosity, and maximum elastic modulus occurred when the ratio of XG to 
LBG was 1:1, while Tako et al. (50) reported a maximum dynamic modulus at a 
XG:LBG ratio of 1:2. Mannion et al (35) found that when XG and LBG were mixed in 
various proportions there was no significant effect on the viscous component, but 
significant increases in the elastic component with maximum synergy occurring at a 
polymer ratio of 70% XG to 30% LBG. This indicated that mixing the two polymers 
resulted in significant increases in gel strength but not in viscosity. HM tablets produced 
from the gums were shown to provide significantly slower release of a poorly water- 
soluble drug than from XG alone, with the greatest prolongation of release occurring at 
the polymer ratio corresponding to the greatest Theological synergy.
The synergistic interaction between galactomannans and XG was first reported 
by Rocks in 1971 (43), since when a large number of techniques have been used by 
various researchers to try and determine the precise nature of this interaction. The ‘lock 
and key’ model first proposed by Rocks (43) and supported by Tako (52) suggested that 
interaction occurs with xanthan molecules in a 5-fold, single-stranded helical structure 
with the side chains inserted into adjacent unsubstituted segments of the LBG backbone. 
A second model, proposed by Dea et al (46), attributes the synergistic effect to an 
interaction between the xanthan helix and the unsubstituted or poorly substituted 
(‘smooth’) regions of the galactomannan. This was supported by the observation that the 
interaction between xanthan and galactomannans was heavily dependent on the amount 
and distribution of galactose. Cairns et al (53,54) suggested that it was necessary for 
xanthan to be denatured before gelling would occur and suggested a sandwich model for
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xanthan/galactomannan junction zones. In this model galactomannan chains are 
sandwiched between two xanthan chains the latter being in the disordered confirmation 
with the first xanthan chain running parallel to the second. Hydrogen bonding between 
OH-3 groups on the galactomannan and OH-4 of the inner mannose on the xanthan 
backbone and hydrophobic interactions at xanthan and locust bean contact points would 
stabilise the structure. From observations of mechanical spectra and Theological studies 
Copetti et al. (48) suggested the coexistence within the structure of mixed gels of both 
heterotypic LBG-XG and homotypic XG-XG junction zones, in which the xanthan 
chains retain their ordered helical conformation, thus supporting the original model 
described by Dea et al. (51) and Morris et al. (55). The exact mechanism of interaction 
between the two polysaccharides is still under debate but is important since the 
production of high gel strengths at low polymer concentrations has implications in the 
pharmaceutical, food and textile industries.
1.5.4 Secondary and tertiary components o f TIMERxN
A secondary component, glucose, is dispersed throughout the polysaccharide 
network and is thought to potentiate the solubilisation of the gums (38). A percentage of 
calcium sulphate is added, which is believed to enhance gel rigidity. The role of calcium 
ions in the gelation of a number of polysaccharides has been documented. Calcium ions 
have been shown to favour the gelling of carrageenan solutions (56). The elastic 
modulus of water-soluble polysaccharides extracted from proliferating marine green 
seaweeds (Ulva spp.) was found to increase in the presence of calcium ion and boric acid
(57). The addition of calcium chloride to matrices containing sodium alginate has been 
shown to prolong the release of chlorpheniramine maleate in simulated intestinal fluid
(58). This was thought to be due to the interaction that occurs between sodium alginate 
and calcium ions at neutral pH (58). Contradictory results were reported by Stockwell et 
al. (59) who found that an alginate gel system without calcium, in the presence of acid, 
formed a compact rigid gel with a low water content. In the presence of calcium ions, a 
more open gel structure with a higher water content was formed, which was attributed to 
the formation of cross-linkages in the gel. The rate of release of three water-soluble 
model drugs from sodium alginate matrices was greater in the presence of calcium. It 
was thought that this was due to the more open diffusional pathway in the cross-linked 
gel.
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Ethylcellulose is an inert, water insoluble, hydrophobic polymer. It has been 
used in conjunction with hydrophilic excipients to produce swellable matrix tablets (60). 
It is proposed that ethylcellulose can act as a binder and contribute to the structure of the 
hydrated layer.
1.6 Factors affecting drug release from hydrophilic matrix tablets
Factors affecting drug release from hydrophilic matrices have been the subject of 
many publications (eg 6). A complex situation exists in which the overall rate of release 
is dependent on many interacting factors operating in the system at any one time. As 
HPMC is extensively used as the base excipient for controlled release, most work in the 
area has been on this material. A review of the factors that have previously been 
investigated in relation to the release of solute from hydrophilic matrices is given.
1.6.1 Physical and chemical characteristics o f the polymer
1.6.1.1 Viscosity
The viscous properties of polymers in HM tablets have been shown to be 
important in determining the final release controlling action of the dosage form. Nakano 
et al. (61) found that the release of theophylline from hydroxypropylcellulose (HPC) 
matrices decreased as the viscosity grade of the HPC increased while Daly et al. (62) 
demonstrated the same effect for the release of chlorpheniramine from low viscosity 
grades of Methocel. Ford et al. (63) studied the release rates of aminophylline and 
propranolol hydrochloride from matrices containing HPMC K100, HPMC K4M, HPMC 
K15M and HMPC K100M (viscosity’s of 2% aqueous solutions were 106, 3850, 12449 
and 93000 cps, respectively). They found similar release rates from the K4M, K15M 
and K100M grades but under the same conditions K100, the lower viscosity grade gave 
consistently higher release rates. The idea of a ‘limiting HPMC viscosity’ was also 
proposed by Sung et al. (64) who, for the systems under consideration, found that drug 
release no longer decreased when the viscosity increased above 15000Pa. Interestingly, 




Three substitution types of HPMC (2906, 2910 and 2208) are described in the 
USP (65). Different proportions of hydrophobic methoxyl groups and of hydrophilic 
hydroxypropyl groups characterise the three polymer types. The three substitution types 
have been shown to control the release of water-soluble model drugs to the same degree 
(66,67). Differences in the release rate of a poorly water-soluble model from different 
polymer substituents have been observed (67). Drug release paralleled the erosion of 
polymer from matrix tablets but was not directly related to the Theological behaviour of 
the polymers. Dahl et al. (68) found that the dissolution of naproxen from different lots 
of HMPC 2208 was directly proportional to the hydroxypropyl content. The slower 
dissolution observed when tablets contained HPMC 2208 substituted with low quantities 
of hydroxypropyl groups was considered due to the greater hydrophobicity of the tablets.
1.6.1.3 Polymer concentration
It has been shown by a number of workers that as drug/polymer ratio is increased 
the rate of release of the drug decreases (6,25,63,69,70). This is likely to be due to an 
increased tortuosity in concentrated gel layers, which would increase diffusional path 
length and decrease release rates. It has also been proposed that increasing the total 
polymer content can influence the surface area of the matrix, which in turn controls the 
release rate (63). Mathematical relationships between polymer concentration and drug 
release have been proposed. Ford et al. (63) studied the rate of release of propranolol 
HC1 and aminophylline from HPMC matrices of various grades at various 
concentrations. They found a linear relationship between the rate of release, calculated 
as the slope of square root of time versus percentage released curve, and the reciprocal of 
the tablet content of HPMC. Using four soluble drugs, Baveja et al. (34) concluded that 
a linear relationship existed between the time taken to release 50% of drug from the 
matrix (tso%) and the ratio of total gum to drug in the tablet (G/D). The relationship held 
for both HPMC alone and matrices containing a combination of HPMC and NaCMC.
1.6.1.4 Particle size
Particle size has been shown to be important in determining the release 
controlling action of HPMC and XG. The effects have been attributed to differences in 
hydration between coarse and finer fractions (6,71) and relative lack of carrier when 
coarse particle sizes are used (72). The effect of Methocel K15M particle size on release 
of promethazine HC1 was found to depend on the percentage of HPMC in the matrix
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(72). At a HPMC loading of 64% similar release profiles were obtained using particle 
size fractions ranging from greater than 355|J,m to less than 75|Lim. At a 26% HPMC 
loading, sieve fractions having a particle size greater than 355jim and 210 to 355|im 
gave a burst release of drug. It was proposed that increased dissolution rates were due to 
the relative lack of HPMC in the matrix. In tablets containing a low proportion of 
polymer in the form of coarse particles it was thought that distribution of the polymer 
around the drug was not sufficient to form a protective barrier. Areas poor in polymer 
were likely to leach drug quickly producing a burst effect and the absence of polymer 
facilitated the rapid penetration of water into the inner regions of the tablet. Water 
uptake studies, measured by differential scanning calorimetry, indicated that initially 
larger size fractions imbibed water faster than smaller size fractions. This was in 
contrast to the proposal by Alderman (6) that burst release of riboflavin from matrices 
containing a low proportion of coarse Methocel K4M granules, was due to slow 
hydration of these particles, although experimental data to confirm this was not 
presented. Similarly, burst release of acetaminophen from xanthan gum matrices 
prepared with relatively coarse particle size fractions (74 to lOOjim and 177 to 420jim) 
was attributed to slow hydration of these particles (71). Particle sizes less than 74jim 
were effective in sustaining drug release. Again, the effects may have been due to 
relative lack of carrier, and not differences in hydration rates as proposed. Burst release 
due to coarse particles has been shown to be more pronounced for less hydrophilic 
grades of Methocel (73).
1.6.1.5 Moisture content
Mosquera et al (74) showed that variations in the moisture content of HPMC 
matrices, despite having an effect on the compression behaviour of the HPMC itself and 
on the mechanical properties of tablets made from it, had no effect on the dissolution rate 
of the poorly soluble drug hydrochlorthiazide from the matrices.
1.6.2 Physical and chemical characteristics o f the drug and other excipients
The solute contained within a matrix can play an active role in determining its 
own release rate. Additionally, the presence of non-polymeric excipients can play a part 
in controlling the rate and kinetics of drug release.
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1.6.2.1 Drug solubility, particle size, molecular weight and wettability
Drug solubility is important in determining release rates since water-soluble 
drugs must firstly dissolve before they diffuse through the matrix while water-insoluble 
drugs can only be released by erosion of the matrix (6,75). Although drug solubility is 
important, a review of the literature suggests that there is no direct relationship between 
drug solubility and release rates. Ranga-Rao et a l (76) studied the release of 23 drugs of 
various solubilities and molecular sizes through matrices of Methocel K4M and mixtures 
of Methocel K4M and NaCMC. It was concluded that the differences in profiles 
observed could not be explained based on those two parameters alone. Furthermore, the 
release phenomena observed for Methocel K4M matrices did not always apply to 
Methocel K4M/NaCMC matrices for the same solutes. It was concluded that other 
factors might be governing drug release including; interactions between the polymers 
and drug; penetration of the solvent into the matrix; erosion of the swollen gel; influence 
of the drug on gel erosion and solubilisation of the drug by the polymer. Baveja et al. 
(77) took a series of structurally related water-soluble bronchodilators and studied the 
dissolution from HPMC based matrices. Although the drugs had almost identical 
aqueous solubilities, they showed different release rates from the tablets. The difference 
was observed in all three grades of HPMC studied. Release rates were correlated with 
the accessible surface area of the drug, a parameter that was mathematically derived, and 
the relationship was tested with another similar chemical entity. Good agreement with 
the predicted result was obtained. Tahara et a l (78) found that with model drugs having 
solubilities between 0.05% and 0.5%, dissolution rates increased with drug solubility. 
For model drugs having solubilities greater than 0.5% dissolution rates were found to be 
less influenced by drug solubility.
Malamataris and Ganderton (79) looked at diffusion and erosion in a matrix 
consisting of an insoluble hydrophobic material (hydrogenated vegetable oil) and a 
hydrophilic gel forming material (carboxypolymethylene) using indomethacin, ibuprofen 
and diclofenac sodium as model drugs. They postulated that matrices containing the 
water-soluble, wettable diclofenac sodium could accommodate the swelling of the gel 
and release was achieved through diffusion and erosion of the gel. However, with the 
less wettable ibuprofen, the matrix eroded rapidly due to deaggregation caused by the 
inability of the matrix to accommodate the swelling of the hydrophilic part.
Different particle size fractions of propranolol HC1 and aminophylline (63 to 
90jiim, 125 to 180pm and 180 to 250pm) have been shown to be released at equivalent 
rates from HPMC matrices (63). Ford et a l (80) indicated that as the particle size of
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promethazine HC1 (a highly water-soluble drug) was increased from 45 to 63|Xm to 500 
to 750jim, only a 12% change in dissolution rate was observed. For the poorly soluble 
drug, indomethacin, release rates from HPMC matrices decreased as particle size of 
indomethacin increased (75).
1.6.2.2 Drug loading
Release rates can be affected by the total concentration of drug in the matrix. 
The dissolution of caffeine and potassium chloride (KC1) at different drug loadings from 
polyvinylpropylene matrices has been studied and percolation theory used to interpret the 
results (81). For all caffeine loadings there was a poor correlation when the percentage 
released was plotted against Vt. With KC1 the correlation was good when the drug 
loading was > 30%. For caffeine a better fit was obtained when the amount released 
(Qt) was plotted against time. Using linear regression the slopes of the Qt/t curves were 
calculated then normalised to give a theoretical release rate. For drug loadings of 
caffeine greater than 70% w/w, the experimental values were below the theoretical value. 
The 70% drug loading was regarded as the percolation threshold above which the 
polymer ceased to span the tablet and instead formed finite clusters which insulated the 
caffeine in those regions producing a slower than predicted release rate. The percolation 
threshold was lower for KC1 (10% w/w), which was attributed to the larger particle size 
of this material.
Drug loading also influences release when the drug itself contributes to the 
hydration and swelling of the matrix. Mitchell et a l (82) showed that as the 
concentration of propranolol hydrochloride in HPMC matrices was reduced the ability of 
the matrices to sustain the release of drug decreased. The drug appeared to be involved 
in maintaining the integrity of the matrix probably by affecting the gelation temperature 
of the polymer (see section 1.6.3.3).
1.6.3 Matrix component interactions
There is considerable potential for interaction between the polymer network, 
added excipients and drugs that may influence release profiles. The presence of drug or 
additive in the hydrophilic matrix is likely to influence release by two mechanisms
1. By changing the rate of hydration, swelling and/or erosion of the matrix




Highly swollen gel systems can be considered analogous to porous media with 
the permeable regions serving as the pores and the impermeable regions as the walls. If 
there is no interaction between the polymer chains and the drug then the effect of the 
polymer chains on the diffusion process may be one of geometrical obstruction. Areas of 
obstruction caused by insoluble excipients, amorphous polymeric areas or poorly 
hydrated regions potentially could increase the tortuosity. Alternatively, dissolution of 
soluble components could leave a matrix of high porosity and low tortuosity, which 
would allow rapid diffusion of drug and rapid matrix erosion.
Ford et al. (63) found that replacement of HPMC by a soluble or insoluble diluent 
increased dissolution rates of model drugs. Only at high diluent levels did differences 
become apparent between the soluble diluent lactose and the insoluble diluent calcium 
phosphate. The results confirmed the findings of Lapidus and Lordi (83) but 
contradicted the statement by Alderman (6) that as little as 10% insoluble solids such as 
calcium phosphate may destroy sustained release from HPMC matrices by producing a 
lack of content uniformity of the gel.
1.6.3.2 Swelling effects
It is known that drugs and additives can actively contribute to the swelling of 
hydrophilic matrices. The swelling of matrices of either Methocel K100MCR or 
polyethylene oxide have been shown to be greater in the presence of the water-soluble 
drug, propranolol HC1, than in the presence of the insoluble drug, flurbiprofen (84). The 
results were attributed to variations in the rate of water penetration. In polyethylene 
oxide matrices, which exhibited greater swelling than Methocel K100MCR matrices, 
release kinetics appeared to be affected to a greater extent by polymer hydration and 
swelling. The phenomenon was more profound with the soluble material propranolol 
HC1. Propranolol HC1 and tetracycline HC1 have been shown to play an active role in 
the swelling behaviour of HPMC matrices (82). The drugs were thought to enhance the 
solubility of the polymer causing it to hydrate and gel more rapidly. Talkudar and 
Kinget (28) postulated that sodium indomethacin contributed to the swelling of XG 
tablets by means of an osmotic or plasticising effect. Fluorescein has been show to 




Cellulose ethers exhibit the property of thermal gelation, which is often 
quantified using gelation temperatures, defined as the temperature at which the relative 
viscosity of a solution is at its minimum value on the viscosity-temperature curve (86). 
The gelation behaviour may be explained as follows: in a solution state at low 
temperature, molecules are hydrated and there is little polymer-polymer interaction. As 
the temperature of the solution or gel rises, the molecules gradually lose their water of 
hydration. When sufficient, but not complete dehydration of the polymer occurs, a 
polymer-polymer association takes place and causes a high viscosity gel to form. The 
temperature at which gelation occurs and the strength of thermal gels are affected by the 
type and degree of substitution present, the concentration of the polymer and the 
presence of other water-soluble materials in the solution (86). Added water-soluble 
components can compete for available water in the gel layer and thereby reduce the 
hydration of the polymer. This can lead to a stronger gel due to increased extent of 
hydrophobic polymer interactions primarily between methoxy-substituents (6). At 
further increased solute concentrations the integrity of the HM can be rapidly lost due to 
precipitation of the polymer (87). The effects of solutes can be important whether 
present in the dissolution medium, present in the matrix or both.
Touitou and Donbrow (86) found that while small organic ions caused 
dehydration or ‘salting-out’ of a methylcellulose matrix, large organic ions improved 
polymer hydration and stabilised the matrix. A hypothesis was put forward that the 
cohesiveness of matrices containing large organic ions was a function of increased 
hydration and stretching of the macromolecular chains. This theory was supported by 
viscosity measurements.
1.6.3.4 Chemical interactions
Chemical interactions could possibly occur between the drug and the polymer, 
the additive and the polymer or the additive and the drug. Instances of all three 
situations have been reported in the literature. The slower than expected release of 
chlorpheniramine maleate from matrices containing sodium carboxymethylcellulose was 
thought to be due to the formation of a complex between the chlorpheniramine cation 
and NaCMC backbone (88). A similar theory has been applied to explain why cationic 
drugs are released at different rates from non-ionic HPMC matrices and HPMC/NaCMC 
(anionic) matrices (76). Lubricants with high hydrophobicity will slow the dissolution 
rate with the effect being less pronounced when the polymer concentration is high (89).
29
Daly et al. (62) showed that gel viscosity of a modified HPMC could be increased using 
sodium lauryl sulphate possibly due to binding between the anionic surfactant and the 
non-ionic polymer.
1.7 Tablet hardness, porosity and geometry
A large number of studies have examined the relationship between release rates 
and tablet hardness, porosity and/or compaction force. Ford et al (80) did not detect any 
relationship between compaction force and the release of promethazine HC1 from HPMC 
K15M matrices. Bansal et al. (90) drew a similar conclusion from a study of a water- 
soluble drug in a mixture of alginate and hydroxypropylcellulose, while Bettini et al. 
(91) found that the initial porosity of Methocel K15M matrices did not influence the 
release of buflomedil pyridoxalphosphate. A number of papers however, have reported 
links between either tablet hardness, compaction force, or porosity in relation to drug 
dissolution from tablet matrices.
Korsmeyer et al. (92) studied tablet matrices containing potassium chloride and 
hydroxypropylcellulose and found that release profiles varied inversely with tablet 
porosity and mean pore diameter. It was proposed that air entrapped within the matrix 
was acting as a transport barrier thus tablets with higher porosity had more entrapped air 
and displayed slower release of drug. When the samples were prepared using a method 
to reduce entrapped air the release profiles changed from first-order to approximate zero- 
order for up to 70% release and the difference between release profiles from tablets 
compacted at high and low compaction forces was less marked. It was suggested that 
evacuating the tablets prior to dissolution lead to water being forced into the pores by 
atmospheric pressure producing a saturated aqueous phase throughout the tablet at the 
beginning of the experiment. The effect of entrapped air on dissolution behaviour has 
been deliberately exploited by Hashim and Li Wan Po (93) who incorporated 
effervescent mixtures into HM tablets in order to change release kinetics.
Perez-Marcos et al. (32) observed that increasing the force used to compact 
frusemide, a drug of low water-solubility, in either 20 or 40% Carbomer lead to a rise in 
the dissolution rate. Release was postulated to be via erosion of the matrix. The 
significant effect of compaction force on release of this sparingly water-soluble drug was 
attributed to the effect of this variable on gel consistency.
The release of theophylline from amylodextrin tablets was controlled by altering 
the force used for compaction (94). Increasing the compaction force from 5 to lOkN
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reduced the burst effect seen at 5kN, decreased the release rate and changed the kinetics 
to almost zero-order for up to almost 60% release. No further change was seen when the 
compaction force was increased from 10 to 15kN. The results were attributed to 
differences in the rate of solvent penetration into the tablet.
Rizk et al. (95) reported a scleroglucan/theophylline/lactose formulation that 
displayed a marked decrease in release rate with increasing hardness. The result was 
correlated with a seven-fold decrease in pore radius and not a decrease in pore volume. 
The effect was possible due to a change in the rate of water uptake and swelling.
The sustained release function of tablets prepared with low-substituted 
hydroxypropyl cellulose (L-HPC) granules was found to be affected by the internal pore 
size distribution of the tablet (96). Granules prepared by roller compaction using a high 
pressure were mechanically strong and resulted in matrix tablets having a high interstitial 
porosity. Drug release from matrices having high porosity, as determined from mercury 
porosimetry, was faster than from tablets having a lower porosity. The observations 
were attributed to faster rates of hydration and swelling in high porosity tablets.
Compaction force was found to influence the rate of release of a water-soluble 
drug from XG/guar gum matrix tablets (36). A faster release was observed in tablets 
having higher tablet porosity, the effects were more pronounced in a phosphate buffer. 
In acidic medium the release was influenced to a lesser extent by compaction pressure.
Relationships between release rate and tablet dimensions have been reported. 
Ford et al. (69) found that the Vtime release rate of promethazine HC1 (a highly water- 
soluble drug) from HPMC matrices was proportional to the surface area of the tablet 
since release rates decreased as the tablet surface area decreased. Modification of the 
geometry of tablets based on retrograded pregelatinised starch was used to control the 
release of a water-soluble model drug (97). Dosage form presentations with a larger 
releasing surface area showed a faster release of drug than dosage forms with a smaller 
surface area. The results were attributed to the differences in surface area available for 
solvent penetration and to the distance that the solvent front had to travel within the 
tablet.
1.8 Factors affecting drug release from hydrophilic matrix capsules
HM capsules, containing formulations in powder or granule form, were originally 
introduced as ‘hydrodynamically balanced systems’ (HBS) for prolonging gastric 
residence time (98). The theory was that capsules having a specific gravity less than that
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of gastric juice could float in the stomach and increase the residence time there. 
Research efforts that have focused on non-floating HM capsules have examined the 
effects of polymer type, microenviroment pH control and formulation variables on drug 
release (14,59,70,99,100).
The release of pseudoephedrine, a highly water-soluble model, from HM 
capsules based on HPMC was unaffected by variations in tamping force used to 
consolidate the powder within the capsule, within the range investigated (99). At least 
25% polymer was required for cohesive powder plugs to be formed. Hussain et a l (14) 
found that blends of hydroxyethylcellulose and sodium carboxymethylcellulose could be 
used to obtain zero-order release kinetics from capsule matrices. This technique for 
obtaining time independent kinetics was previously applied to tablet matrices. It was 
found that slowly hydrating polymers such as methylcellulose, hydroxypropyl cellulose 
and sodium carboxymethylcellulose did not give sustained release from capsule matrices 
but grades of HPMC (F4M premium, E4M premium and K4M premium) were found to 
give sustained release action (6). The effect of capsule size on the dissolution of a 
soluble model from hydrophilic matrix capsules was investigated by Alderman (6). Hard 
gelatin capsules ranging from size 3 (0.36g) to size 0 (0.87g) controlled the release of the 
model to the same degree. It was also suggested that capsule forms required slightly 
more polymer to achieve the same dissolution times as tablets, possibly because of lower 
powder density. Data to substantiate this was not presented.
Although HM capsules have been considered as HBS no reports have been found 
in the literature regarding the use of HM capsules as simple hydrophilic matrix systems.
1.9 In vitro dissolution testing of hydrophilic matrices
The formulation development of any solid oral dosage form normally starts with 
dissolution testing. Dissolution testing is essential for screening and proper assessment 
of different formulations. Although standardisation of dissolution testing has been 
successfully implemented for immediate release dosage forms (65), enormous 
difficulties have been encountered in establishing proper dissolution test conditions and 
parameters for testing controlled release dosage forms. Formal guidelines to evaluate 
these products do not exist therefore the current trend is to evaluate every controlled 
release dosage form on an individual basis (101). One of the difficulties in generalising 
test conditions arises because many controlled delivery systems are designed to possess 
diverse physicochemical and pharmacokinetic properties. The majority of studies that
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have focused on the dissolution profiles of controlled release solid oral dosage forms use 
USP dissolution apparatus with either paddle or basket method. Despite their 
widespread use, the USP paddle and basket methods are not ideal for testing extended 
release products. Firstly, the USP apparatus II does not allow an automatic flow of the 
dissolution medium with variable pH, which is desirable for evaluating and testing 
extended release products. Secondly, the system is not suitable for testing the dissolution 
of very low solubility drugs because of a limited ability to maintain sink conditions. 
Thirdly, dosage forms, such as floating capsules or tablets, can not be positioned 
appropriately in the system to test dissolution characteristics. To overcome some of 
these difficulties several modifications have been suggested in the literature (101). 
However, none of these are yet comprehensive enough to be adopted as a standard 
testing procedure.
Difficulties also exist in simulating in vivo conditions in vitro. Since most 
controlled release preparations are designed for prolonged release and therapeutic effect, 
variability in in vivo conditions over time (such as presence and nature of food in the GI 
tract, time of day that the dosage form is administered etc), can substantially affect the 
release profiles of a drug. The first challenge in predicting in vivo predictability is to 
select a suitable dissolution medium. In an ideal situation, an extended release system 
would be tested in vitro throughout the entire physiological pH of the GI tract. However, 
difficulties exist in determining the time intervals that would relate to a particular section 
of the GI tract. Since ionic strength can be important to dissolution behaviour of 
hydrophilic matrices (58,87,102), this should be a consideration when designing 
dissolution media. The exact physico-chemical properties of the GI contents is difficult 
to predict since it is determined by many factors including; (a) fed/fasted state (b) nature 
and quantity of food (c) excipients of the dosage form and co-current administration of 
other drugs (d) interpersonal variability due to for example, age and illness. The second 
challenge to selecting in vitro dissolution conditions is establishing dissolution test 
parameters. Knowledge about mechanical stress and hydrodynamic conditions within 
the GI tract is limited and difficult to simulate. Furthermore, the variability in motility 
patterns in fed and fasted conditions complicates the task of setting a unique agitation 
condition during in vitro testing. The difficulty in selecting appropriate in vitro agitation 
conditions to correlate with in vivo observations is exemplified by the findings of 
Shameem et al. (103), who compared in vitro and in vivo release behaviour of HPMC 
based tablet matrices in seven volunteers. They found that the fastest in vivo release 
under fasting and fed conditions was similar to the in vitro curve determined by the
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rotating basket method at 150rpm. The slowest release from the tablets under a fasting 
condition was less than the in vitro dissolution curve by the paddle method at lOrpm. 
They attributed the large inter-subject differences observed to differences in the GI 
destructive force generated by GI motility and residence among subjects. This means 
that in vitro testing under highly destructive conditions may not necessarily be more 
physiologically meaningful than testing under less strenuous conditions. A difficulty 
with in vitro testing is that drug release influencing factors that are significant in vitro 
may be of limited importance in vivo. HM’s that have been shown to be sensitive to 
changes in ionic strength of the medium in vitro have not shown the same sensitivity in 
vivo (60,104).
Although the ultimate test of product behaviour is in vivo pharmacokinetic and 
pharmacodynamic data it has been argued that a knowledge of the behaviour of a dosage 
form in the GI tract can be a useful step in formulation development (105). Gamma 
scintigraphy is a non-invasive imaging technique that has been widely used to study the 
behaviour of solid oral dosage forms in man (60,105,106). In this work, in vitro 
dissolution tests have been used as the first step in studying the functionality of 
controlled release formulations while a gamma scintigraphy study has been used to aid 
the evaluation of the behaviour of dosage forms based on heterodisperse polysaccharides 
in vivo.
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2. Assessment and validation of methods for bulk physical 
characterisation of heterodisperse polysaccharide-based granules and tablets
2.1 Introduction
Physical characterisation of pharmaceutical solids can be carried out at three 
levels; the molecular level (properties associated with individual molecules), the 
particulate level (properties pertaining to individual solid particles) and the bulk level 
(properties associated with an assembly of particles) (107). This work is concerned with 
the bulk physical properties of heterodisperse polysaccharide (HP)-based granules and 
tablets. Bulk physical properties can be defined in terms of material density, porosity, 
pore size distribution, surface area and in the case of granules, flow properties. The 
parameters of specific surface area, bulk density, porosity, pore area and pore size 
distribution are considered here. Bulk density can be easily measured by determining the 
weight and apparent volume of solid samples. Specific surface areas can be measured 
using gas adsorption techniques, which depend on the ability to predict the number of
adsorbate molecules required to exactly cover the surface of a material with a single
molecular layer of inert gas (107). Accuracy of the technique is highly dependent on 
material characteristics and experimental conditions. Quantitative estimates of pore 
volume, pore diameter and pore area can be obtained using the technique of mercury 
porosimetry. This is based on capillary rise phenomena whereby a pressure is required 
to make a non-wetting liquid move up a narrow capillary (108). Quantitative data is 
obtained by relating pressure applied and volume of mercury intruded to pore size 
distribution, pore volume and pore surface area. Mercury porosimetry has gained 
popularity as a research tool due to the relative simplicity of the technique and the 
extensive range of data that can be generated (109). Due to its ease of use mercury 
porosimetry is often used as a black box which produces pore size distributions (110). 
However, basic limitations of the technique exist and problems may arise if it is applied 
to materials for which it has not been properly tested. To ensure that the data obtained is 
truly representative of the porous material potential sources of error need to be 
thoroughly evaluated and care must be taken with interpretation of results. For this 
purpose it is useful to compare mercury porosimetry results with results obtained using 
other methods of pore structure analysis.
In this study, HP-based granules and tablets were analysed using mercury 
porosimetry, gas adsorption measurements, scanning electron microscopy and liquid
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penetration studies. The objective was to determine the suitability of these methods, 
alone and in combination, for characterising specific surface area, bulk density, porosity, 
pore area and pore size distribution of HP-based granules and tablets.
To achieve this it was necessary to; (1) ensure that the techniques gave 
information which was truly representative of the porous body; (2) determine the 
accuracy, precision and reproducibility of the methods; (3) ensure that the methods were 
suitable for the analysis of a large number of samples; (4) assess whether the 
measurements obtained would be potentially useful for physical properties/dissolution 
behaviour correlation studies.
2.2 Materials
Xanthan gum (Lot No. P5086), locust bean gum (Lot No. B7924), glucose (Lot 
No. CD4R02005), calcium sulphate (Compactrol NF, Lot No. 50320X) microcrystalline 
cellulose NF, BP (Emcocel 50M, Lot No. 3467) and TIMERxN (Lot No. NS664) were 
supplied by Penwest Pharmaceutical Co. (Patterson, NY, USA). TIMERxN is a 
proprietary formulation of heterodisperse polysaccharides, which contains two tertiary 
components, calcium sulphate and ethylcellulose, in addition to locust bean gum, 
xanthan gum and glucose. Mercury was obtained from Belgrave Mercury Ltd. (London, 
U.K.) and magnesium stearate (Batch No. 29846) from Fisons Scientific Equipment 
(Loughborough, U.K). Acetone, 2-propanol (HPLC grade) and cyclohexane (HPLC 
grade) were obtained from Fischer Scientific Ltd. (Loughborough, U.K.). Silica-alumina 
reference material (Lot No. A-501-23) was obtained from Norton Chemical Process 
Products Co. (Ohio, USA). The sintered glass disc was obtained from Amer Products 
Ltd. (Brimsdown, Enfield, U.K.) and silica gel from BDH Chemicals Ltd. (Poole, 
England). Ethylcellulose aqueous dispersion, NF containing 21% w/v ethylcellulose 
(Aquacoat, Lot No. J3381, FMC, USA) was obtained from Colorcon Ltd. (Dartford, 





HP-based material was either prepared by wet granulating the primary 
components or obtained pre-granulated from Penwest Pharmaceutical Co. To clearly 
distinguish between the materials, preparations obtained from Penwest Pharmaceutical 
Co. are referred to by their proprietary name, e.g. TIMERxN, while granules prepared at 
Bath are referred to as Bath heterodisperse polysaccharide (BHP)-based material. BHP- 
based granules have been allocated a three character alphanumeric code. The letter G, 
denoting granules is followed by a number that indicates the chapter in which the 
manufacturing process is described. A letter identifying the specific batch follows this 
(e.g. G3A). The preparation of two batches of granules (batches G2A and G2B) is 
described in section 2.3.1.2. Batch G2A was used for mercury porosimetry studies while 
batch G2B was used for gas adsorption studies. A number of other batches are referred 
to in this chapter since they were used to assess some of the analytical techniques 
however, their preparation is described in proper context in chapter 3. Both granule and 
tablet samples were used to assess the analytical techniques. Tablets were compacted 
from both TIMERxN and BHP-based granules. Tablets compacted from BHP-based 
granules are identified by the letter T followed by the remainder of the granule batch 
code (e.g. T3A are tablets compacted from granule batch G3A).
2.3.1.1 Tablets
TIMERxN has excellent compaction properties, which enabled tablets to be 
produced using a wide range of compaction forces. This would not have been possible 
using granules produced by wet granulation of the primary components. TIMERxN was 
compacted using a compaction simulator, which enabled compaction force and speed to 
be accurately controlled. An appropriate tablet weight was selected by determining the 
weight of material that would be required to produce a 3.5mm x 10mm compact at zero 
porosity. This is a standard procedure for compaction simulation work (111). To 
calculate this the true density of TIMERxN was required. A helium pycnometer 
(Ultrapycnometer 1000, Quantachrome Co., Greenvale, NY, USA) was calibrated 
immediately before use using a calibration sphere of known volume. TIMERxN was 
dried in an oven (Model 1H-150, size 2, Gallenkamp, Loughborough, U.K.) at 60°C for 
24hr prior to analysis to reduce the moisture content of the sample. An accurately 
weighed sample (approximately 3g) was placed in a sample cell of known volume and
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purged with helium for 15min to remove adsorbed gases and moisture. Pre-drying of the 
sample reduced the purge time required. 3 determinations of the volume of helium 
displaced by the sample were made and the corresponding sample density calculated. 
The mean value was found to be 1.596g/cm3. To assess the performance of the 
pycnometer the same procedure was repeated on a sample of microcrystalline cellulose 
50M (MCC). A value of 1.544g/cm3 was obtained which corresponded closely to the 
value reported by Doelker (112) (1.543 g/cm3). The product of the true density of 
TIMERxN and the apparent volume of a 3.5mm x 10mm tablet (0.275cm3) gave the 
sample weight at a theoretical zero porosity (438mg). A compaction simulator (ESH 
testing Ltd., Machine No. 4287, Brierly Hill, U.K.) equipped with a regularly calibrated 
load cell (lOOkN) was fitted with 10mm flat-faced F tooling. Linear variable differential 
transformers attached to the upper and lower punches of the simulator were used to 
monitor the displacement of the punch tips from a reference position. This facilitated the 
determination of the separation of the punch faces at any point in time. The die and 
punches were cleaned with acetone and pre-lubricated prior to compaction with a 
suspension of 1.5% magnesium stearate in acetone. Accurately weighed samples 
(approximately 438mg) were introduced into the die cavity and compacted using a 
compaction speed of either 3mm/s or lOOmm/s. A single ended sawtooth 
displacement/time profile was obtained. By adjusting the penetration distance of the 
upper punch into the die the force used to compact the material was controlled. Tablets 
were produced using target upper punch forces of 2, 4, 8, 12, 16 and 24kN. 2kN was the 
lowest force that still produced an intact tablet able to withstand gentle handling, while 
24kN was the highest force achievable within the limits of the load cell.
BHP-based granules were compacted using a single punch tabletting press (Type 
F3, Manesty, Speke, Liverpool, U.K.) fitted with a 10mm flat-faced punch and die set. 
Accurately weighed sample, approximately 400mg were placed in the die cavity. The 
granules were compacted manually which allowed the weight and tablet thickness to be 
tightly controlled. The punch and die were not lubricated.
2.3.1.2 Granules
Batch G2A was prepared as follows: 25% locust bean gum (LBG), 25% xanthan 
gum (XG) and 50% glucose were dry blended for 5min using a high shear mixer 
(Cuisine Systeme Automatic 5000, Magimix, Surrey, UK.). Total batch size was 300g. 
The pre-blended solids were wet massed with 21% distilled water and tray dried at 60°C
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in an oven (Model 1H-150, size 2 Gallenkamp, Loughborough, U.K.) producing material 
with a loss on drying (LOD) value of approximately 5%. LOD’s were determined using 
an infrared moisture balance (Mettler LP16, Switzerland). The material was heated at 
70°C until no further weight loss occurred (approximately 20min). The material was 
screened through a 0.63mm mesh using a mechanical granulator (Type MGL 4A, 
Frewitt, Switzerland). The granules were sieved for 30min (Endecotts Ltd., London, 
U.K.) through an I.S.O standard aperture diameter V2 sieve progression ranging from 
710p,m to 63jj.m. The sieves were agitated using a Fritsch sieve shaker (Type 03-502, 
Fritsch, Germany). To maintain a constant particle size the granules were size selected 
to give granules with a normal size distribution and a target median particle size of 
182jnm. Size selection was important since granules particle size can affect porosity (see 
section 3.4.3). Quantities from each sieve fraction were selected in the following 
proportions: 500 to 710pm (2%), 355 to 500pm (4%), 250 to 355p.m (26%), 180 to 
250pm (36%), 125 to 180pm (26%), 90 to 125pm (3%), 63 to 125^im (2%) and 0 to 
63pm (1%). Sieve fractions were recombined using turbula rotation (Type T2C, Glen 
Creston Ltd., Stanmore, Middlesex, U.K.) for 5min at 50rpm.
Batch G2B was prepared as follows: 25% XG, 25% LBG, 35% glucose and 10% 
calcium sulphate were blended for 5min in a high shear mixer. Total batch size was 
300g. A suspension containing 15% w/v ethylcellulose was prepared by diluting 
ethylcellulose aqueous suspension (Aquacoat™) with water. As the dry material was 
mixed 100ml of suspension was added slowly over a period of 4min. Mixing was 
continued for a further minute. The material was tray dried in an oven at 60°C for 24hr 
then hammer-milled (Type DHF48 Glen Creston Ltd., Stanmore, U.K.) using a 3mm 
screen. Particle size of the granules was determined using a Malvern Mastersizer (Type 
MSX02SM, Malvern Instruments Ltd., Malvern, U.K.) fitted with a dry powder feeder. 
The mean volume median diameter D[v, 0.5] (n=3) was 144pm.
2.3.2 Mercury porosimetry
Pore structure determinations were made using a Micromeritics Autopore II 
porosimeter (Type 9220, Micromeritics Instruments Co., Georgia, USA) capable of 
operating in the range of 3.4 to 414,000kNm'2. The porosimeter was equipped with a 
low pressure chamber operating from atmospheric pressure (172kNm*2) down to 
3.4kNm'2 and a high pressure chamber operating from 172 up to 414,000kNm"2. The
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pressure at which mercury could be introduced into the penetrometer (fill pressure) could 
be controlled between 3.4 and 69kNm'2. Assuming the contact angle of mercury to be 
130° and the surface tension of mercury to be 485.0gcm/s respectively, pores having 
median diameters in the range 360 to 0.003pm could be analysed. Pressure was 
generated by a hydraulic pump and the movement of mercury in the penetrometer stem 
was followed using a conductance detector. Samples were stored over dry silica in a 
vacuum dessicator for at least 24hr before analysis. Pre-treatment of the samples in this 
way removed moisture from the materials reducing the time required to evacuate the 
samples. Between 2.5 and 4g of granules were placed in a 15ml powder penetrometer 
that had a stem volume of 0.392ml. TIMERxN tablets were placed in a 5ml solid 
penetrometer (1.131ml stem volume) while tablets prepared from BHP-based granules 
were placed in a 5ml solid penetrometer (0.392ml stem volume). Between 2 and 5 
tablets were used in each case. Samples were evacuated down to a pressure of 50pmHg 
to remove adsorbed gases and moisture. Penetrometers were filled with mercury at a 
pressure of 3.4kNm*2 for tablet samples and 69kNm*2 for granular samples. The 
penetrometer, fill pressure and sample size were carefully selected to ensure that between 
10 and 90% of the stem volume was used. Measurements were carried at a consistent 
room temperature of 21°C using an equilibration time of 5s. The surface tension, contact 
angle and density of mercury at 21°C were taken to be 485.0gcm/s2, 130° and 
13.5438g/ml respectively. Between 30 to 50 points in the required range were taken. 
Porosimetry analysis was carried out on granule batches G2A, G3G, G3L and G3E and 
on tablets compacted from TIMERxN using a compaction speed of 3mm/s and 
compaction forces of 2, 4, 8, 12, 16 and 24kN.
The performance of the porosimeter was assessed using a silica-alumina 
reference material supplied by Micromeritics, taken from a portion of material that had 
been repeatedly analysed by the company using different instruments and various 
operators at a number of locations. Approximately lg of material was analysed using a 
powder penetrometer with a 5ml bulb. An equilibration time of 10s was allowed and the 
fill pressure was set at 69kNm'2. The results fell within the limits established by 
Micromeritics, indicating that the instrument was performing satisfactorily (Appendix I).
2.3.3 Scanning electron microscopy
Scanning electron microscopy was used to look at the surface of a number of 
batches of granules which had been produced using different granulation techniques 
(batches No. G3I, G3L G3K, and G3F). The granules were known to have different
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porous structures as determined using mercury porosimetry. The preparation of these 
granules is described in chapter 3. Pores on the surface of TIMERxN tablets compacted 
using a range of forces at a speed of 3mm/s were also examined. Samples were stored in 
a vacuum dessicator over dry silica prior to examination. This removed moisture, which 
helped maintain integrity of the coating thereby preventing the material from charging 
(113). Granules were scattered onto adhesive, conductive mounting discs. Loose 
particles were removed by dusting with compressed air. Tablets were mounted on 
aluminium studs using carbon dag (a conductive paint). A layer of gold was deposited 
onto the sample surface using a sputter coater (Edwards high vacuum Model S150B, 
Sussex, U.K.) running at a voltage of 1.4kV for 8min. Samples were imaged with a 
scanning electron microscope (Jeol T6310, Japanese Electron Optics Ltd., Tokyo, Japan) 
using an electron beam potential of 5keV.
2.3.4 Surface area analysis by nitrogen adsorption
Nitrogen adsorption onto the surface of granule batch G2B was measured using a 
surface area analyser (ASAP 2000, Micromeritics Instruments Co., Georgia, USA). The 
instrument required a minimum total sample surface area of at least 20m2 for analysis. 
Since the surface area of the granules was predicted to be low (in common with many 
pharmaceutical excipients), it was estimated that at least 70g of sample was required for 
each analysis in order to meet the minimum surface area requirement. To accommodate 
this quantity of material the bulb of a standard glass sample tube (25cm3) was expanded 
to a volume of approximately 128cm3. Outgassing of the sample was necessary to 
remove physio-adsorbed gases and vapours, which can alter surface potential and block 
or fill pores. To decrease the outgas time the material was dried in an oven at 80°C 
(Model 1H-10, Size 2, Gallenkamp, Loughborough, U.K.) which reduced the moisture 
content to 0.6% w/w. The sample was quickly transferred to the sample tube to prevent 
re-adsorption of atmospheric moisture. The sample was outgassed by vacuum pumping 
down to a pressure of 9mmHg. The sample tube was transferred to the analysis port and 
cooled to the boiling point of nitrogen (77K) by immersing the sample holder in a dewar 
filled with liquid nitrogen. The sample was exposed to increasing partial pressures of 
nitrogen and the volume of gas adsorbed was measured at each partial pressure. A series 
of 18 pressure/volume measurements were made over a sequence of ascending relative 
pressures from 0.00004 to 0.90263. A duplicate measurement on the same sample was 
carried out. To check the performance of the surface area analyser, the surface area of a
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sample of microcrystalline cellulose 50M was also determined. Analysis was carried out 
on approximately lg  of dry material. The sample was heated to 60°C during degassing 
to reduce the degas time.
2.3.5 Liquid penetration studies
Analysis of liquid flow through complex pore systems is based on capillary 
theory (108). The rate of penetration of a non-wetting liquid is dependent on the contact 
angle 0 between liquid and solid, the surface tension of the liquid and the viscous 
resistance exerted by the capillaries which is dependent upon the cross section of the 
pores, their total perimeter and size distribution (114). Tablets having a more coarse 
intergranular structure may permit a more rapid movement of liquid through the pores 
than a tablet with the same porosity but a more even pore structure (115). A piece of 
apparatus to determine the rate of penetration of cyclohexane, a liquid that did not appear 
to wet HP-based materials, into tablets and granules was constructed. The apparatus was 
based on a design by Shah et al. (73). Figure 2.1 shows the equipment used. A circular 
disk of sintered glass with a porosity value of P4 (16|im) was sealed into a 15ml glass 
funnel and connected to the centrepiece of 3-pronged piece of glass tubing using 
polytetraethylene tubing. A reservoir fitted with an on/off tap was connected to the right 
hand side of the glass tubing while a 0.2ml pipette with 0.01ml divisions was connected 
to the left hand side of the glass tubing. The glass tubing was fixed to a board and held 
vertically. The apparatus was filled with cyclohexane that contained a small amount of 
dimethylyellow dye to render the liquid yellow. This enabled the movement of 
cyclohexane in the pipette to be followed. Experiments were carried out in a controlled 
temperature environment (21°C) to ensure that any loss of cyclohexane by evaporation 
was kept constant. The level of cyclohexane in the apparatus was adjusted so that the 
pipette was filled with liquid up to the zero mark. The reservoir was closed of using the 
tap and the sample to be tested placed on top of the sintered glass. Granule samples 
(approximately 300mg) were placed in an open ended cylindrical container in order to 
maintain a constant contact surface area with the sintered glass. As cyclohexane was 
wicked by the sample the pipette gradually became depleted of liquid. The volume of 
cyclohexane removed from the pipette was followed as a function of time. Cycloheaxne 
penetration studies were carried out on (a) tablets that had been compacted from 
TIMERxN using a range of forces and a compaction speed of lOOmm/s (b) on granules 
that were known to have a range of porosity’s as determined by mercury porosimetry
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(batches G3A, G3B and G3E) and (c) on tablets compacted to equivalent relative density 
from granule batches G3D, G3J, G3N, G30 and G3P (tablets T3D, T3J, T3N, T30 and 
T3P). These batches were expected to have different porosities despite having 
equivalent tablet thickness. Three samples were analysed from each batch of material.
Figure 2.1 Apparatus used to determine cyclohexane uptake rates.
2.3.6 Measurement o f bulk density
Bulk density was calculated by dividing the mass of a tablet or a sample of 
granules by its apparent volume. The apparent volume of a tablet was calculated using 
equation 2.1.
V  =  j t r 2h (2 .1 )
Where h was tablet height or thickness and r was tablet radius. Tablet dimensions were 
measured using a digital micrometer (Digit-cal electronic calipers, TESA S.A., 
Switzerland). To measure the apparent density of granules a sample of material (2 to 4g) 
was accurately weighed out and slowly poured into a 10ml graduated measuring 
cylinder. Care was taken to prevent consolidation of the particles. The volume of the 
sample was read from the cylinder. A mean of three determinations was found and the 
standard deviation from the mean calculated.
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2.4 Results and discussion
2.4.1 Mercury porosimetry
The volume of mercury V penetrating tablet and granule samples was measured 
directly as a function of applied pressure P. This P-V information provided a unique 
characterisation of pore structure. Porosimetry results from granule batch G2A and from 
TIMERxN tablets compacted using a force of 4kN and a speed of 3mm/s were used as 
model sets of data. Various means of extracting quantitative information from the raw 
data were considered using graphical representation of the data to aid interpretation of 
the information. Regions of the P-V data that represented penetration of mercury into 
spaces between granules or tablets was distinguished from data that represented filling of 
pores within the actual material. Porosimetry profiles of granule and tablet samples were 
analysed to determine likely areas of misinterpretation and to identify the degree to 
which values obtained were likely to represent ‘real’ values. The performance of the 
porosimeter and the reproducibility and limitations of the technique were also assessed.
2.4.1.1 Quantification of raw data
Using the Washburn equation (116) (equation 2.2) pressure P was transformed 
into a pore diameter D:
_ 4<7lvCOS0
D  =     (2.2)
where 0 was the contact angle of mercury (130°) and O l v  was the surface tension of 
mercury (485gcm/s2). The P-D information was presented in a number of graphical 
forms. Figures 2.2 and 2.3 show incremental intrusion plots over the complete analysis 
range for model granule and tablet samples, respectively. Incremental intrusion volume 
(ml/g) was presented on a linear scale and pore diameter (pm) on a logarithmic scale. 
These incremental plots represent both the penetration of mercury into spaces between 
granules or tablets and also pore filling within granules and tablets themselves. The 
point at which inter-particulate or void filling ends and pore filling begins is indicated by 
a sharp rise in intrusion volume which occurs at around 4 to 7p,m for the granule sample 
and at approximately 4.5p,m for the tablet sample. Only data representing pore filling 
provides useful information. To analyse this data the void space was ‘removed’ and the 
cumulative volume of mercury intruded (ml/g) was calculated from the point of pore
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filling down to a cut off point of 0.02pm. Selection of pore filling and cut-off points are 
considered in greater detail in sections 2.4.1.2 and 2.4.1.3, respectively. Cumulative 
intrusion volume on a linear scale was plotted against the logarithmic of pore diameter. 
Figure 2.4 shows cumulative intrusion plots over the range 6.5 to 0.02pm for granules 
and 4.5 to 0.02pm for tablets. Data from cumulative intrusion curves was quantified by 
determining the pore diameter which corresponded to 50% of the intrusion volume 
(median pore diameter) and, in some instances, the pore diameter which corresponded to 
25% and 75% of the cumulative volume (first and third interquartile points). Median 
pore diameter based on volume distribution is the most common method of describing 
pore size distribution (109) however, peak values from other pore size distributions can 
be used. Diameter calculations based on volume were selected for this study, as this was 
appropriate for correlation with water penetration phenomena.
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In order to calculate sample porosity determination of the apparent volume and 
pore volume of each sample was necessary. The difference between the volume of 
mercury filling the empty penetrometer and the volume with the sample present gave the 
apparent volume of the sample. Empty penetrometer volume was determined by 
carrying out a blank run while the volume with the sample present was determined by 
weighing the penetrometer after the low pressure run, converting mass into volume using 
the density of mercury at 21°C (13.5438g/ml) and back calculating to a pressure below 
which the pores were filled. This point corresponded closely to the last pressure point of 
the low pressure run (172kNm2). Using apparent volume, bulk density values for the 
samples were calculated. To confirm that values of bulk volume determined by 
porosimetry were acceptable, the values were compared to bulk density values calculated 
using bulk volumes determined from geometrical calculations. Table 2.1 shows bulk 
density values obtained for TIMERxN tablets compacted using a number of compaction 
forces and a speed of 3mm/s. Both methods of determining bulk volume produced 
similar results. Total porosity P of samples were determined using equation 2.3
Where Vp was the pore volume (total volume of mercury intruded) and Va was the 
apparent volume of the sample.
Volume-pressure data was also used to obtain a pore area distribution using 
equation 2.4, which is commonly used to calculate pore area (110):
Pore diameter was also described using an average pore diameter. This was calculated 
by multiplying pore volume by four and dividing by pore area (4V/A). This produced a 
value that took into account both pore volume and the number of pores (pore area values 
partly reflect the number of pores). Average pore diameters were useful when 
comparing pore size distributions of batches that had similar pore structures.

















Table 2.1 Bulk density values of TIMERxN tablets compacted at a speed of 3mm/s. 
Values were calculated using apparent volumes derived from (a) mercury porosimetry 
and (b) geometrical calculations.
2.4.1.2 Determination of pore filling point
In order to calculate pore parameters a clear difference must exist between inter- 
particulate and intra-particulate pore space filling, in the case of granules, or void space 
filling and pore filling in the case of tablets. If a transition point cannot be clearly 
distinguished then calculation of values to describe porous structure becomes impossible. 
Transition points were determined by examination of incremental and cumulative 
intrusion plots. Plots included data collected over the completed range of penetrometer 
filling, which was 69 to 103400 kNm'2 in the case of the model granule sample and 3.4 
to 241000 kNm'2 in the case of the model tablet sample. Cumulative intrusion curves for 
both granules and tablets (figures 2.5 and 2.6, respectively) showed a distinctive knee 
point or inflection on each curve. This occurred at a pore diameter of approximately 3 to 
4 pm for the tablet sample and approximately 6 to 8pm for the granule sample. 
Incremental intrusion plots (figures 2.2 and 2.3) of the same samples showed difference 
in the plots before and after these points. In figure 2.3 the large intrusion volume before 
4.5pm appeared to represent filling of the voids between tablets while the intrusion peaks 
after this point represented filling of pores within tablets. Similarly, in figure 2.2, 
intrusion at pore diameters greater than 7pm appeared to represent inter-particulate 
filling and intrusion of pores less than 4pm represented filling of pores within the 
granules themselves. Distinct inflection points in cumulative intrusion plots occurred in 
all subsequent granule samples which were analysed and in the majority of subsequent 
tablet samples analysed (Chapter 3). Only data collected from tablets that had been
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compacted at very low forces (<2kN) using a high compaction speed failed to show a 
defined inflection point. It has been reported that in powder and granule systems it is 
often difficult to difficult to determine the point at which inter-granular filling stops and 
intra-granular filling begins (109). In BHP-based granules the defined inflection point 
observed could be a consequence of the relatively small pore size of this material. The 
largest pore diameter of BHP-based granules was approximately 7pm, much smaller than 
that reported for other pharmaceutical excipients. Ganderton and Selkirk (117) found that 
that 22% of the pores of lactose granules had diameters in the range 14 to 56(im, while 
Sheskey and Williams (118) reported that the median pore diameter of Methocel F4M 
granules was 15p,m (median particle size was 267pm). Granules having large pore 
diameters are likely to be penetrated by mercury at low pressures including the 
penetrometer fill pressure. The smaller pore size of BHP-based granules meant that pore 
filling was unlikely to occur during penetrometer filling and applied pressures were
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needed to penetrate the largest pores. This meant that the point of pore filling could be 
readily identified. This is an unusual situation for pharmaceutical excipients (109). 
Possible reasons for the existence of very small pores in BHP-based granules is 
considered in section 3.4.1.2.
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From intrusion curves it was estimated that the transition point (ie pore filling 
point) lay between 4 and 7pm for the granule sample and between 3 and 6pm for the 
tablet sample. It was not possible to select the exact point at which pore filling began 
therefore introduction of an error was unavoidable. To examine the effect of this on 
quantitative values, experimental data from model tablets was computed using a number 
of theoretical pore filling points. Theoretical fill points were selected above and below 
4.5pm which was considered to be a reasonable estimated pore fill point (table 2.2). A 
comparison of pore parameters calculated using data collected over the pore diameter 
range 5 to 0.02pm with pore parameters using data collected over the pore diameter 
range 3 to 0.02pm showed that there was only a small difference between the results. It 
was concluded that a pore filling point selected anywhere within the estimated range 
would be acceptable. When pores larger than 5pm were included in the calculations the 
porosimetry data did not change substantially suggesting that there were effectively no 
pores greater than 5pm in the tablet sample. Interestingly, SEM’s of model tablets 
showed the existence of surface pores greater than 5pm. It was concluded that these 
larger pores were predominately surface cavity windows and did not contribute largely to
50
total porosity. Other researchers have reported that for porous media in which a cavity- 
window structure can be recognised, it appears improbable to find agreement between 
mercury porosimetry and two-dimensional photographs (119). Bulk density data 
provided confirmation that pore filling points had been correctly identified. Comparison 
of bulk density data obtained from mercury porosimetry with bulk density values 
calculated from geometrical dimensions showed that the results were similar (table 2.1). 
This suggested that that the knee point on cumulative intrusion curves did correlated to 
the point at which pore filling began since accurate measurements of bulk density also 
depended on the correct identification of this point. For subsequent tablet and granule 
samples pore filling point was decided for each individual sample from visual 
examination of cumulative and incremental intrusion curves.
Theoretical pore filling point (pm)
Pore param eters 20 10 5 4.5 3 1
Specific pore area (m2/g) 2.66 2.66 2.66 2.66 2.64 2.43
Median pore diameter (pm) 0.71 0.70 0.69 0.69 0.65 0.40
Porosity (%) 28.3 28.1 27.8 27.8 26.8 16.6
Table 2.2 Pore parameters of model tablets calculated using data collected from a range 
of theoretical pore filling points down to 0.02p.m.
2.4.1.3 Determination of cut-off point
The Micromeritics Autopore II porosimeter is capable of operating up to a 
pressure of 414,000kNm'2. However, since the materials being studied were not 
microporous and since mechanical damage to the material could, theoretically, occur at 
high pressures it was considered unnecessary to analyse up to the maximum achievable 
pressure. It was also known that the instrument itself can lose accuracy at high pressures 
and that the contribution made to the overall results can be substantially affected by the 
measurements of large quantities of small pores at high pressures (109). It was therefore 
important to determine a reasonable point at which the data could be truncated.
Data from the model tablet sample was computed between the diameter at which 
the pores began to be filled, taken as 4.5pm, and a range of minimum pore diameters. 
Figure 2.7 shows how calculated specific pore area values changed as the cut off point
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moved towards larger pore diameters. Including pores of very small diameter in the 
analysis resulted in a very high pore area. As smaller pores were eliminated from the
with pore diameter began to fall as the truncation point moved towards pores greater than 
0.015pm. This illustrated how small pores could substantially alter estimated pore areas 
because small volumes of small pores largely contribute to this value. Although selected 
cut-off points largely influenced pore area values, table 2.3 shows that estimates of 
median pore diameter and porosity were much less influenced by selected cut-off points. 
Smaller pores contributed little to total pore volume while median pore diameter 
calculations based on volume measurements were also more affected by large volume 
pores than by low volume pores (see section 2.4.1.4). A cut off point of 0.02pm was 
selected for subsequent studies since these were the smallest pores that could be included 
without adversely affecting the reproducibility of pore area estimates.
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Figure 2.7 Variation of pore area with data cut-off point
for model tablets illustrating the contribution of small pores to surface
area.
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Minimum pore diameter (pm)
Pore param eters 0.007 0.01 0.015 0.02 0.025 0.03 0.04
Median pore diameter (pm) 0.67 0.66 0.69 0.69 0.69 0.70 0.70
Porosity (%) 28.4 28.1 28.0 27.8 27.7 27.7 27.6
Table 2.3 Contribution of small pores to median pore diameter and porosity of a model 
tablet sample
2.4.1.4 Interpretation and analysis of mercury porosimetry results using model data
Table 2.4 shows values for total porosity, median pore diameter and specific pore 
area obtained for TIMERxN tablets compacted at a speed of 3mm/s and for granule 
batch G2A. Calculations were based on data collected from the estimated point of pore 
filling down to a minimum pore diameter of 0.02pm.
Pore parameters Tablets Granules
Pore area (m2/g) 2.644 0.896
Median pore diameter (pm) 0.66 1.08
Porosity (%) 27.3 10.1
Table 2.4 Pore parameters of model tablets and granules.
Incremental intrusion plots of points within this range are presented in figures 2.8 
and 2.9. Differential plots, derived from cumulative curves, gave a relative pore size 
distribution (figure 2.10). The visual impression of pore structure was assessed to 
examine how it related to the quantitative pore data given in table 2.4. Values for 
median pore diameter of tablets (0.66pm) and granules (1.08pm) were firstly assessed. 
Comparison of figures 2.8 and 2.9 showed that for both samples the majority of pores lay 
in the pore diameter range 0.2 to 3pm. Differential plots showed that the granules had a 
unimodal distribution of pores while the tablet sample had an essentially bimodal pore 
distribution (figure 2.10). The modal pore diameter in each case appeared to be 
approximately 0.3pm. However, the data in table 2.4 shows that the median pore
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diameter of the tablets was much smaller than that of the granules. This reason for this 
discrepancy became apparent when the intrusion data was divided into groups of pores 
and the median diameter of pores within each group calculated. The intrusion plot was 
sub-divided into three regions: pores between the estimated pore filling point and 0.9pm, 
pores between 0.9 and 0.1pm and pores between 0.1 and 0.02pm. Tables 2.5 and 2.6 
detail the porosity, median pore diameter and specific pore area of pores within each 
division for granule and tablet samples, respectively.
Pore diameter range
Pore param eters 6.5 to 0.9pm 0.9-0.1pm 0.1 to 0.02pm
Pore area (m2/g) 0.094 0.303 0.499
Median pore diameter (pm) 1.90 0.49 0.04
Porosity (%) 5.7 3.7 0.7
Table 2.5 Sub-division of pore data from model granules into three pore diameter 
ranges. The characteristics of pores within each sub-division are detailed.
Pore diameter range
Pore characteristic 4.5 to 0.9pm 0.9-0.1pm 0.1 to 0.02pm
Specific pore area (m2/g) 0.240 1.671 0.733
Median pore diameter (pm) 1.89 1.67 0.06
Porosity (%) 11.2 15.0 1.1
Table 2.6 Sub-division of pore data from model tablets into three pore diameter ranges. 
The characteristics of pores within each sub-division are detailed.
The quantitative data now gave a better indication of how the pore size 
distribution of the tablets and granules differed. This information could not be deduced 
from median pore diameters calculated over the complete pore range (table 2.4). The 
median pore diameter of pores in the range 0.9 to 0.1pm was much higher in tablets than
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in granules. The percentage of total pore volume made up of pores within each range 
was calculated. This showed that 56% of granule pores had a median diameter greater 
than 0.9|im while only 41% of tablet pore volume was greater than this. As median pore 
diameters are calculated by volume values are biased towards larger pore diameters. 
Therefore, in this case, median pore diameters, as calculated in table 2.4, do not 
accurately reflect the pore size distribution of the tablets. These examples highlight the 
fact that differences between the pore size distributions of samples can be identified 
more effectively if the data is examined within different pore size distribution ranges. 
Examination of intrusion plots is essential in selecting areas to examine in more detail. 
Although not useful in these examples, first and third interquartile data points can also be 
used to give a better indication of pore size distribution (see section 3.3.4.1).
Overall, the median pore diameters obtained by mercury porosimetry were 
possibly lower than ‘real’ values due to the presence of structural hysteresis or ‘ink- 
bottle’ shaped pores. This describes a situation were the pores consist of an irregular 
network, with constrictions, cavities and junctions etc. However, equations 2.1 to 2.3 
necessitated the assumption that pores in the material were cylindrical. Since this was 
unlikely, pore diameter values were not ‘real’ values but the best estimate of pore size 
distribution obtainable. Pore diameters can also be characterised by a hydraulic radius 
that is determined from a permeability coefficient obtained by measuring the rate at 
which dry air is drawn through a material (114). However, mercury porosimetry is 
















Figure 2.8 Pore distribution of model granules illustrated using 
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Considering the porosity of tablet and granules sample. Table 2.4 shows that the 
tablets were much more porous than the granules. From figures 2.8 and 2.9 it can be 
seen that pores of larger diameters accounted for the greater part of total porosity while 
small pores took up progressively less volume. Tablets had a bimodal pore size 
distribution while the majority of the pore volume of granules was accounted for by 
pores larger than 0.9p.m. Tables 2.5 and 2.6 show pore volume distributions within each 
of the three pore diameter ranges selected for analysis. This quantitative information 
correlated well with the visual impression of pore volume distribution obtained from 
incremental intrusion plots. Porosity values calculated from mercury porosimetry were 
compared to porosity values obtained using the apparent volume and mass of the sample 
(table 2.7). In all cases porosity values determined from porosimetry were smaller, 














Table 2.7 Porosity of TIMERxN tablets obtained from (a) mercury porosimetry 
measurements and (b) determinations of apparent volume from tablet geometry.
Pore area values determined using mercury porosimetry were examined using the 
model granule data. Using the data in table 2.5 it was calculated that although 56% of 
granule pores were greater than 0.9|J,m these pores only contributed to 10% of total pore 
surface area. In comparison, pores in the diameter range 0.1 to 0.02jim accounted for 
6% of total porosity but made up 56% of total pore area. This again illustrated the fact 
that smaller pores contribute more to surface area than larger pores. The specific pore 
area of granules determined from mercury porosimetry (0.896m2/g) was approximately 
three times greater than the specific surface area calculated from gas adsorption 
measurements on a similar batch of granules (see section 2.4.3). Although area 
determinations obtained from mercury intrusion are essentially pore surface areas they 
are often used as a measure of particle surface area (121). This difference between the 
values obtained in each case can be explained with reference to structural hysteresis. 
Surface area calculations based on intrusion of mercury into pores assume cylindrical 
pores, which have a larger surface area than a pore of equal volume displaying structural 
hysteresis. The phenomena of structural hysteresis means that values obtained from 
mercury porosimetry are likely to be less accurate than values obtained from gas 
adsorption techniques. Values obtained from mercury porosimetry tend to be higher than 
corresponding values obtained from gas adsorption measurements (110).
2.4.1.5 Assessment of reproducibility
It was anticipated that mercury porosimetry would be used to analyse a large 
number of granule and tablet batches. This meant that it would not feasible to carry out
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replicate analysis on each batch of material. To ensure confidence in the results it was 
decided to carry out a number of replicate determinations on a selection of tablet and 
granule batches that had various pore structures. Manufacture of the granule batches 
used in these reproducibility assessments is described in chapter 3. Replicate values of 
porosity, median pore diameters and specific pore areas on tablets compacted from 
TIMERxN using a speed of 3mm/s and a range of compaction forces is illustrated 
graphically in figures 2.11, 2.12 and 2.13, respectively. Calculations were based on data 
collected from the estimated point of pore filling down to 0.02pm. For tablets 
compacted at each force the mean value of two determinations was found. The 
difference between the mean value and the individual values was calculated as a 
percentage of the highest value. The percentage difference was found to be 2.0% or less 
in the case of porosity values, 3.7% or less for specific pore area values and 4.0% or less 
for median diameter determinations. This showed that results obtained from mercury 
porosimetry were reproducible. Similarly, in the granule samples, (table 2.8) high 
reproducibility of each of the three pore parameters under consideration was obtained. 
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Figure 2.11 Porosity of samples taken from TIMERxN tablets 


























Figure 2.12 Median pore diameter determinations on TIMERxN 
tablets compacted using forces of 4, 8, 12 and 16kN
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Figure 2.13 Specific surface area determinations on TIMERxN 
tablets compacted using forces of 4, 8, 12 and 16kN.
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Batch No.
Pore characteristic G3G G3L G3E
Specific pore area (m2/g) 0.699 0.635 0.392 0.405 0.871 0.893
Median pore diameter(pm) 1.82 1.75 2.18 2.01 0.99 1.08
Porosity (%) 4.95 4.13 3.45 3.40 9.83 10.11
Table 2.8 Replicate porosimetry determinations on three granule batches
2.4.1.6 Limitations of mercury porosimetry
Although reproducible results were obtained fundamental problems in the 
analysis of pore structure by mercury porosimetry were recognised. Firstly, the 
penetration of very large pores would be limited by the height of the sample, which 
determined a minimum pressure. However, scanning electron micrographs of the surface 
of tablets showed that only tablets compacted using a force of 2kN and a speed of 3mm/s 
had external cavity windows large enough to be penetrated at the pressure used to fill the 
penetrometer (69kNm‘2). It had also been shown that cavity windows did not contribute 
largely to pores volume therefore pore filling at very low pressures was unlikely to 
present problems. Secondly, accuracy of measurement of pore diameters was limited by 
the extent to which the contact angle selected represented the actual contact angle of 
mercury on the samples. Equipment to accurately determine the contact angle was not 
available however, for comparative purposes it was considered adequate to choose a 
reasonable value for the contact angle in order to ascertain whether or not two samples 
had the same pore size distribution and pore volume. For these studies a value of 130° 
was employed, which is one of the most frequently quoted values (110). Thirdly, 
compressibility of the dilatometer and mercury can occur causing base line errors. 
Carrying out blank runs and subtracting blank run data from the experimental run can 
eliminate this. Base line errors are only likely to be significant where the amount of 
sample to be analysed is very small, when tight levels of accuracy and reproducibility 
specifications are being imposed or if the porosity of the sample is very low. Since 
neither of these factors applied blank corrections were not carried out for this work. 
Fourthly, mechanical damage of samples can occur at high pressures. Taking the
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relatively low pressure applied into account, compared with the forces applied during 
compaction, the occurrence of elastic deformation was unlikely. No signs of damage 
were observed when tablets were visually examined post analysis. It has been reported 
(109) that damage to pharmaceutical materials is unlikely to be observed. By 
eliminating many of the sources of error and with careful interpretation of the data it was 
considered that reproducible and representative results were being obtained.
2.4.2 Scanning electron microscopy
Figures 2.14, 2.15 and 2.16 show SEM’s of three batches of granules that had 
different total pore volumes. The granule shown in figure 2.14 came from a batch of 
material having a porosity of 3.40% (batch G3L), the granule in figure 2.15 from a batch 
having a porosity of 4.64% (batch G3I) and figure 2.16 from material having a porosity 
of 10.36% (batch G3F). The granules selected were representative of the sample of 
material examined under the microscope. In these examples it appears that granules with 
the highest porosity had much more surface detail than granules with lower porosity. 
From this it could be concluded that SEM’s could be used to rank samples in terms of 
porosity. However, an examinations of the granules in figure 2.17 shows that this 
material was made up of particles showing surface detail and particles showing little 
surface detail. The total porosity of this material was still relatively high at 11.14% 
(batch G3K). It was concluded that granule porosity for some samples was difficult to 
estimate because the total porosity was made up of the total porosity values of granules 
that had different porous structures. SEM’s of tablet samples were useful for elucidating 
the compaction characteristics of granules (see Chapter 3) but were not useful for 
describing tablet pore characteristics.
2.4.3 Surface area determination by nitrogen adsorption
The volume of nitrogen adsorbed onto the surface of granule batch G2B and on 
to the surface of a sample of microcrystalline cellulose (Emcocel 50M) was plotted as a 
function of the relative pressure applied (P/Po). Figure 2.18 shows the isotherms for 
batch G2B, which were Type II isotherms, typical for powdered relatively non-porous 
solids (107). Both isotherms possessed a defined knee point, which represented 
monolayer coverage of the adsorbate. The sorption isotherms were interpreted using the 
equation developed by Brunauer, Emmett and Teller (BET) (122). The BET equation 
(equation 2.5) was applied over the linear P/P° range, which was 0.07 to 0.4 for batch 
G2B and 0.03 to 0.2 for microcrystalline cellulose.
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1 + £ = « £  (2.5)
V ( A - P )  WmC VnCP(
Where V was the volume of gas adsorbed at pressure P, P was the partial pressure of 
nitrogen, Vm was the volume of nitrogen adsorbed in the monolayer, P0 was the 
saturation pressure of nitrogen at and C was a constant exponentially related to the heat 
of adsorption of the nitrogen gas on the sample. The surface area was determined as a 
product of the number of molecules in a completed monolayer and the effective cross 
sectional area of nitrogen (equation 2.6).
S, = VmN(,Acs (2.6)
M
Where St was the total surface area, N0 was Avogadro’s number and Acs was the cross 
sectional area of nitrogen (0.1620nm2).
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Figure 2.14 SEM of a granule taken from batch G3L which had a porosity of 3.40%. 
Shows a very smooth particle with little surface detail.
1 O K U
Figure 2.15 SEM of a granule taken from batch G3I which had a porosity of 4.64%. 
Some surface detail visible.
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Figure 2.16 SEM of a granule taken from batch G3F which had a porosity of 10.36%. 
Degree of surface detail is greater than either batch G3L or G3I.
1 0  K U
Figure 2.17 SEM of granules taken from batch G3K, which had a porosity of 11.14%. 
Both smooth and rough particles visible.
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The results obtained for batch G2B are shown in table 2.10. Good reproducibility 
was observed along with low standard deviations. This is a low value typical of many 
other pharmaceutical excipients (e.g. lactose 0.53m2/g (107)). The results were 
consistent with the observations made by electron microscopy, which indicated little 
surface detail. Correlation coefficients were on the limit or slightly below the accepted 
range (0.999 to 1) which can indicate that insufficient material has been used in the 
analysis (123). C values give a measure of the affinity of the adsorbate for the adsorbent. 
C values can range from 3 to 1000 depending on the adsorption isotherm of the material. 
In this case C values were toward the lower end of the acceptance range indicating that 
nitrogen had a relatively low affinity for the granules. This would have reduced the 
accuracy of the results. Although the standard deviation was low and the two results 
were similar the relatively small value of C and the low surface area of the material 
would indicate that krypton or xenon at the temperature of liquid nitrogen would be more 
suitable adsorbates. Krypton and xenon have lower vapour pressures, which would 
cause a larger amount of gas to be adsorbed onto the solid, resulting in more accurate 
measurements for materials with low specific surface area values. A further difficulty 
with measuring surface areas with this technique was the length of the analysis time. 
Due to the large sample weight the outgassing step took 24 to 36hr. Heating the sample 
can reduce the outgas time, but increased temperatures, especially under vacuum, can 
change the properties of organic materials (123). The results for Emcocel 50M are 
shown in table 2.11. Values quoted in the literature for Emcocel and similar grades of 
MCC range from 1.18 (124) to 1.27m2/g (125), which suggested that values obtained 
may be highly dependent on analysis technique and experimental conditions. The results 
obtained here are higher than those reported elsewhere, possibly due to the low mass of 
material used for the measurement.
It was concluded that surface area determination by nitrogen adsorption would 
not be suitable for HP-based materials. However, the results were useful in that they had 
indicated that the surface area of the granules was low. To attempt to correlate surface 
area values with dissolution of model drugs from tablets or granules it would be 
necessary to produce materials that had largely different surface areas. If surface area 
values were low then physical modification of the material to produce batches with 
significantly different surface areas would be difficult. Attempts to correlate granule 
and/or tablet specific surface areas with dissolution profiles would be unlikely to
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Figure 2.18 Type II isotherm of nitrogen adsorbtion 
onto batch G2B
succeed. In terms of bulk characterisation of HP-based granules and tablets it was 
concluded that determination of specific surface areas would not be useful.
Run 1 Run 2
BET surface area ± SD (m2/g) 0.338 ± 0.007 0.321 ± 0.007
C 32.36 37.57
Correlation coefficient 0.9917 0.9990
Table 2.10 Results from BET surface area analysis on granule batch G2B
67
Run 1 Run 2
BET surface area ± SD (m2/g) 
C
Correlation coefficient





Table 2.11 Results from BET surface area analysis on Emcocel 50M
2.4.4 Cyclohexane penetration studies
Cyclohexane penetration into TIMERxN tablets compacted at a speed of 
lOOmm/s using a range of forces is shown in figure 2.19. The porosity of the tablets as 
determined by mercury porosimetry and geometrical calculations is given in table 2.7. 
The graphs clearly showed that tablets having different pore volumes (i.e different tablet 
thickness) showed different rates of wicking, particularly between tablets compacted 
using the lower compaction forces. The data was quantified by calculating the slope of 
the linear region of each plot, which gave the rate of wicking into the tablets. The 
regression in each case was at least 0.99. Plotting compaction force against the inverse 
of the wicking rate enabled the relationship to be clearly examined (figure 2.20). The 
graph shows that measurement of wicking rates can distinguish between tablets which 
have largely different pore volumes, but does not substantially differentiate between 
those tablets compacted using forces of 2, 4, 8 and 12kN. Wicking studies on BHP- 
based granules that had different pore volumes but similar bulk volume showed that no 
difference in wicking could be observed between the batches (figure 2.21). The wicking 
of cyclohexane into BHP-based tablets that had equivalent relative densities is shown in 
figure 2.22. The tablets were compacted from granules that had various bulk physical 
properties (table 2.12). The graphs show that although differences can be observed in 
the wicking behaviour of some tablet batches the relatively high standard deviations 
made it difficult to obtain significantly different measurements. This method was not 
continued as a means of characterising tablet pore structure.
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Figure 2.19 Cyclohexane penetration into TIMERxN tablets 
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Figure 2.21 Cyclohexane penetration into HP-based grami
Pore parameters G3K(2) G3N G3L(2) G3D
Median pore diameter (p,m) 2.33 2.13 2.73 2.22
of pores >0.9p,m
Porosity (%) 10.60 4.33 3.81 5.67
Bulk density (g/cm3) 0.53 0.45 0.51 0.62
Table 2.12 Pore structure of granules batches G3K(2), G3N, G3L(2) and G3D
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2 . 5  Conclusions
As a technique for determining the pore structure of HP-based granules and 
tablets, mercury porosimetry produced reproducible, quantitative information. With 
careful interpretation of the data it was felt that representative values of porosity and 
median pore diameter were being obtained. Examination of graphical presentations was 
essential to correctly interpret the data. The method was suitable for the analysis of both 
HP-based tablets and granules. The high degree of reproducibility provided confidence 
that sources of error had been avoided since these were likely to have become apparent 
in systematic reproducibility or repeatability experiments. Good reproducibility also 
gave confidence that one determination on subsequent batches of material would be 
satisfactory.
Measurements of surface area appeared to be less useful. Although 
determinations of surface area by gas adsorption appeared to yield reasonable surface 
area values the technique was not continued as a method of characterisation. This was 
due to three reasons; firstly, technical difficulties existed with the out gassing of such a 
large quantity of material which lead to very long experimental times. Determinations 
on large number of samples would therefore have been difficult. Secondly, although the 
two results obtained were very similar, the accuracy of the result was questionable
71
because of the very small surface areas involved. The use of krypton as the inert gas in 
place of nitrogen would improve the accuracy, but the small surface areas would still 
pose problems. Thirdly, since the material showed little surface detail and the particle 
size was relatively large then physical modification of the material to produce batches 
with significantly different surface areas was likely to be difficult. Attempts to correlate 
granule and/or tablet specific surface areas with dissolution profiles were unlikely to 
succeed. In terms of bulk characterisation of HP-based granules and tablets it was 
concluded that determination of specific surface areas was not useful. Determination of 
liquid penetration rates gave only a limited amount of quantitative information and was 
not useful for distinguishing porosity differences between tablets that had relatively large 
pore volumes. The method was not suitable for the bulk characterisation of granules. As 
scanning electron microscopy did not give quantitative data its use was limited on its 
own as a characterisation technique but was essential for using in conjunction with other 
methods.
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3. Modification and characterisation of the bulk physical properties of 
heterodisperse polysaccharide (HP)-based granules and tablets
3.1 Introduction
One of the aims of this work was to obtain HP-based tablets that had substantially 
different porosities, pore size distributions and pore areas. It was considered that this 
could easily be achieved by compacting granules into tablets that had different tablet 
thicknesses. The only prerequisite was a material that would form intact tablets at high 
and low compaction forces. However, tablets having different tablet thicknesses have 
correspondingly different external surface areas. In the context of dissolution this means 
that the initial releasing surface area of the tablets differs. For the purposes of 
subsequent work it was necessary to produce tablets that had the same initial surface area 
yet different pore structures.
A tablet can be described physically as a large aggregate of small, strongly 
cohered granules (126). It was therefore proposed that the physical characteristics of the 
granules from which a tablet was compacted would affect the porous structure of the 
final tablet. Additionally, it was considered that tablet porous structure was likely to be 
dependent on the volume reduction behaviour of the material. This would be influenced 
to some extend by granule physical characteristics including bulk density (127).
It was considered that the pore structure of HP-based granules could be modified 
by controlling the processing conditions used to produce the granules. HP-based 
granules can be easily produced by wet massing the primary components, drying and 
size reducing the material. Many variables can be introduced into the various processing 
steps that could affect the particulate characteristics of the resulting material. The 
granulation of pharmaceutical materials has been extensively studied however, the 
majority of studies investigating the effect of processing conditions on the physical 
characteristics of granules have focused on lactose (128,131). A number of more recent 
papers have considered the granulation of glucose and mannitol (132,133) and HPMC 
(118). No literature could be found concerning the effect of processing conditions in 
relation to the physical properties of multi-component mixes. The initial part of this 
work therefore was concerned with assessing the effect of process variables on the pore 
structure and bulk density of HP-based material.
A study of the volume reduction behaviour of materials naturally splits into two 
parts: characterisation of the compaction process and characterisation of the finished
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product. Investigations into compaction behaviour of pharmaceutical excipients have 
frequently centred on powder systems rather than granules, possibly because of the 
greater complexity of granular systems. Granular systems that have been studied have 
mainly been lactose based granulates (127,129,134,135). Little information exists on the 
compaction of multi component aggregates. The compaction of granules prepared by 
wet massing of HP-based material was considered here. BHP-based granules and 
TIMERxN (a proprietary formulation of HP-based material) were both used to obtain 
HP-based tablets having a range of physical characteristics.
3.2 Materials
Xanthan gum (Lots No. P5086 and 23071), locust bean gum (Lots No. B21577 
and 22886), glucose (Lots No. CD4R02005 and CD6029107) and TIMERxN (Lot No. 
NS664) were supplied by Penwest Pharmaceuticals Co. (Patterson, NY, USA). Xanthan 
gum (Lot No. P5086), locust bean gum (Lot No. B21577) and glucose (Lot No. 
CD4R02005) were used to prepare all granule batches except G3K(2) and G3L(2). The 
latter two batches were prepared using xanthan gum (Lot No. 23071), locust bean gum 
(Lot No. 22886) and glucose (Lot No. CD6029107). Acetone and 2-propanol were 
obtained from Fisher Scientific Ltd. (Loughborough, U.K.). Magnesium nitrate 
hexahydrate (Lot No. KN09725JN) was obtained from Sigma Chemical Co. 
(Loughborough, U.K.). Calcium sulphate (Lot No. 92918620) was obtained from 
Mendell (Penwest Pharmaceutical Co., Patterson, NY, USA). Surelease™ E-7-19010 
(Lot No. F7A0318), an aqueous solution containing 18.8% w/w ethylcellulose, 4.4% 
w/w ammonium hydroxide and 2.2% oleic acid, was obtained from Colorcon Ltd. 
(Dartford, Kent, U.K.).
3.3 Methods
3.3:1 Characterisation o f xanthan gum, locust bean gum and glucose
The true density of each powder was determined using a helium pycnometer 
(Accupyc 1330, Micromeritics, Norcross, GA). A mean of 3 determinations was 
calculated (table 3.1). The aerodynamic particle size distribution was measured 
(Aerosizer, Amhesrt Instruments, Hadley, MA) using a low shear forces, a feed rate of 
5000 particles/s and a 300s sample run time. Each raw material was analysed in
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triplicate (table 3.1). Loss on drying (LOD) of the material was determined 
thermogravimetrically using an infra red balance. Approximately 5g, accurately 
weighed, was heated at 75°C until no further weight loss occurred (approximately 
20min). The percentage weight loss was recorded.
D [4,3] dim) True density 
(g/cm3)
LOD (%)
Xanthan gum (P5086) 63.3 ± 8.6 1.54 9.4
Xanthan gum (23071) 70.9 ± 12.0 1.54 7.3
Locust bean gum (B21577) 72.3 ±10.1 1.56 11.0
Locust bean gum (22886) 85.0 ± 8.9 1.53 7.1
Glucose (CD4R02005) 39.4 ±7.5 1.53 8.6
Glucose (CD6029107) 45.3 ± 11.9 1.53 8.1
Table 3.1 Raw material characteristics
3.3.2 Preparation o f granules
Batches containing 3-components (xanthan gum, locust bean gum and glucose) 
were prepared using 14 different sets of processing conditions. This included 8 batches 
of granules prepared as part of a factorially designed set of experiments. The aim was to 
obtain granules having different pore structures and bulk densities while evaluating the 
factors that were important in controlling bulk physical characteristics. The factorial 
design was used to investigate the effect of volume of water added, agglomeration time 
and drying temperature on pore structure and bulk density. Section 3.3.2.3 describes the 
preparation of 3 batches of granules containing calcium sulphate and/or ethylcellulose. 
These were prepared in order to investigate the effect of tertiary components on granule 
compactibility.
3.3.2.1 Design of factorial experiment
A three factor, two level factorially designed experiment was set up to evaluate 
the effect of agglomeration time (factor A), volume of water added (factor B) and drying
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temperature (factor C) on the bulk physical properties of granules. The levels of each 
factor are detailed in table 3.2. The design of the study enabled the maximum 
information to be extracted from the data and reduced the total number of experiments 
needed to obtain the required information. Levels of factor A and factor B were 
determined by preliminary experiments and represented minimum and maximum levels 
achievable. ‘Low’ level of water was the minimum volume of water required to produce 
fine granules while ‘high’ level was the maximum volume of water which could be 
added before the granulation became unworkable. Following ‘low’ agglomeration time, 
added water appeared to be uniformly distributed through the material while ‘high’ 
agglomeration time was the maximum length of time that the wet mass could be mixed 
before mass agglomeration occurred. ‘Low’ temperature drying involved slow 
evaporation of water at room temperature (controlled at 21°C) until the material reached 
equilibrium moisture content (minimum of 48hr). ‘High’ temperature drying achieved a 
more rapid removal of water using elevated temperatures (60°C).
Level
Factor Description Low High
A Agglomeration time (min) 2 8
B Volume of water added (%w/w) 15.9 20.6
C Drying temperature (°C) 21 60
Table 3.2 Factors and levels selected for factorial design
The combination of factors and levels used to process the 8 granule batches is 
shown in table 3.3. The factors and levels were designated symbols traditionally used in 
experimental design with the letters indicating the factor at its highest level (136). For 
example, ab, indicated factors A and B at a high level (+1) and factor C at a low level (- 
1).
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Treatm ent Factor Batch No.
combination A B C
(1) -1 -1 -1 G3A
a +1 -1 -1 G3B
b -1 +1 -1 G3C
ab +1 +1 -1 G3D
c -1 -1 +1 G3E
ac +1 -1 +1 G3F
be -1 +1 +1 G3G
abc +1 +1 +1 G3H
Table 3.3 Treatment combinations used in factorially designed experiment
3.3.2.2 Processing conditions
Processing conditions used to produce the 8 batches of granules in the 
experimental design (batches G3A to G3H) and a further 6 batches, G3I to G3N, are 
described below. The treatment combinations used to produce batches G3I to G3N are 
shown in table 3.4. Batches prepared as part of the experimental design were carried out 
in random order to reduce bias. To look at reproducibility batches G3K and G3L were 
prepared again giving batches G3K(2) and G3L(2).
Dry mixing and wet massing was carried out in a uni speed high shear mixer 
(Cuisine Systeme Automatic 5000, Magimix, Surrey, U.K.). Xanthan gum (25%), locust 
bean gum (25%) and glucose (50%) were dry blended for 5min. Total batch size was 
300g. As high shear mixing was continued the granulating fluid was added over a period 
of one minute. This ensured an essentially constant rate of addition for each experiment. 
A ‘high’ (20.6%w/w) or ‘low’ (15.9%w/w) volume of distilled water was added to 
batches prepared as part of the experimental design (table 3.2). Batch G3K was 
agglomerated using a mixture of distilled water (15.9%w/w) and 2-propanol (19%v/w). 
All other batches were agglomerated with 15.9%w/w water. The total volume of water 
added was maintained constant so that effects due to volume of water available for 
hydration were eliminated (excepts for batches G3B, G3D, G3F and G3H were the effect 
of increased water was specifically examined). For batches G3A to G3H mixing was 
continued for either a ‘high’ (7min) or ‘low’ (lmin) mixing time. For all other batches
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mixing was continued for 7min. Batches G3L, G3N and batches G3A to G3H were tray 
dried. The material was distributed on a tray into an approximately 1 to 2cm thick layer. 
The tray was either placed in an oven (Model 1H-150, size 2 Gallenkamp, 
Loughborough, U.K.) at 60°C for 24hr or left to dry in a temperature controlled room 
(21°C) for 48hr. The drying times selected were sufficient to ensure that the material 
had reached an equilibrium moisture content (approximately 7 to 11% at 21 °C and less 
than 5% at 60°C). Fluid bed drying was used to obtain a higher rate of drying (batches 
G3I, G3J and G3K). This was achieved using a Uniglatt fluid bed drier (Uniglatt, Glatt 
AC, Switzerland) operating at either 60°C or 80°C for between 20 and 30min resulting in 
a LOD of less than 5%. Microwave drying was also used to achieve a rapid drying rate 
(batch G3M). Wet material was dried in batches of approximately 25g using a 750W 
domestic microwave (Type ST22 Proline Micro Chef, U.K.). 15min drying time per 
batch was required to obtain granules with a LOD less than 5%. During microwave 
drying heat was generated due to the high dipolar component of water coupling with the 
high frequency electromagnetic field. To dissipate generated heat and therefore prevent 
charring cold water was placed in the chamber.
Size reduction was carried out either when the material was wet or after it had 
been dried. Batches prepared as part of the experimental design were firstly dried then 
size reduced by passing the dry material though a hammer mill (Type 14-586, Glen 
Creston Ltd., Stanmore, Middlesex, U.K.) fitted with a 3mm screen. Hammer milling 
reduced particle size through high-velocity impact of the hammers against the powder. 
The remaining batches were size reduced using an oscillating granulator (Type MGL 4A, 
Frewitt, Switzerland), which reduced particle size by shear and attrition. Batches G3L 
and G3M were dried then passed through a 0.63pm screen (dry screening). Batches G3I, 
G3J, G3K and G3N were wet screened through a 0.32pm mesh and then dried. The rate 
of oscillation was constant in each case. To maintain a constant particle size the dry 
material was size selected to give granules with a normal size distribution and a 
theoretical median particle size of 182pm. Size selection was important since granule 
particle size can affect porosity (see section 3.4.3), compactibility (137,138) and 
ultimately, release controlling action (6,82). The granules were sieved through an I.S.O 
standard aperture diameter V2 sieve progression ranging from 710pm to 63pm 
(Endecotts Ltd., London, U.K.). The sieves were agitated using a Fritsch sieve shaker 
(Type 03-502, Fritsch, Germany) for 30min. No further change in weight of material 
retained on each sieve occurred when further sieving time was given. Quantities from 
each sieve fraction were selected in the following proportions: 500 to 710pm (2%), 355
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to 500jj,m (4%), 250 to 355*im (26%), 180 to 250^im (36%), 125 to 180pn (26%), 90 to 
125jLLm (3%), 63 to 125jim (2%) and 0 to 63|im (1%). Sieve fractions were recombined 
using turbula rotation (Type T2C, Glen Creston Ltd., Stanmore, Middlesex, U.K.) for 
5min at 50rpm. Moisture contents were determined by loss on drying (LOD) 
measurements. LOD’s were measured using an infrared moisture balance (Type LP16, 
Mettler, Switzerland). At least 5g of material was heated at 70°C until no further weight 









Water Fluid bed dried (60°C) Wet screened G3I
Water Fluid bed dried (80°C) Wet screened G3J
Water/2-propanol Fluid bed dried (80°C) Wet screened G3K
Water Tray dried (60°C) Dry screened G3L
Water Microwave dried Dry screened G3M
Water Tray drying (60°C) Wet screened G3N
Table 3.4 Processing conditions used to prepare granule batches G3I to G3N
3.3.2.3 Preparation of granules containing tertiary components
One Patterson form of HP-based material, TIMERxN, contained 10% calcium 
sulphate and 5% ethylcellulose in addition to locust bean gum, xanthan gum and glucose 
(see Section 1.5.4). Batches of BHP-based granules containing one or more of these 
tertiary components was prepared according to the formulations shown in table 3.5. The 
dry materials were blended as before. Batches G 30 and G3Q were prepared by adding 
26.3%v/w of Surelease™ (an aqueous suspension containing 18.8%w/w ethylcellulose) 
over lmin. The granules were wet screened through a 0.32mm mesh using a mechanical 
granulator and tray dried for 24hr at 60°C. Batches G3N and G3P were agglomerated 
using 15.9%w/w water. The material was wet screened and tray dried for 24hr at 60°C. 
Particle size was standardised as described in section 3.3.2.2.
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Batch No.
Components G3N G 30 G3P G3Q
Xanthan gum (%) 25 25 25 25
Locust bean gum (%) 25 25 25 25
Glucose (%) 50 35 40 45
Calcium sulphate (%) - 10 10 -
Ethylcellulose (%) - 5
- 5
Table 3.5 Formulation of granules containing tertiary components
3.3.3. Standardisation o f granule and tablet moisture content
Under ambient conditions HP-based material retains approximately 4 to 9%w/w 
moisture. This is similar to the behaviour of cellulose ethers, which retain large amounts 
of water in their amorphous portions (137). Nokhodchi et al. (137) found that at any 
compaction speed and at a constant force an increase in the moisture content of HPMC 
K4M resulted in a decrease in porosity of the tablet. The presence of water also 
improved the mechanical properties of the tablet. For these studies it was therefore 
decided to control and standardise the moisture content of HP-based material. This was 
achieved by storing granules and tablets under controlled humidity conditions. A 
saturated solution of magnesium nitrate was prepared by adding an excess of magnesium 
nitrate hexahydrate to approximately 300ml of distilled water and agitating the solution 
overnight using a magnetic stirrer. The solution was prepared at room temperature. 
Sufficient solution was added to a glass chamber to cover the bottom of the vessel with a
2.5 to 5cm layer of solution. Samples of material to be compacted were distributed in a 
fine layer on weighing boats and supported above the saturated solution. The chamber 
was tightly sealed and allowed to equilibrate for at least 48hr at a controlled temperature 
of 21°C. 48hr was found to be the minimum time required for the samples to reach 
equilibrium moisture content. A saturated solution of magnesium nitrate produces an 
atmosphere that has a relative humidity of 55% at 20°C (139). Storage under these 
conditions resulted in material that had a final moisture content in the range 7 to 9%w/w. 
After compaction, tablets were returned to the chamber until further processing.
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3.3.4 Preparation o f tablets
Determination of the general compaction behaviour of each type of material, that 
is, the type of deformation and bonding that was occurring, was important in the 
characterisation of HP-based material. For TIMERxN this was achieved by compacting 
the material over a wide range of compaction forces using 3 different compaction speeds 
and characterising the resulting tablets using mercury porosimetry. For BHP-based 
granules the compaction behaviour of three batches of granules was examined. The 
granules were compacted using a range of compaction settings. To examine the effect of 
tertiary components on compactibility, batches G3N, G30, G3P and G3Q were 
compacted to equivalent relative density (equivalent tablet thickness) and tablet 
mechanical strength was determined.
The second stage in tablet characterisation involved evaluation of the effect of 
initial granule physical structure on final tablet structure. Batches of BHP-based 
granules were (a) into tablets having equivalent relative density and (b) under constant 
applied force and compaction speed. The pore structure of the final tablets was assessed 
using mercury porosimetry. The granules compacted were selected on the basis of their 
physical characteristics and included batches with different pore structures and bulk 
densities. The physical characteristics of the batches chosen is discussed in section 3.4.5. 
The aim was to obtain tablets with largely different pore structures and to identify factors 
that influenced final tablet pore structure.
3.3.4.1 Compaction to equivalent relative density
Tablets compacted to equivalent relative density had the same external tablet 
surface area. To obtain tablets having equivalent relative density, selected batches of 
granules (see Section 3.4.5) were compacted using a single punch tabletting press (Type 
F3, Manesty, Speke, Liverpool, U.K.) fitted with a 10mm flat-faced punch and die set. 
The granules were compacted manually which allowed the weight and tablet thickness to 
be tightly controlled. Accurately weighed pre-conditioned samples (approximately 
400mg) were hand filled into the die cavity and compacted by rotating the fly wheel 
manually. The punch and die were not lubricated. Tablet thickness was measured using 
a digital micrometer (Digit-cal electronic calipers, TESA S.A., Switzerland). The 
distance moved by the upper punch was adjusted so that the final tablet thickness was 
between 4.0 and 4.2mm. This was important since variations in tablet dimensions would
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change tablet porosity. Final tablet weight was recorded. Tablet dimensions were re­
measured prior to further analysis (at least 12hr after compaction).
3.3.4.2 Compaction under controlled compaction force and speed
A compaction simulator (ESH testing Ltd., Machine No. 4287, Brierly Hill, 
U.K.) equipped with a regularly calibrated load cell (lOOkN) was fitted with 10mm flat­
faced F tooling. The die and punches were cleaned with acetone and pre-lubricated prior 
to compaction with a suspension of 1.5% magnesium stearate in acetone. To study the 
compaction properties of TIMERxN, accurately weighed samples (approximately 
438mg) were introduced into the die cavity and compacted using three compaction 
speeds: 0.033mm/s, 3mm/s and lOOmm/s. The distance moved by the upper punch was 
adjusted to produce tablets compacted with target forces of 2, 4, 8, 12, 16 and 24kN. 
Samples were taken from material that had been stored under ambient conditions. The 
LOD of the material was approximately 6%.
B-HP based granules were also compacted under conditions of controlled force 
and speed. A constant weight of approximately 439mg was maintained. Samples that 
had been conditioned at 55%RH for at least 48hr prior to compaction were introduced 
manually into the die cavity. The punch and die set were lubricated as before. Batch 
G3D was compacted at two target compaction forces (8 and 19kN) using target 
compaction speeds of 0.033mm/s, 3mm/s and 100mm/s. Batches G3K and G3L were 
compacted to target forces of 8kN and 19kN using a compaction speed of 3mm/s. 8kN 
was the minimum compaction force which would produce a intact tablet while 19kN was 
selected as an upper limit.
3.3.5 Analysis by mercury porosimetry
Pore structure determinations were made using a Micromeritics Autopore II 
porosimeter (Type 9220, Micromeritics Instruments Co., Georgia, USA). Samples were 
stored over dry silica in a vacuum dessicator for at least 24hr prior to analysis to remove 
adsorbed moisture. Preconditioning in this way was shown not to affect the results 
obtained. Granule samples were analysed using between 3 to 5g of material per run. A 
15ml powder penetrometer with a 0.392ml stem volume was employed and filled with 
mercury using a fill pressure of 68.9kNm2. TIMERxN tablets were analysed using a 5ml 
solid penetrometer (1.131ml stem volume) using between 2 and 5 tablets per run and a 
fill pressure of 3.4kNm2. Tablet batches T3L, T3D and T3K were analysed using a 15ml
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solid penetrometer (1.131ml stem volume) using approximately 8 tablets per run. All 
other tablets were analysed using a 5ml solid penetrometer (0.392ml stem volume) using 
2 to 3 tablets per run and a fill pressure of 3.4kNm2. The penetrometer, fill pressure and 
sample size were carefully selected to ensure that between 10 and 90% of the stem 
volume was used. The surface tension, contact angle and density of mercury at 21°C 
were taken to be 485gcm/s2, 130° and 13.5438g/ml respectively. Pore characteristics 
were calculated from P-V data that was collected from the filling of pores that had 
diameters of 0.02pm or greater. Results from one analysis on each batch of material are 
reported, except in the case of tablet batches detailed in section 3.4.5 were the mean of 
two determinations is given. Mercury porosimetry was used to characterise; (a) granule 
batches G3A to G3N, G3K (2), G3L(2); (b) TIMERxN granules; (c) tablets compacted 
from TIMERxN using different compaction speeds and forces; (d) tablets compacted 
from selected batches of BHP-based granules; (e) sieve fractions of batch G3G collected 
during size separation. This was carried out to assess whether granules having different 
particle sizes had different pore structures.
3.3.6 Characterisation o f the particle size, bulk density and flow properties o f  
TIMERxN and BHP-based granules.
A knowledge of the particulate characteristics of the powders compacted was 
important in understanding volume reduction behaviour. The particle size of TIMERxN 
was determined by sieve analysis. 300g of TIMERxN was passed through an I.S.O 
standard aperture diameter V2 sieve progression ranging from 710pm to 63pm as 
described in section 3.3.2.2. The weight collected in each sieve fraction was recorded. 
A cumulative percentage undersize plot was constructed and the first, second and third 
interquartile points were determined. A cumulative percentage undersize plot was also 
constructed for BHP-based granules using the weights selected from each sieve fraction. 
The interquartile coefficient of skewness (IQCS) was calculated using equation 3.1:
/ecs=M M
(c -  a) + (a -  b) (3.1)
Where a, b and c were the second, first and third interquartile points, respectively.
Before determining bulk density the materials were firstly stirred to redistribute 
the particles. Between 2 and 4g of material was accurately weighed and slowly poured
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into a graduated 10ml measuring cylinder. Care was taken to prevent agitation of the 
cylinder and consolidation of the particles. The volume of the sample was recorded. 
Bulk density was determined by dividing the weight of the sample by its volume. A 
mean of three determinations was recorded. Tapped density of the materials was found 
using a jolting volumeter (STAV 2003 JEL, Germany). The sample was tapped 300 
times which was found to be sufficient agitation to obtain a maximum change in volume. 
The new volume was recorded.
3.3.7 Determination o f tablet hardness and mechanical strength
Values of tablet mechanical strength were used as a measure of the effect of 
tertiary components on granule compactibility. A 1mm stainless probe was attached to a 
texture analyser (Type TA-XT2, Stable Microsystems, Surrey, England) that was fitted 
with a 50kg load cell. The tablet to be tested was placed underneath the probe, which 
was lowered at a speed of l.Omm/s. The force (kN) generated as the probe penetrated 
the tablet was measured as a function of the distance moved by the probe (mm). The 
area under the curve between the minimum and maximum forces reached was calculated, 
which gave the work of failure. Six determinations on each batch were made and the 
mean value and standard deviation about the mean calculated.
Tablet crushing strengths were determined from the force required to fracture 
tablets by diametral compression on a motorised tablet hardness tester (Model 2E, 
Schleuniger, Switzerland). The mean value of six determinations is presented along with 
the standard deviation about the mean.
3.3.8 Scanning electron microscopy
Granules were scatted onto adhesive, conductive mounting discs. A layer of gold 
was deposited onto the sample surface using a sputter coater (Edwards high vacuum, 
Model S150B, Sussex, U.K.) running at a voltage of 1.4Kv for 8min. Samples were 
imaged with a scanning electron microscope (Jeol T6310, Japanese Electron Optics Ltd., 
Tokyo, Japan) using an electron bean potential of 5keV.
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3.4 Results and discussion
3.4.1 Effect o f processing parameters on the bulk physical properties o f BHP-based 
granules
The results from the experimental design were analysed to determine significant 
and non-significant processing effects on granule characteristics. The information 
obtained from this was collated with information obtained from the analysis of batches 
G3I to G3N. The general characteristics of the granules were considered and parameters 
that appeared to affect physical characteristics evaluated.
3.4.1.1 Determination of significant effects
The responses of specific pore area, median pore diameter (of pores down to 
0.9jim), bulk density and pore volume were selected for statistical analysis. The median 
pore diameter of pores having diameters 0.9)im and greater was chosen as a response. 
This was because visual examination of incremental intrusion plots showed that different 
methods of processing mainly affected larger pores. Table 3.6 shows the results (or 
yields) obtained for each response and for each treatment combination. A mean estimate 
of every effect on these physical characteristics was determined using the Yates 
technique, described recently by Davies (136). The data was first tabulated in standard 
order (see appendix II). The first and second yields (y<i) and y(a>) were added and the 
sum entered as the first entry in column I. The third and fourth yields were added to 
obtain the second entry in column II. This was continued until the sum of all the pairs 
was obtained. The first yield was then subtracted from the second yield to obtain the 
fifth entry in column I. This was continued until the difference between all the pairs was 
obtained. The addition and subtraction process was repeated sequentially on n columns 
(n=3 for experiments with three factors). The first entry in column III gives the total of 
all the yields in the trial. The remaining entries gave the total effect for the main effects 
and interactions. The Yates technique was applied to the yields obtained for each of the 
four responses. For this 2 factorial design 4 estimates of every effect were obtained, 
therefore to calculate the magnitude of the effect the final value was divided by four. 
Table 3.7 gives the effect of each factor, or combinations of factors, for each of the 
chosen responses (porosity, pore area, median pore diameter and bulk density). Pi, a 
measure of the probability of the effect occurring, was calculated using equation 3.2.
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Where i = ith effect 1, 2, 3...etc.
When the effects in order of increasing magnitude were plotted on a probability 
scale, from the most negative to the most positive, against P* on a linear scale, an idea of 
effects that were possibly statistically significant was obtained (136). Figures 3.1, 3.2,
3.3 and 3.4 show Yates plots for porosity, median pore diameter, pore area and bulk 
density, respectively. Effects that were merely random were expected to fall on a 
straight line, the effects that fell off it were possibly real and were examined further. The 
linearity of figure 3.1 indicated that changes in porosity were random and could not be 
attributed to any one factor or combination of factors. The deviation from linearity of 
point C on figure 3.2 indicated that using a lower drying temperature (factor C) might 
have significantly changed the median pore diameter of the granules. Drying 
temperature also appeared to affect pore area (figure 3.3) while factors A and C appeared 
to affect bulk density (figure 3.4). To determine the statistical significance of the effects 















(1) 0.448 3.10 5.85 0.54 G3A
a 0.486 3.14 4.22 0.56 G3B
b 0.819 3.38 6.12 0.54 G3C
ab 0.498 2.93 5.67 0.62 G3D
c 0.886 1.90 10.11 0.55 G3E
ac 0.833 1.75 10.36 0.63 G3F
be 0.774 2.56 4.20 0.58 G3G
abc 0.819 1.79 6.12 0.62 G3H














a -0.0857 -0.333 0.532 0.055
b 0.0512 0.191 -1.597 0.020
ab -0.0782 -0.276 1.222 0.005
c 0.2522 -1.138 2.742 0.030
ac 0.0557 -0.126 1.572 0.005
be -0.1402 0.158 -2.457 -0.010
abc 0.1012 -0.033 0.632 -0.025
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Figure 3.2 Identifcation of possible significant effects 
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Figure 3.4 Identifaction of possible significant effects 
on bulk density
The sum of squares for the main effects and interactions was obtained by 
squaring the effect total and dividing this square by the number of observations in the 
experiment (ie, 8). When the sum of squares was divided by the appropriate degrees of 
freedom the corresponding variance of mean square s2 was obtained. This divided the 
total variance of the results into the seven effects. Since the experiment was unreplicated 
each effect had one degree of freedom and the mean squares was equal to the sum of 
squares. To carry out an F test some effect or effects from the seven was required as an 
estimate of the error variance. The most satisfactory method would have involved 
running the experiment with replicates. However, this would have resulted in an 
excessively large number of experiments. In the absence of replication the experimental 
error was estimated by pooling the mean squares from higher order interactions. The 
two-way interactions AB, BC and AC, and the three-way interaction ABC were pooled. 
The ratio of the two variances was calculated using the error variance as the denominator 
and the observed values were compared to F tables at the 5% and 1% levels. Results 
from the analysis of variance on pore diameter data are presented in table 3.8. 
Comparing the experimental F values with F tables, Fc was significant (etc <0.01) when 
df = 1,4. This meant that a high drying temperature (factor C) significantly decreased the 
median diameter of the larger pores. No other effects were significant. Analysis of
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variance on bulk density data showed that factor A significantly affected bulk density 
when etc <0.05 and d.f. = 1,4. Pore area and porosity were not found to be significantly 
affected by any factor or combinations of factors.
Factor d .f Mean square r
A 1 0.2220 3.74
B 1 0.0731 1.23
AB 1 0.1526




Table 3.8 ANOVA table for median pore diameter data
aError mean square based on AB, BC, AC and ABC interactions, 4 d.f
*a<0.01
3.4.1.2 Effect o f granulation conditions on bulk physical characteristics o f BHP-based 
granules
The bulk physical characteristics of granule batches G3A through to G3H and of
batches G3I to G3N are detailed in tables 3.5 and 3.9, respectively. By changing the
process conditions used to produce the granules, porosity could be varied between 3.23 
and 11.14%. Overall, the variation in porosity achieved was relatively low compared 
with variations in porosity that has been obtained for other pharmaceutical excipients. 
By using different granulating techniques Wikberg and Alderbom (129) produced 
lactose granules that had porosity values ranging between 11.6 and 31.3%. Similarly, 
Sheskey et al. (118), using wet granulation techniques, produced HPMC granules that 
had substantially different pore volumes. The small variations in porosity observed for 
BHP-based granules could firstly be attributed to the presence of glucose in the 
formulation. Glucose is highly soluble in water (1:1) (139) and during wet granulation 
small glucose particles and the surface of large glucose particles can dissolve and 
recrystallise as glucose monohydrate (132). It has been shown that during wet
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granulation of glucose, partly dissolved particles bond to each other through solid 
bridges formed during recrysallisation, producing granules that have low porosity (4 to 
1%) (132). During wet granulation of XG, LBG and glucose a similar effect is likely to 
occur. Dissolved glucose is likely to form solid bridges with other glucose particles and 
with HP components resulting in the formation of very dense granules with low porosity. 
Pore diameters of BHP-based granules were much smaller than pore diameters that have 
been quoted for lactose granules (117,140). This again reflects the dense closed pore 
network that is formed.
Neither the volume of water added nor agglomeration time significantly affected 
any of the pore parameters measured. Increased moisture and increased agglomeration 
time had been expected to decrease granule porosity by affecting granule growth and 
densification. According to granulation theory, reviewed by Augsburger and Vappalla
(141), low levels of moisture produce granules that consist of moist particles held 
together by liquid bridges in a pendular state. The pendular state refers to a situation 
were the water forms discrete lens shaped rings at points of contact. As more liquid is 
added nuclei agglomerate to the funicular state and coalescence of granules can occur. 
In the funicular state rings of water coalesce to form a continuous network of liquid 
interspersed with air. The action of the mixer brings the particles closer together so that 
internal pore space in the aggregates is reduced. Addition of a ‘low’ level of water to the 
dry blend produced nonspherical granules that were soft in texture, had a ‘dry’ surface, 
were light in colour and appeared to have a low density. Under these conditions the 
granules were probably in the pendular state. After the addition of a ‘high’ level of water 
granules were more spherical, firmer and denser in colour and in texture than at the ‘low’ 
level of addition. Coalescence of granules was observed probably due to increased 
plasticity imparted by the higher moisture content. As mixing was continued at the 
‘high’ level of addition further coalescence occurred. However, despite the fact that 
material agglomerated with a ‘high’ volume of water differed visually in texture from 
that agglomerated with less water, no correlation was observed between volume of water 
added and/or mixing time and the final porosity of the dry material. The relationship 
between granule pore structure and amount of granulating liquid has also been studied 
for lactose and HPMC. Sheskey et al. (118) reported that the porosity and median pore 
diameter of HMPC decreased with an increased amount of granulating liquid (118). 
Tapper and Lindberg (130) and Jaegerskou et a l (140) found that the porosity of lactose 
granules decreased with increasing volumes of water added. Wikberg and Alderbom
(142) however, did not find a correlation between porosity and volume of granulating
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liquid added in lactose granulates. If final porosity was a function of densification 
during wet massing, screening and drying then this might account for the discrepancy in 
the results. In the case of BHP-based granules, final pore structure may not have been 
affected by mixing time and volume of granulating liquid because; (a) the effect of the 
hammer mill on the dry granules may have obscured any effects due to volume of water 
added and/or mixing time; (b) maximum densification may already have been reached at 
‘low’ volume and ‘low’ mixing. Further addition of water and increased mixing may 
simply have produced aggregates of granules that were subsequently broken down 
during dry screening. Mixing time significantly (p<0.05) increased bulk density possibly 
due to rounding and smoothing of the particles over time.
The granules that were most porous were obtained when the components were 
granulated with an alcohol/water mix and dried rapidly by fluid bed drying. This could 
be due to reduced densification as a result of the surface tension of the granulating liquid. 
Wells and Walker (143) showed that the surface tension of a binding solution decreased 
as the proportion of alcohol in the solution was increased. Ritala et al. (144) found that 
the densification of dicalcium phosphate was greatest when the binding solution had a 
high surface tension. Increasing surface tension was thought to facilitate densification by 
increasing liquid bonding strength. As surface tension of the binding solution increased 
the agglomerates became stronger and more cohesive resulting in granules which had 
low porosity values. Wikberg and Alderbom (129) showed that the addition of alcohol 
increased the porosity of lactose granules.
The least porous material was batch G3L (3.23%). The processing condition 
likely to have caused this was the dry screening step. Dry screening was achieved using 
an oscillating granulator that reduced particle size through shear and attrition. This 
possibly resulted in breakage across granules rather that between granules. The abrasive 
action might also have smoothed the surface of the dry dense HP-based material 
producing granules with a relatively even and solid surface and a correspondingly low 
porosity.
Batches prepared as part of the experimental design were dried and then 
screened. For batches G3I, G3J, G3K and G3N, size reduction was the penultimate step 
while the final step was drying. The order of processing was considered relevant since 
the final granule pore structure was possibly a function of wet mixing, screening and 
drying. It was feasible that the effect of one step on pore structure may have been 
obscured by the effect of a subsequent step. It was considered that the effect of any one 
factor should be considered in relation to the order of processing steps. This was
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relevant when considering the effects of drying temperature and drying method. In the 
experimental design drying temperature was found to significantly (oc<0.01) change the 
median pore diameter of the larger pores. At the higher drying temperature a decrease in 
pore diameter was observed. Batches G3I to G3N were dried using a number of 
different drying methods. The batches that were dried most rapidly were batch G3M 
(microwave dried), batch G3I (fluid bed dried at a high temperature) and batch G3K 
(contained alcohol in the granulating fluid, which increased the evaporation rate giving a 
high rate of drying). Examination of the data in table 3.9 shows that these batches were 
associated with relatively high median pore diameters. The conclusion that rapid drying 
produced granules having a higher median pore diameter was not in agreement with 
observations made from the factorially designed experiment where higher temperatures 
decreased median pore diameter. The differences between effects of drying may have 
been due to the order of processing. In the experimental design a variable introduced as 
a consequence of drying temperature was the final moisture content of the material. 
Batches dried at the high temperature contained less moisture after drying (less than 5%) 
than batches which had come to equilibrium moisture content under ambient conditions 
(7 to 11%). This may have affected the subsequent size reduction step. Hammer mills 
reduce particle size through high-velocity impact between rapidly moving hammers and 
the material particles. The dryness of the granules and the feed rate are important 
variables relative to the material (145). Drier granules were possibly more brittle and 
may have under gone greater attrition in the mill than granules containing a higher 
content of water. Water can act as a plasticiser in pharmaceutical excipients (137) and 
may have promoted plastic and elastic deformation during milling. In batches where 
drying preceded size reduction the observed changes in median pore diameter were 
probably due to the drying process itself rather than as a secondary effect to final 
moisture content. Drying rate may have been particularly important in these batches 
because of the presence of the water-soluble component glucose. It is possible that 
dissolution of glucose occurred during the early stages of drying as well as during wet 
massing. As water evaporates during drying glucose will recrystallise and the rate of 
drying may affect the degree of crystallisation. At slow drying rates larger crystals may 
develop while with faster drying rates smaller crystals are likely to be formed (132). 
Median pore diameters appeared to be larger when the rate of drying was faster. From 
incremental intrusion plots it could be seen that intermediate sized pores (0.9 to 0.1 J im )  
were predominately affected by drying rates. With faster drying rates and the formation
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of small crystals a more open network may have been formed producing a higher 
proportion of intermediate sized pores.
Batches with bulk densities ranging from 0.44 to 0.62g/cm were obtained. The 
variation between multiple measurements was no greater than 0.02g/cm3. High bulk 
densities were associated with a high agglomeration time. However, it was difficult to 
correlate any other factors or combination of factors to changes in bulk density. This 
may be because bulk density was affected by many particle characteristics including 
shape and apparent density.









G3I 0.840 1.79 4.64 0.47
G3J 0.674 2.25 5.97 0.47
G3K 0.855 2.72 11.14 0.53
G3L 0.401 2.01 3.40 0.52
G3M 0.498 2.86 5.54 0.44
G3N 0.482 2.13 4.33 0.45
Table 3.9 Physical characteristics of batches G3I to G3N.
3.4.2 Reproducibility o f granule batches
To thoroughly examine the effect of process variables on granule pore structure it 
would have been necessary to prepare more than one batch of granules under each set of 
processing conditions. However, this was not feasible due to the large number of 
batches involved. To ensure that the changes in pore parameter due to changes, in 
processing conditions were not simply random, two batches were produced under similar 
conditions as previously. The pore characteristics of each batch of granules were very 
similar (table 3.10), which indicated that batches having high and low porosity could be 
reproduced. This gave confidence that the differences observed were not accidental. 
Average pore diameter was used in place of median pore diameter since this took into 
account both the volume and number of pores and therefore was a useful parameter for
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comparative purposes. These batches were prepared using different lots of raw material 
from that used in previous batches. The particle size, density and moisture content of 




G3K G3K(2) G3L G3L(2)
Specific pore area (m2/g) 0.851 0.749 0.401 0.426
Average pore diameter (pm) 0.444 0.426 0.233 0.249
Pore volume (%) 11.14 10.60 3.40 3.81
Table 3.10 Reproducibility of granule batches
3.4.3 Effect o f particle size on pore structure
The results of mercury porosimetry analysis on sieve fractions of batch G3G are 
shown in table 3.11. Data in the last row came from granules that had been size selected 
and therefore consisted of particles having a wide size distribution. Examination of the 
data showed that the specific pore area of the granules increased as particle size 
increased, median pore diameter decreased with increasing particle size while porosity 
values remained similar within each size range. Granules that included particles taken 
from each of the sieve fractions had intermediate values of each pore parameter. To 
examine the data more thoroughly the characteristics of pores within 3 different pore size 
ranges was calculated. Tables 3.12 to 3.14 details the characteristics of pores within 
different pore diameter ranges for each of the sieve fractions. It can be seen that smaller 
pores contributed to the majority of specific pore area (table 3.12). The volume of pores 
(table 3.13) in the pore diameter range 0.2 to 0.02pm for particles with a size range of 
355 to 500pm was more than double that for particles in the size range 125 to 180pm 
(table 3.13). This accounted for the observed increase in specific pore area with 
increasing particle size. Table 3.13 shows that the volume of large pores (>0.9pm) 
tended to decrease with increasing particle size while the volume of smaller pores (0.9 to 
0.2pm and 0.2 to 0.02pm) increased. The net outcome was a minimal change in total
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porosity but a shift in median pore diameter towards lower values. Overall, granules 
with a smaller particle size had a greater proportion of larger pores and a smaller 
proportion of smaller pores. The general conclusion was that for any batch of granules 
measured pore characteristics can vary depending on the particle size of the granules 
analysed. Therefore, when deciding whether or not a process variable affects the actual 
pore structure of the granules particle size should be considered. This is important since 
changes in process variables may also change the particle size distribution. For example, 
Sheskey and Williams (118) reported that the median pore diameter of Methocel K4M 
granules increased as the volume of granulating liquid was increased. An increase in 
granulating fluid added was also associated with a substantial increase in particle size, 
which could also cause an increase in pore diameter. Size selection of HP-based material 
prior to analysis ensured that changes in pore structure were not a consequence of 




Specific pore area 
(m2/g)
Median pore 
diameter ( |L im )
Porosity
(%)
125 to 180 0.425 2.01 4.72
180 to 250 0.626 1.75 4.12
250 to 355 0.743 1.55 4.47
355 to 500 0.924 1.15 4.87
0 to 710 0.783 1.32 4.21
Table 3.11 Pore characteristics of different particle size fractions of batch G3G
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Pore diameter range (pm)
Sieve fraction (pm) >0.9 0.9 to 0.2 0.2 to 0.02
125 to 180 0.049 0.046 0.334
180 to 250 0.032 0.042 0.567
250 to 355 0.035 0.052 0.660
355 to 500 0.033 0.067 0.830
0 to 710 0.033 0.051 0.703
Table 3.12 Specific pore area of sieve fractions of batch G3G
Pore diameter range (pm)
Sieve fraction (pm) >0.9 0.9 to 0.2 0.2 to 0.02
125 to 180 3.58 0.68 0.48
180 to 250 2.65 0.63 0.83
250 to 355 2.70 0.71 1.03
355 to 500 2.56 0.90 1.37
0 to 710 2.44 0.70 1.06
Table 3.13 Porosity of sieve fractions of batch G3G
Pore diameter range (jim)
Sieve fraction (pm) >0.9 0.9 to 0.2 0.2 to 0.02
125 to 180 2.60 0.55 0.047
180 to 250 2.92 0.50 0.045
250 to 355 2.72 0.46 0.053
355 to 500 2.77 0.49 0.057
0 to 710 2.54 0.47 0.049
Table 3.14 Median pore diameter of sieve fractions of batch G3G
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3.4.4 Characterisation o f  the compaction behaviour o f TIM ERxN and BHP-based
granules
3.4.4.1 Compaction behaviour of TIMERxN
The variation in porosity of TIMERxN tablets as a function of compaction force 
at 3 different compaction speeds is shown in figure 3.5. Mean compaction forces 
achieved did not differ from the target force by more than 10%. The variation from the 
mean force was not more than 0.4kN for forces less than 4kN and not more than 1.4kN 
for tablets compacted at forces greater than 4kN. Porosity decreased as the compaction 
pressure was increased. The reduction in porosity was dependent on the velocity of the 
upper punch. Compaction at low speed (0.033mm/s) produced a tablet that had a lower 
porosity than tablets compacted at a higher speed (lOOmm/s) when a similar compaction 
force was applied in each case. In order to understand the effect of compaction speed on 
porosity the sequence of events that occurs during a compaction process must be 
considered. When a force is applied on a powder or granule bed, a number of 
mechanisms become involved in the transformation of the loose particles into a porous, 
coherent compact. The compaction process, reviewed by Nystrom (146), can be 
described by a number of sequential phases. Initially, the particles in the die rearrange to 
give a closer packing structure. At a certain load, the packing characteristics of the 
particles or interparticulate friction between the particles prevent any further 
interparticulate movement. The subsequent reduction of compact volume is 
accompanied by reversible (elastic) deformation and irreversible (plastic) deformation of 
the whole or part of a particle. The degree of irreversible and reversible deformation can 
be characterised by the viscoelastcity of the material (147). For many materials 
fragmentation of particles also occurs (146). When the applied pressure is further 
increased the particle fragments can rearrange to form new positions and can also 
undergo deformation, which can further decrease compact volume. As a consequence of 
the compression of a powder, particle surfaces are brought into close proximity to each 
other and can form bonds. Intermolecular bonding (van der Waals forces, electrostatic 
forces and hydrogen bonding) constitutes the dominating bond mechanism for 
pharmaceutical materials (146). When the applied force is removed relaxation of the 
material occurs and the compact is ejected from the die. The actual porous structure is 
formed because of stress relaxation phenomena. Stress relaxation can be defined as the 
relative increase in volume after compression and occurs because the elastic component 
of the material can store mechanical energy when a stress is applied and release it when
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the stress is removed (147). When TIMERxN was compacted at low compaction speeds 
the amount of stress relaxation relative to the creation of stress was high. After 
compaction, the newly formed tablet contained low internal stresses therefore the 
increase in volume was low which resulted in a lower porosity. In contrast, at high 
compaction speeds stress relaxation during compression was lower, so immediately after 
upper punch release the tablet still contained a lot of internal stress, which resulted in 
tablets having higher porosities. The fact that tabletting speed affected the consolidation 
behaviour of TIMERxN was a function of the viscoelasticity of the material (147). At 
low compaction speeds the viscous component dominated, which resulted in irreversible 
deformation while the elastic component was relatively unimportant due to stress 
relaxation. At higher compaction speeds the elastic component dominated total rigidity, 
which resulted in a considerable volume increase after compression. The final porosity 
of the tablet was the result of a balance between viscosity and elasticity (i.e irreversible 
and reversible deformation). TIMERxN can be described as strain-rate sensitive since it 
shows time-dependent deformation (148). This suggests that it deforms by plastic flow. 
Substances that consolidate principally by fragmentation show relatively little velocity 
dependence (148). SEM’s of the upper surface of TIMERxN tablets supported the 
theory of plastic deformation. Figures 3.6 (a) to (c) show the surface of TIMERxN 
tablets compacted at different compaction forces using a speed of 3mm/s. Marked 
changes in the surface of the tablet occurred as the compaction force was increased. At 
low compaction pressures discrete granules could be identified. As the compaction 
pressure was increased the primary particles became fused so that boundaries became 
undetectable. The high plasticity of the material facilitated the formation of permanent 
particle-particle contact regions.
The change in median pore diameter of TIMERxN tablets as a function of 
compaction force is shown in figure 3.7. As expected, median pore diameter tended to 
decrease with increasing compaction force. Higher compaction speeds generally resulted 
in tablets having larger median diameters. Since median pore diameter gives only 
limited information on pore size distributions (see section 2.4.1.4), incremental intrusion 
plots were also examined. Figure 3.8 shows incremental intrusion plots for TIMERxN 
tablets compacted using forces of 4, 8 and 24kN. It can be clearly seen that as 
compaction force was increased the pore size distribution shifted towards smaller pores. 
Volume reduction occurred largely through reduction in size of larger pores while the 
smaller pores were less affected. This is characteristic of plastic deformation (149). For 
materials that deform mainly by fragmentation, porosimetry data would be expected to
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show the existence of new populations of pores rather than a shift in existing pore size 
distribution. The shift in pore size distribution was also well illustrated by plotting the 
first, second and third incremental points from the cumulative intrusion plot (figure 3.9). 
This clearly identified the pores that disappeared when a force was applied.
The change in pore area of TIMERxN tablets with increasing compaction force is 
shown in figure 3.10. A trend of decreasing pore area with increasing compaction force 
was observed. This was likely to be due to plastic deformation and to a general decrease 
in pore volume. Pore areas were higher in tablets compacted at the higher compaction 
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Figure 3.5 Variation of porosity of TIMERxN tablets 




Figure 3.6 Scanning electron micrographs of TIMERxN tablets compacted using a 
speed of 3mm/s and compaction forces of (a) 2kN (b) 8kN and 24kN
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Figure 3.7 Variation of median pore diameter of TIMERxN 
tablets with compaction force and speed
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Figure 3.8 Incremental intrusion into TIMERxN tablets 
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Figure 3.10 Variation of specific pore area of 
TIMERxN tablets with compaction force and speed
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3A.4.2 Compaction behaviour ofBHP-based granules
BHP-based granules compacted very differently to TIMERxN. Table 3.15 shows 
the pore characteristics of tablets that were compacted from granule batch G3D. The 
granules were compacted using two compaction speeds to two target forces: high (19kN) 
and low (8kN). Actual mean forces reached ranged between 18.9 and 19.0 (maximum 
standard deviation from mean values was 1.3kN) for the ‘high’ force and 8.0 to 8.2kN 
(maximum standard deviation from mean values 0.25kN) for the ‘low’ force. Large 
differences in applied force and compaction speed produced only small variations in 
tablet porosity and median pore diameter. Similar observations were made for batches 
G3L and G3K (tables 3.16 and 3.17). Compaction forces less than 8kN and a faster 
compaction speed (lOOmm/s) failed to produce intact tablets. This high resistance to 
deformation was in contrast to TIMERxN, which compacted easily under a wide ranges 
of tabletting conditions. It was considered that the differences could be due to the 
excipient composition of each material and/or material physical characteristics. 
TIMERxN and BHP-based granules both contained 50% heterodisperse polysaccharides 
and a large proportion of glucose. However, TIMERxN also contained the tertiary 
components calcium sulphate and ethylcellulose. It was considered that the presence of 
ethylcellulose might have improved compactibility by promoting plastic deformation 
(126). To evaluate this, the compactibility of batches ofBHP-based granules containing 
none, one or both of these tertiary components was studied using tablet mechanical 
strength as a measure of compactibility (see section 3.3.7). The presence of 
ethylcellulose and/or calcium sulphate in the granules was found to result in only a minor 
increase in diametric crushing strength and visual observations suggested that the 
presence of tertiary components did not substantially improve the compactibility of 
BHP-based granules. Therefore, to try and account for the difference in compactibility 
between these two materials the physical characteristics of batch G3D and TIMERxN 
were considered. Table 3.18 summarises some of these characteristics. It was noted that 
batch G3D had a larger median particle size than TIMERxN. The particle size in each 
case followed a normal distribution. Although the degree of deformation or 
compactibility in relationship to particle size is not fully understood (126), it is thought 
that a reduction in particle size reduces the effect of the rate of compaction on the 
relationship between tablet porosity and applied compaction pressure (150). This can be 
interpreted as a reduced viscoelasticity of particles with a reduced particle size and may 
explain why BHP-based granules could not be compacted into intact tablets at high 
compaction speeds. However, the differences in particle size between the batches was
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not considerable and was unlikely to account for the large difference in compaction 
behaviour. The substantial difference in porosity between the two materials was 
considered to be the key to differences in compactibility. TIMERxN particles had a 
relatively high porosity (19.7%) while batch G3D had a relatively low porosity (5.7%). 
As previously discussed, wet granulation of the dry blend probably contributed to the 
formation of dense, low porosity granules through partial dissolution of the glucose 
component. The high resistance to deformation of BHP-based granules under an applied 
load granules was likely to be a consequence of the high granule strength of the material 
due to recrysallisation of dissolved glucose and the formation of solid bridges. This 
meant that the breaking of such a dense structure required the application of very high 
pressures. Therefore, the granules probably deformed plastically at their contact points 
rather than fragmenting to a large extent. The compaction of glucose granules has been 
studied by Juppo (133) who reported that glucose granules were more resistant to 
densification than either mannitol or lactose and attributed this to the strength of the 
glucose granules. TIMERxN possibly had a higher porosity because the components are 
agglomerated using an alcoholic slurry containing ethylcellulose. In the absence of 
water minimal dissolution of glucose would occur resulting in less crystalline, more 
porous granules. For porous particles it is thought that repositioning of the primary 
particles constituting the granule can occur under an applied load resulting in granule 
deformation (i.e, a change in granule shape) (126). For TIMERxN this might account for 
the degree of plastic deformation that was observed. For BHP-based granules, low 
porosity and a likely high granule strength meant that deformation within granules was 
difficult to achieve even under high applied force. From studies on the compaction 
behaviour of lactose and dipentum granules Wikberg and Alderbom (129,142) suggested 
that the degree of deformation that granules undergo during compaction is governed by 
the original granule porosity. A reduced granule porosity was thought to reduce the void 
space between the particles and hence increase the bonding force of the interparticulate 
attraction. However, although porosity difference may partly explain the difference in 
compactibility between TIMERxN and BHP-based granules the data presented in section
3.3.4 suggested that within different batches of BHP-based granules differences in 






Porosity (%) Median pore 
diameter (pm)
3 8 7.94 1.65
0.033 8 7.35 1.68
3 19 6.57 1.84
0.033 19 6.15 1.91
Tables 3.15 Variation in porosity and median pore diameter of tablet batch T3D with 
compaction force and speed
Porosity (%)
Compaction force (kN) T3L T3K
8 7.94 6.57
19 7.35 6.15
Table 3.16 Variation in porosity of tablet batches T3L and T3K with compaction force
Median pore diameter (pm)
Compaction force (kN) T3L T3K
8 1.85 2.06
19 1.73 2.12
Table 3.17 Variation in median pore diameter of tablet batches T3L and T3K with 
compaction force
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Characteristic TIMERxN Granules G3D
Porosity (%) 19.30 5.67
LOD (%) 5.7 7 to 9
Particle size (pm) 98 184
Median pore diameter (pm) 0.39 2.22
Bulk density (g/cm2) 0.77 0.62
Table 3.18 Some physical characteristics of TIMERxN and granule batch G3D
Incremental intrusion into granule batch G3D and into tablets compacted from 
G3D is shown in figure 3.11. The pore size distribution of the tablets was essentially 
bimodal with the larger pores being predominantly intergranular pores and the smaller 
pores arising from both inter- and intragranular pores. The absence of new populations 
of smaller pores suggested that the material did not fragment to a large extent. Table 
3.16 shows that the median pore diameter of the tablets did not substantially change as 
compaction force was increased. The median pore diameter of all tablets compacted 
from G3D was smaller that that of the granules themselves (2.22pm) although 
incremental intrusion plots clearly showed that the greater proportion by volume of pores 
generated during compaction had pore diameters larger than 2pm. The lower median 
pore diameter of the tables probably reflects the fact that a large number of smaller pores 
were formed as a result of compaction although this was not clear from intrusion plots. 
Therefore, some degree of fragmentation was probably occurring. Fragmentation during 
compaction is often identified using surface area values determined from air permeability 
measurements (128,129). Quantitative values for pore area derived from mercury 
porosimetry data are not ideal for characterising the volume reduction behaviour of HP- 
based granules. Pore area values from mercury porosimetry are biased towards very 
small pores and the existence of structural hysteresis may largely influence the values 
obtained. Difficulties in obtaining consistent values of specific pore area for HP-based 
tablets probably reflects these problems (see section 3.4.5) Values obtained from air 
permeability measurements relate more to overall pore size distributions which makes 
the technique more suitable for analysing volume reduction behaviour (129).
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The difference between the compaction behaviour of TIMERxN and BHP-based 
granules illustrated the fact that compaction behaviour was a function of both the 
inherent properties of the material and its physical form. The compaction mechanism of 
TIMERxN was relatively easy to define. The material was viscoelastic and under an 
applied load deformed both plastically and elastically. A degree of fragmentation 
possibly occurred since this is common to most pharmaceutical excipients. The 
compaction behaviour for TIMERxN was similar to that reported for xanthan gum (29) 
and HPMC (137). Classification of the compaction mechanism of BHP-based granules 
was more difficult since the material was very resistant to densification. A high applied 
load possibly resulted in some granule repositioning but since the granules were 
relatively coarse this was likely to have resulted in a small contribution to total porosity 
reduction. As a consequence, irreversible changes in the physical characteristics of 
granules possibly constituted the major part of the volume reduction process. This 
probably consisted of a small amount of fragmentation along with plastic deformation of 
the granules themselves at points of contact. The poor compactibility of BHP-based 
granules limited the range of tablet thicknesses that could be obtained. In contrast, 
TIMERxN could be used to obtain tablets having a wide range of tablet thicknesses.
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Figure 3.11 Incremental intrusion into granule batch G3D and 
into tablets compacted from the granules
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3.4.5 Effect o f initial granule characteristics on tablet pore structure
A number of granule batches having a range of physical characteristics were 
selected for compaction studies (table 3.19). These batches were selected for 
compaction studies because they had a range of physical characteristics. Granule batch 
G3K(2) had a high porosity (10.6%) while batch G3L(2) had a low porosity (3.8%). 
Batch G3J was selected because it was a batch with intermediate porosity (6.77%) and 
had a relatively large median pore diameter (3.09|im). The compaction of batch G3E 
was studied because its porosity was similar to G3J but it had a much lower median pore 
diameter. Batches with high and low bulk density were represented by batches G3D and 
G3N, respectively. Table 3.20 shows that compaction of these granules produced tablets 
that had different porosities and median pore diameters. A range of porosities from 
18.6% down to 9.8% was observed. Considering the fact that the tablets were only 
between 4.0 and 4.2mm in thickness this was a notable difference in porosity. Initial 
granule characteristics obviously dictated the pore structure of the resulting tablets. This 
situation is not always observed. With some materials profound differences in tablet 
properties have been found to be largely obscured after compaction (128,131,143,151). 
It is possible that granules with a lower mechanical strength will lose much of their pore 
structure under applied loads, while stronger granules will exert a greater influence on 
final tablet structure. No correlation was observed between the initial median pore 
diameter or porosity of BHP-based granules and the median pore diameter and porosity 
values of the final tablets. This observation was in contrast to that made by Wikberg 
(134) who found that an increased porosity of lactose and dipentum granules before 
compaction promoted the formation of a more closed tablet pore structure. This effect of 
porosity on deformation is probably not seen in BHP-based granules because the 
resistance to densification in both high and low porosity batches is very high. It is 
possible that the granules had reached a threshold strength below and above which 
variations in granule porosity did not affect compaction behaviour. Therefore granule 
strength might play a part in dictating the relationship between porosity and deformation. 
For BHP-based granules initial granule bulk density appeared to be a major factor 
influencing tablet porosity. Table 2.21 details the change in porosity (that is the 
difference between granule and tablet porosity), during compaction, as a function of the 
bulk density of the initial granules. As a general observation, the difference between the 
porosity of the starting granules and the porosity of the final tablet decreased as bulk 
density of the initial granules increased. When the granules were compacted under 
constant force and speed, rather than to equivalent relative density, a similar conclusion
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was drawn. Figure 3.12 shows granule and corresponding tablet porosity of four batches 
compacted using a force of 8kN and a speed of 3mm/s. Three batches had similar bulk 
densities (0.48 to 0.53g/ml) while the fourth batch had a higher bulk density (0.62g/ml). 
A greater increase in porosity occurred for the batches with lower bulk density values. 
Bulk density values were likely to reflect differences in particle shape of each batch of 
granules. More irregularly shaped particles were likely to have a larger bulk volume and 
pack less effectively during compaction producing a compact with comparatively large 
pore spaces. The fact that only a rough relationship appeared to exist between bulk 
density and change in porosity may have been due to other participating factors, some of 
which may have been interdependent. Particle shape and/or porosity may have affected 
the propensity of the particles to fragment. Particle shape might have affected bonding 
during compaction since irregular particles with an irregular surface geometry might 
have bonded more effectively than smooth particles. Bulk density values will have been 
influenced by particle porosity as well as particle shape since presumably high porosity, 
irregular granules would have a lower bulk density than low porosity, irregular granules. 
Mechanical strength could be a function of porosity and shape. Overall, the granule 
physical characteristics affecting tablet structure appeared to be complex, although bulk 
density appeared to be an important factor in determining tablet pore structure.
Compaction of the granules thus produced tablets with different porosities and 
different pore size distributions. Pore area values calculated for BHP-based tablets were 
found to be non-consistent and therefore were not used. The variation in pore areas 
could reflect the type of packing that was occurring, that is irregularly shaped pores 
displaying structural hysteresis. This can largely affect pore areas derived from mercury 
porosimetry data (see section 3.4.4.2).
I l l
Batch No. Median pore diameter 
of pores > 0.9 (im
Porosity (%) Bulk density 
(g/ml)
G3K(2) 2.33 10.60 0.53
G3J 3.09 6.77 0.47
G3E 2.22 5.67 0.55
G3L(2) 2.73 3.81 0.51
G3N 2.13 4.33 0.45
G3D 2.22 5.67 0.62
Table 3.19 Bulk physical characteristics of granules









Table 3.20 Pore structure of tablets having equivalent tablet thickness
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Figure 3.12 Granule and tablet porosity as a function of 
granule bulk density
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3.4.6 Effect o f tablet shape on tablet pore structure
Table 3.22 shows the pore characteristics of three differently shaped tablets 
compacted from granule batch G3L(2). Porosity and median pore diameter only differed 
slightly despite tablet shape being substantially different. The complex stress patterns 
that develop in a mass of particulate material when compacted in a cylindrical die have 
been mapped by Train (1957) (152). A close relationship was found to exist between the 
pressure response and the apparent density produced at a given point within the 
compacting mass. It might be expected that the pressure applied on regions of the 
powder bed would vary depending on die geometry. Therefore regions of densification 
would differ between different table shapes. Only small differences in pore structure 
was observed between each tablet possibly because of the resistance of this particular 
material to densification.
16mm disk 10mm cylinder caplet
Median pore diameter (pm) 2.08 2.28 2.21
Porosity (%) 8.34 9.38 10.87
Table 3.22 Variation of pore structure with tablet shape
3.4.7 Effects o f tertiary components on mechanical properties o f tablets
Table 3.23 shows the work of failure and hardness of tablets compacted from 
BHP-based granules formulated with and without tertiary components. The granules 
were produced under similar processing conditions. Tablets containing ethylcellulose 
had higher work of failures and associated lower standard deviations than tablets that did 
not contain ethylcellulose. The high standard deviation of tablets formulated without 
ethylcellulose suggested that these tablets were failing by brittle fracture. The work 
required to fracture the tablet probably varied depending on the fracture plane penetrated 
as the probe entered the tablet. Ethylcellulose possibly enhanced the plasticity of the 
granules so that the resulting tablets were less brittle. Both calcium sulphate and 
ethylcellulose appeared to increase the compactibility of the granules to some extent 
since the inclusion of these components produced tablets with higher tablet strength. 
Although the presence of tertiary components appeared to slightly improve the
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compactibility of BHP-based granules the material was still more difficult to compact 
than TIMERxN.
Tertiary Batch No. W ork of failure (N/s) Hardness (kN)
component ±S.D ±S.D
None G3N 115.4 ±79.6 2.65 ±0.17
Ethylcellulose G3Q 162.8 ±35.6 5.60 ±0.21
Calcium sulphate G3R 115.2 ±79.6 8.00 ±3.05
Ethylcellulose + 
calcium sulphate
G3S 147.5 ± 32.8 5.27 ±0.18
Table 3.23 Mechanical properties of tablets with and without tertiary components
3.5 Conclusion
Variation in the processing conditions used to produce BHP-based granules 
produced granules that had varying pore structures. Porous granules were produced by 
wet granulating with an alcohol mix and fluid bed drying the wet mass. Relatively non- 
porous granules were produced by passing dry material through a screen using an 
oscillating granulator. Median pore diameter was significantly altered by changing the 
drying conditions. This was thought to be a consequence of the residual moisture 
content on milling. TIMERxN was easily compacted into tablets that had different 
porosities by altering the compaction force and speed used to produce the tablets. 
Although pore structures were substantially different, the tablets had different thickness 
and therefore different initial releasing surface areas. To obtain compacts that had the 
same tablet surface area but different pore structures BHP-based granules were 
compacted into tablets that had a constant thickness. These granules were resistant to 
densification but this was advantageous in that the physical characteristic of the initial 
tablets strongly dictated the pore structure of the resulting tablets. Tablets with different 
porosities and different pore size distributions were produced in this way. The bulk 
density of the initial granules appeared to largely influence the porosity of the final 
tablet.
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Tablets having different porosities, pore size distributions and bulk densities were 
obtained. This enabled a study to be initiated on the influence of tablet pore structure on 
the release retarding ability of HP-based matrices.
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4. Investigation of the release-controlling action of tablets and granules 
comprised of swellable hydrophilic materials in relation to the initial bulk 
physical characteristics of the materials
4.1 Introduction
A number of studies have reported correlations between the initial bulk 
characteristics of swellable hydrophilic matrix tablets and the release controlling action of 
the matrices (31,32,69,92,94,96). It has been proposed that initial matrix porous 
structure can influence drug release by affecting the rate of solvent penetration into tablets 
(31,95); the susceptibility of the swollen matrix to erosion (32); the rate of matrix swelling 
(95); the degree of matrix swelling (96); the diffusion pathway through the matrix (92) 
and the releasing surface area of the swollen material (69). Other studies have found no 
correlation between initial bulk characteristics and dissolution profiles (63,90,91). It 
appears that parameters such as porosity, pore size distribution, tablet size and shape 
affect the rate of dissolution of model drugs from some matrices but are not important in 
determining drug release from other matrix systems.
In this study the release controlling action of swellable hydrophilic tablets and 
granules, including HP-based and non HP-based formulations, was examined as a function 
of the bulk physical characteristics of the initial dry material. Variations in tablet bulk 
characteristics have often been achieved by changing tablet thickness (63,94) and 
compaction studies had shown that TIMERxN granules could be compacted into tablets 
of varying tablet thickness. These tablets were known to have different initial releasing 
surface areas, porosity’s and pore size distributions. Since it was considered that tablet 
thickness could theoretically influence dissolution rates, the release of model drugs from 
hydrophilic matrices having different initial tablet thickness was evaluated. It was also 
known that HP-based granules could be produced that had a range of bulk physical 
characteristics and that these granules could be compacted into tablets that had equivalent 
tablet thickness but different porous structures. These matrices had similar initial 
releasing surface areas however, it was considered that differences in porous structure 
could affect the rate of water penetration into the tablet, the rate of swelling and/or the 
tortuosity and mechanical strength of the swollen matrix. The release of model drugs 
from HP-based tablets and granules was therefore examined as a function of porous
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structure. The release-controlling action of hydrophilic matrix tablets having different 
porous structures but equivalent tablet thickness had not previously been studied in detail.
4.2 Materials
Benzamide (Lot No. 6366081) was obtained from Aldrich Chemical Co. 
(Loughborough, U.K.). Xanthan gum (Lot No. P5086), locust bean gum (Lot No. 
B21577) glucose (Lot No. CD6D29107) and TIMERxN (Lot No. NS664) were supplied 
by Penwest Pharmaceuticals Co., (Patterson, NY, USA). Microcrystalline wax (Lot No. 
3749) was obtained from Poth, Hille & Co. Ltd (U.K.). Acetone, 2-propanol, 
dichloromethane, magnesium stearate (Lot No. 30120362) and polyethylene glycol 4000 
were obtained from Fisons Scientific Equipment Ltd. (Loughborough, U.K.). Anhydrous 
lactose 50M (Lot No. 8NC03A) was obtained from Kraft Inc. (Norwich, N.Y.). 
Diclofenac sodium (Lot No. 94-01342) was obtained from Heumann Pharma GmbH 
(Nurenberg, Germany). Sodium stearyl fumarate (Lot No. 212-01X) was obtained from 
Mendell (Penwest Pharmacuticals Co., Patterson, NY, USA). Polyvinylpyrollidone (PVP 
K29/32 Lot No. TX30118), firusemide (Lot No. 36H30119) and monobasic anhydrous 
potassium phosphate (Lot No. 106H0476) were obtained from Sigma Scientific 
Equipment Ltd. (Loughborough, U.K.). Sodium hydroxide solution (Lot No. 
9627477A456) was obtained from Fischer Chemicals Co., (Loughborough, U.K.). 
Carbomer 934P (Carbopol 934P NF, Lot No. B981083) was obtained from BF Goodrich 
(Brecksville, Ohio, USA). Methocel K15M Premium EP (Lot No. KJ26012N01) was 
obtained from Colorcon (Kent, U.K). Lactose (Microtose 200mesh) was obtained from 
Meggle GmbH (Wasserburg, Germany). 1pm cellulose nitrate filters were obtained from 
Whatman International Ltd. (Maidstone, U.K).
4.3 Methods
4.3.1 Characterisation o f benzamide, diclofenac sodium and frusemide
Benzamide and diclofenac sodium were selected as model drugs. The USP (65) 
classifies the aqueous solubility of drugs according to the number of parts of the drug 
required for dissolving one part of drug: < 1 for very soluble, 1 to 10 for freely soluble, 10 
to 30 for soluble, 30 to 100 for sparingly soluble, 100 to 1000 for slightly soluble and
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1000 to 10,000 for very slightly soluble drugs. Using this classification diclofenac sodium 
falls into the category of slightly soluble and benzamide as soluble. The percentage 
solubility (w/v) of each model drug in water (pH 7) and the drug loadings used in this 
study are given in table 1. Figures 4.1 and 4.2 show the molecular structure of benzamide 
and diclofenac sodium, respectively. Benzamide (benzoylamide) has a strong UV 
absorbance at low concentrations. The loss on drying value, determined 
thermogravimetrically by heating the sample at 70°C for 5min using an infrared moisture 
balance (Type LP16, Mettler, Switzerland), was approximately 0.3%. Benzamide was 
screened through a 180pm mesh before use. A low drug loading was used in order to 
minimise the extent that the model interfered with (a) granule compactibility and (b) the 
pore structure of the resulting matrices. Diclofenac sodium also has a high UV 
absorbance at relatively low drug concentrations. It retains approximately 2% of moisture 
under ambient conditions and, since it is highly cohesive, was not sieved before use. The 
drug loadings selected enabled the formulations to be conveniently assayed by UV 
detection in 1000ml of water.
Frusemide was used as a model drug to study the release controlling action of 
Carbopol formulations, which were reported to be sensitive to changes in tablet thickness 
(32). Frusemide is insoluble at pH 7.0 but is soluble in pH 5.8 phosphate buffer (32). Its 
molecular structure is shown in figure 4.3 and its solubility and the drug loading used are 
shown in table 4.1.
Model drug Solubility (%w/v) Drug loading (%)
Benzamide 1.35* 2.67
Diclofenac sodium 0.187** 5 and 10
Frusemide Soluble at pH 5.8 5
* (153), ** (154)





Figure 4.1 Molecular structure of benzamide
COONa
Diclofenac Sodium





Figure 4.3 Molecular structure of frusemide
4.3.2 Assay o f benzamide, diclofenac sodium and frusemide
The model drugs were assayed by detection of UV absorbance in aqueous solution 
at the Amax of each drug. The UV absorption of solutions of benzamide and diclofenac 
sodium in distilled water was scanned in the range 200nm to 350nm using a UVATS 
spectrophotometer (Lambda 3B, Perkin-Elmer Ltd., Beaconsfield, U.K.). The Amax was 
found to be 228nm for benzamide and 273nm for diclofenac sodium. A stock solution of 
benzamide (0.02%) was prepared by dissolving 50mg of benzamide, accurately weighed, 
in 250ml of distilled water. Aliquots of the stock solution were diluted to produce a
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series of solutions having target concentrations of 0.0004%, 0.0008%, 0.0012% and 
0.0016% (w/v) benzamide. The absorbance of each solution at 228nm was determined 
using a UV/VIS spectrophotometer (Unicam 8625, Cambridge, U.K) against a distilled 
water blank. The procedure was repeated twice using a new stock solution in each case 
so that three sets of calibration data from three different stock solutions were obtained. A 
stock solution of diclofenac sodium (0.1%) was prepared by dissolving approximately 
500mg of diclofenac sodium, accurately weighed, in 500ml of distilled water. Aliquots of 
the stock solution were diluted to produce a series of solutions having target 
concentrations of 0.0005%, 0.0015%, 0.0030% and 0.0045% diclofenac sodium. The 
procedure was repeated twice using a new stock solution in each case. The UV 
absorbance at 273nm of each solution was determined against distilled water. 3 
calibration plots were constructed for each model drug. Linear regressions were carried 
out using a computer graphics package (MicroCal Origin, MicroCal Software Inc., 
Northhampton, USA). A t-test was used to determine whether significant differences 
existed between each set of calibration data.
A stock solution of frusemide (0.025%) was made up by dissolving 125mg of 
frusemide, accurately weighed, in 500ml of pH 5.8 phosphate buffer. Aliquots of stock 
solution were diluted with buffer to produce a series of solutions having target 
concentrations of 0.0005%, 0.0010%, 0.0020% and 0.0030%. The UV absorbance of the 
solutions at the Amax of frusemide (271nm) (154) were determined using pH 5.8 
phosphate buffer as a blank. The procedure was repeated twice using a fresh stock 
solution in each case. Calibration plots were constructed and analysed as described 
above.
The absorbance of a solution of each model drugs was determined before and after 
filtration by cellulose filters to determine if the filters retained any of the model drugs. No 
decrease in absorbance at the Amax of each model was observed. The maximum variation 
in absorbance before and after filtration was 3.3% of the unfiltered solution (n=3).
4.3.3 Assessment o f model drug stability
It was important that the model drugs remained stable in solution at 37°C over the 
period of dissolution. The UV absorbance of solutions of benzamide, diclofenac sodium 
and frusemide maintained at 37°C was monitored at the Amax of each model drug. No
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loss of absorbance at the Amax of the drug occurred over a 24hr period. The absorbance 
of benzamide varied by a maximum of +0.7%, the absorbance of diclofenac sodium by a 
maximum of +5.6% and the absorbance of frusemide by a maximum of +3.2%.
4.3.4 Preparation o f HP-based tablets and granules
The effect of tablet thickness on the release of benzamide and diclofenac sodium 
from tablets that contained a high proportion of TIMERxN (48.6%) and tablets that 
contained a low proportion of TIMERxN (10%) was investigated. TIMERxN was used 
as the release controlling material because it was easily compacted into tablets having high 
and low tablet thickness (see section 3.4.4.1). Drug release from tablets that had different 
pore structures but equivalent tablet thickness was studied using benzamide as a model 
drug. The tablets were compacted from granules that had been prepared using a range of 
processing conditions and were known to have different porous structures. The effect of 
tablet shape on release rates was studied using diclofenac sodium as a model drug. The 
dissolution behaviour of benzamide from uncompacted granules was examined as a 
function of granule porosity.
4.3.4.1 Tablets compacted to equivalent tablet thickness
Benzamide was distributed extragranularly through four batches of granules (batch 
no’s. G3E, G3L(2), G3K(2) and G3J). The preparation of these batches was described in 
Chapter 3. 2.67% benzamide was mixed with 97.33% granules using turbula rotation at 
30rpm for 5min (Type T2C, Glen Creston Ltd., Stanmore, Middlesex, U.K). A single­
punch tablet press (Type F3, Manesty, Speke, Liverpool, U.K.) was fitted with a 10mm 
flat-faced punch and die set. Granules that had been preconditioned at 55%RH prior to 
compaction were manually filled into the die and compacted to equivalent relative density. 
The tablet press was hand operated, which enabled tablet thickness and weight to be 
accurately controlled. A constant weight of approximately 400mg was maintained and 
tablet thickness was measured using digital calipers (Digit-Cal, TESA S.A, Switzerland). 
Tablets compacted from granule batches G3E, G3L(2), G3K(2), and G3J(2) are identified 
by the batch no’s, T3E, T3L(2), T3K(2) and T3J, respectively.
The porosity of one batch of tablets was reduced by using polyethylene glycol 
(PEG) as a pore filler. PEG is a hydrophilic material that is readily soluble in 
dichloromethane (124). Tablets compacted from granule batch G3L(2) were immersed in
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a 10% solution of PEG 4000 in dichloromethane for 5s. Following evaporation of 
dichloromethane the tablets were re-immersed for a further 5s. When the 
dichloromethane had evaporated PEG was left in the pores, thereby reducing the porosity 
of the tablets.
4.3.4.2 Tablets compacted to different tablet thickness
A formulation containing a high proportion of TIMERxN was prepared by 
blending TIMERxN (97.3%) with benzamide (2.67%) by geometric trituration. Tablets 
were compacted from the blend using a single-punch tablet press, which was operated 
manually. The press was fitted with a 10mm flat-faced punch and die set, which was 
lubricated with a 1.5%w/v suspension of magnesium stearate in acetone prior to 
compaction. A constant weight of approximately 400mg was maintained. The distance 
moved by the upper punch was adjusted to produce tablets having high and low tablet 
thickness.
Tablets containing a low percentage of HP-based material were prepared by 
blending TIMERxN (10%), diclofenac sodium (7.5%) and lactose (81.5%) by geometric 
trituration. Magnesium stearate (1%) was added as a lubricant and distributed using 
turbula rotation for 5min at 30rpm. The tablets were compacted using a single-punch 
tablet press fitted with 10mm flat-faced punches. The distance moved by the upper punch 
was adjusted to produce tablets having three different tablet thicknesses.
The effect of restricted matrix swelling on dissolution profiles was examined using 
tablets coated with a water impermeable barrier. Tablets having high and low tablet 
thickness were compacted from a TIMERxN/benzamide blend that contained 47% HP 
material (97.3% TIMERxN). Molten microcrystalline wax, which is water-insoluble, was 
applied to one base and to the lateral surface of each tablet and allowed to dry. This left 
one base free for drug release during dissolution.
4.3.4.3 Tablets compacted to different geometrical shapes
XG (25%), LBG (25%), glucose (45%) and diclofenac sodium (5%) were blended 
for 5min in a high shear mixer (Cuisine Systeme Automatic 5000, Magimix Ltd., Surrey, 
U.K.). Total batch size was 300g. The blend was wet agglomerated for 5min using 
21.6% distilled water and tray dried at 60°C in an oven (Model H-150, Size 2, 
Gallenkamp, Loughborough, U.K.) for 24hr. The dry material was passed through a 
0.63mm mesh using an oscillating granulator (Type MGL 4A Frewitt, Switzerland). The
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granules were sieved for 30min (Endecotts Ltd., London, U.K.) through an I.S.O 
standard aperture diameter V2 sieve progression ranging from 710pm to 63|im. The 
sieves were agitated using a Fritsch sieve shaker (Type 03-502, Fritsch, Germany). 
Quantities from each sieve fraction were selected in the following proportions: 500 to 
710pm (2%), 355 to 500pm (4%), 250 to 355pm (26%), 180 to 250pm (36%), 125 to 
180pm (26%), 90 to 125pm (3%), 63 to 125pm (2%) and 0 to 63pm (1%). Sieve 
fractions were recombined using turbula rotation (Type T2C, Glen Creston Ltd., 
Stanmore, Middlesex, U.K.) for 5min at 30rpm giving particles with a median particle size 
of 184pm. Accurately weighed samples (approximately 373mg) were compacted using 
flat faced 8mm circular punches, flat faced 9.5mm x 9.5mm square punches and 5mm x 
16mm caplet shaped punches. The tablet press was operated manually. The dimensions 
of the tablets were measured prior to dissolution using a digital micrometer and used to 
calculate average tablet surface area, tablet volume and bulk density. The bulk 
characteristics of caplet shaped tablets were calculated by assuming a cylindrical shape of 
similar dimensions.
4.3.4.4 Preparation of reference tablets
In order to compare dissolution profiles that had been obtained from different 
dissolution experiments it was necessary to ensure that the dissolution conditions were 
similar in each case. This was achieved by using reference tablets containing the 
appropriate model drug. The dissolution profile of one reference tablet was followed 
during each dissolution experiment. If the dissolution of the reference tablet fell within set 
limits at the 2hr and 6hr time points then this gave confidence that the dissolution 
conditions in each experiment were consistent. The limits were established by measuring 
the release profiles of between 6 and 12 reference tablets and determining the highest and 
lowest percentage released at each time point.
A reference batch of tablets containing benzamide was prepared by blending 
benzamide (2.67%) and TIMERxN (96.32%) by geometric trituration. Magnesium 
stearate (1%) was added as a lubricant and distributed by turbula rotation (Type T2C, 
Glen Creston, Middlesex, U.K.) at 30rpm for 3min. The blend was tableted using a single 
punch tablet press fitted with 10mm concave punches. The target weight was 450mg.
Reference diclofenac sodium tablets were prepared by blending TIMERxN (94%) 
and diclofenac sodium (5%) by geometric trituration. 1% sodium stearyl fumarate was 
added as a lubricant and distributed using turbula rotation for 5min at 30rpm. The blend
124
was compacted on a single-punch tablet press using 10mm flat-faced punches. The target 
weight was 400mg.
4.3.4.5 High and low porosity HP-based granules
The dissolution of benzamide from HP-based granules was examined using 
granules that contained benzamide distributed intragranularly. A ‘low’ porosity batch 
(batch No. G4A) and a ‘high’ porosity batch (batch No. G4B) were prepared.
Batch G4A: XG (24.25%), LBG (24.25%), glucose (48.50%) and benzamide 
(3%) were blended for 5min using a high shear mixer. The dry blend was agglomerated 
using 17.8% distilled water, which was added over lmin. Total mixing time was 5min. 
The wet material was tray dried in an oven at 60°C for 24hr giving material with an LOD 
of less than 5%. The dry material was screened through a 0.63mm mesh using an 
oscillating granulator and size selected as described in section 4.3.4.3, giving granules 
with a theoretical median granule size of 184p.m.
Batch G4B: The dry materials were blended as described for batch G4A. The dry 
blend was agglomerated using a 1:1 mixture of 2-propanol and distilled water 
(27.8%w/w). The wet material was screened through a 0.32mm mesh using the 
oscillating granulator. The granules were then dried using a fluid bed drier (Uniglatt, 
Glatt AC, Switzerland) operating at 80°C for 20min. This reduced the LOD of the 
material to less than 5%. The granules were size selected as described in section 4.3.4.3, 
giving material with a theoretical median granule size of 184p.m.
4.3.5 Preparation o f Carbopol and Methocel tablets
Carbomers (Carbopol™) are synthetic high molecular weight polymers of acrylic 
acid. They disperse in water to form acidic colloidal solutions of low viscosity that when 
neutralised produce highly viscous gels (124). Carbomer grades with a low residual 
benzene content 934P or 974P are sometimes used in oral preparations (124,155). The 
material has a relative high bulk density (1.76g/cm2) and an average particle size of 2 to 
7jim (124). Perez-Marcos et al. (32) found that the rate of release of frusemide from 
Carbopol™ matrices was sensitive to the force used to compact the matrices. The release 
of frusemide from Carbopol matrices was therefore evaluated here. The effect of 
compaction force on the dissolution of frusemide from frusemide/Methocel matrices and 
frusemide/TIMERxN matrices was also examined.
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A firusemide/lactose granulate was prepared using the method described by Perez- 
Marcos et al. (32). 5% PVP K29/32 was dissolved in distilled water. Frusemide (39.5%) 
and lactose (59.4%) were blended in a mini high shear mixer (CHI00 mini chopper, 
Kenwood Ltd., Surrey, U.K). Total batch size was 25g. 22%v/w of PVP solution was 
added and the materials were agglomerated for 2min. The wet mass was tray dried in an 
oven (Model 1H-150, Size 2, Gallenkamp, Loughborough, U.K) at 50°C for 3hr. The 
granulate was ground in a pestle and mortar and passed through a 250jim mesh. The 
granulate (12.56%) was blended by geometric trituration with (a) Carbopol 934P 
(87.44%), (b) Methocel K15M (87.44%) and (c) TIMERxN (87.44%). The blends were 
conditioned at 55%RH prior to compaction. Methocel K15M was selected as a 
hydrophilic matrix component as it is a high viscosity grade of HPMC that is frequently 
studied as a controlled release matrix excipient (63,64,91). The bulk density was found to 
be 0.29g/cm2 and the true density determined by helium pycnometry (see section 2.3.1.1) 
was found to be 1.41g/cm3. The mean particle size of Methocel K15M as determined by 
time of flight of flight measurements (see section 3.3.1) was 28.4 ± 0.5|im. A second 
granulate containing diclofenac sodium in place of frusemide was prepared using the 
method described above for frusemide. The diclofenac sodium granulate (12.6%) was 
blended with Carbopol 934P (87.4%). The blends were compacted using a single-punch 
tablet press fitted with 10mm flat-faced F tooling. The punch and die were lubricated 
with a 1.5% suspension of magnesium stearate in acetone prior to compaction. 
Compaction settings were adjusted to produce tablets having high and low tablet 




Dissolution studies using USP II apparatus were carried out at 37°C ± 0.2°C in a 
Pharmatest dissolution apparatus (Type PTW S3C, Pharmatest Ltd., Gwent, U.K) with 
paddles positioned 3cm above the point of curvature at the bottom of the vessel. The 
speed of paddle rotation was 50rpm, lOOrpm or 150rpm, as indicated under the 
appropriate figure. The tablets to be analysed were supported in stainless steel wire cages 
(approximately 3.5cm x 2.5cm) to allow both axial and radial swelling and to ensure
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release from all surfaces. The dissolution medium was either 1000ml of distilled and 
degassed water or, in the case of frusemide formulations, 1000ml of degassed pH 5.8 
phosphate buffer. A standard solution containing a known concentration of the active 
material was used as a reference. Distilled water or, in the case of frusemide formulations, 
pH 5.8 phosphate buffer was used as a blank. Sampling of the dissolution medium was 
carried out either manually, using filters with an average mesh size of lpm  to filter the 
medium, or automatically, when the medium was passed through 20pm mesh filters. 
Manual sampling was appropriate when a fine mesh filter was required to limit the 
interference of tablet excipients on the UV assay of the drug. The dissolution of 
diclofenac sodium from tablets having different geometrical shapes was followed by 
manual sampling: at predetermined intervals samples of dissolution medium were 
withdrawn using a syringe and filtered through 1pm cellulose nitrate filters. An equal 
volume of fresh distilled water heated to 37 ± 0.2°C was added to each dissolution vessel 
following sampling to maintain constant volume. The filtrate was analysed using an UV 
spectrophotometer (Unicam 8625, Cambridge, U.K.) at 273nm. It was shown that the 
cellulose nitrate filters did not decrease the absorbance of a solution of diclofenac sodium. 
The quantity of drug released at each time point was calculated taking into account the 
amount removed by sampling and the progressive dilution of the dissolution medium. The 
dissolution of all other batches was followed using automatic sampling: at programmed 
intervals the dissolution medium was pumped automatically through 20pm filters 
(Pharmatest Ltd., Gwent, U.K.) using a peristaltic pump (IsmaTec SA, Type MS-CA, 
Glattbragg, Switzerland) to a flow cell were spectrophotometric measurements were 
made (Unicam 8625, Cambridge, U.K.) at the appropriate wavelength. An 8-way valve 
(MS-FX, Twist Technologies, Cambridgeshire, U.K.) sequentially directed medium from 
each vessel to the flow cell. The percentage drug released was calculated at each time 
point using Pharmatest software (Pharmatest Ltd., Gwent, U.K). Drug release was 
expressed as a percentage of the total drug present in the dosage form, as determined 
from content uniformity measurements (see section 4.3.8). The mean of either 3 or 5 
determinations was reported, with error bars representing the standard deviations from 
the mean. Linear regression analysis on dissolution data was carried out on 
approximately the first 70% of drug released (SigmaPlot Scientific graphical software, 
version 2.01, Jandel Scientific, San Rafael, CA, USA).
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4.3.6.2 Low agitation conditions
A standard USP II dissolution set up was not suitable for determining the 
dissolution of granules as the high degree of agitation caused aggregation of the granules 
and a high variability in the results. To obtain very low agitation conditions the paddles 
from the USP II apparatus were replaced with baskets normally used under USP I 
conditions. The baskets were then removed leaving the shafts, which were rotated at 
25rpm. The granules were finely distributed over the surface of the dissolution medium. 
Samples were analysed automatically as described in section 4.3.6.1. Low agitation 
conditions were also used when studying the dissolution behaviour of a number of tablet 
batches. This was to examine the release behaviour of formulations having different bulk 
physical characteristics, under low hydrodynamic flow conditions.
4.3.7 Assessment o f excipient interference
As dissolution of a drug from a HM occurs progressive quantities of the inert 
matrix can also undergo dissolution. Soluble and insoluble matrix excipients can 
potentially interfere with the UV assay of model drugs. During the dissolution of model 
drugs from Carbopol, TIMERxN and Methocel K15M formulations the dissolution 
medium remained clear and was easily filtered through 20pm Pharmatest filters. 
Dissolution tests on placebo formulations showed that the excipients did not interfere with 
the UV assay of the model drugs. During the dissolution of drugs from BHP-based 
matrices the medium became viscous and opaque. 20pm filters effectively filtered the 
medium for up to approximately lOhr dissolution however, for longer dissolution runs 
filtration through lpm  was necessary to limit interference by excipients. This necessitated 
manual sampling of the dissolution medium. UV absorbance measurements were carried 
out during the dissolution of a placebo formulation. This showed that the absorbance of 
filtered solutions containing HP-based material at the Amax of diclofenac sodium, was less 
than <6% of the total drug absorbance after complete dissolution of the tablet matrix.
4.3.8 Determination o f content uniformity
Prior to dissolution experiments the initial drug content of the formulations were 
determined. Samples were stirred with a spatula prior to sampling. 10 accurately 
weighed samples (approximately lOOmg) were removed from regions within the powder
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bed using a spatula. The samples were dispersed in 250ml of distilled water and allowed 
to equilibrate for 5 to 6hr. A sample of the solution was filtered through a ljum cellulose 
nitrate filter and the UV absorbance of the solution at the appropriate wavelength was 
determined. The readings were converted into concentration values using the calibration 
data.
4.3.9 Analysis using mercury porosimetry
The pore structure of tablets and granules was quantified by mercury porosimetry 
using the methods described in section 3.3.4.
4.4 Results and discussion
4.4.1 Calibration data
Calibration data for benzamide, diclofenac sodium and frusemide are shown in 
tables 4.2 to 4.4, respectively. Calibration curves are given in appendix 2. Calibration 
plots for benzamide were found to be linear in the range 0 to 0.0016%, calibration plots 
for diclofenac sodium were found to be linear in the range 0 to 0.0035% and calibration 
plots for frusemide were linear in the range 0 to 0.0030%. Calibration plots encompassed 
a concentration range of 0 to 125% of the maximum concentration achievable after 100% 
dissolution. Student’s t-tests showed that there were no significant differences within 
each set of calibration data (p<0.05).
Calibration plot No.
1 2 3 M ean (n=3)
Intercept 0.0022 0.0038 -0.0010 0.0017
Slope 719.75 705.00 698.75 707.83
Standard deviation 2.32 11.07 10.91 -
Regression (r2) 0.9999 0.9996 0.9996 -
Table 4.2 Calibration data for benzamide
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Calibration plot No.
1 2 3 Mean (n=3)
Intercept 0.0028 0.0010 0.0022 0.0020
Slope 300.93 294.40 297.76 297.70
Standard deviation 1.66 3.06 3.00 -
Regression (r2) 0.9995 0.9998 0.9998 -
Table 4.3 Calibration data for diclofenac sodium
Calibration plot No.
1 2' 3 Mean (n=3)
Intercept 0.0229 0.0232 0.0021 0.0161
Slope 519.30 535.50 539.41 531.40
Standard deviation 13.32 12.06 25.41 -
Regression (r2) 0.9990 0.9991 0.9967 -
Table 4.4 Calibration data for frusemide
4.4.2 Dissolution o f model drugs from HP-based tablets and granules containing a 
high proportion o f HP material
Figure 4.4 shows benzamide release profiles from TIMERxN tablets containing 
48.6% HP and 48.6% glucose, compacted to high and low tablet thickness (5.17 ±. 
0.04mm and 3.72 ±. 0.04mm, respectively). Although the thickness, and therefore the 
porosity and pore size distribution of the tablets were largely different (table 4.5) the
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release profiles were very similar. The dissolution profiles followed approximately zero- 
order release kinetics (r2 = 0.998) for the first 70% of drug released. Figure 4.5 shows 
the release of benzamide from tablets that had different pore structures but equivalent 
tablet thickness. The porosity of the tablets ranged from 4.8% to 18.6% while the median 
pore diameter ranged from 1.42|im to 2.87pm (table 4.6). Tablets that were immersed in 
PEG had the largest median pore diameter and this reflected the observation from the 
incremental intrusion plot that the smaller pores had largely disappeared in these tablets. 
Despite the pore structures being substantially different, the tablets released benzamide at 
similar rates. The large variations in standard deviation observed were due to poor 
distribution of benzamide within the granules arising from the difficult in distributing a 
small quantity of finely graded benzamide within relatively large granules. However, a 
low dose model drug was deliberately selected to minimise the extent to which the model 
changed tablet porosity. The mean time taken for 25%, 50% and 75% of benzamide to be 
released was calculated for tablet batches T3K(2), T3J, T3E and T3L(2). Statistical 
analysis using Student’s t-tests showed that the means were not significantly different 
from each other (p<0.05).
The release profiles from each batch approximated to zero-order release kinetics 
(r2 = 0.987 to 0.998), similar to the release kinetics observed for TIMERxN based tablets. 
Simple monolithic matrices are commonly associated with first-order release kinetics, that 
is, decreasing release rates with time (6), however, zero-order kinetics have sometimes 
been observed. For water-soluble drugs time independent release is thought to occur 
when the swelling and erosion fronts become synchronised thereby maintaining a gel-like 
layer of constant thickness (19). Zero-order kinetics have also be reported when the rate 
of release is erosion controlled, which can occur when the viscosity of the polymer is very 
low (27), or when the formulation contains a very low proportion of gum (156). 
However, since most of the drug was released while a large proportion of the matrix 
remained intact this suggested that diffusion was an important mechanism of release in 
these matrices. This is usually the case for water-soluble materials (6). Zero-order 
release of water-soluble drugs from xanthan gum matrices has also been reported (28).
Figure 4.6 shows that under conditions of low agitation no effects due to pore 
structure became apparent. Figure 4.7 shows the dissolution profiles of benzamide from 
granules when the granules were scattered over the surface of the dissolution medium. It 
can be seen that granules having ‘high’ and ‘low’ porosity (table 4.7) controlled the 
release of benzamide to the same degree. Dissolution from granules was rapid compared
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with tablets because of the shorter diffusion pathway that the benzamide molecules 
needed to take to reach the dissolution medium.
The results suggested that the release controlling action of HP-based material was 
not dependent on tablet porosity, pore size distribution or tablet thickness. It was 
considered that this was because of the swelling characteristics of the material. In contact 
with aqueous medium the outer surface of the tablet rapidly hydrated, and swelled 
forming a gel-like barrier that limited water penetration. It is proposed that the 
formulation had a high affinity for water due to the high proportion of glucose and the 
hydrophilic nature of xanthan gum, and that this affinity for water, not initial porosity or 
pore size distribution, determined the rate of hydration of the dry matrix. As water 
penetrated through the outer hydrated layer into the core of the tablet a thick swollen 
layer developed. It is considered that the extensive swelling of the material meant that 
differences in initial pore structure and/or tablet thickness became negligible so that the 
tortuosity of the matrix was similar in each case. Therefore, each matrix limited the rate 
of water penetration to the same extent and presented a similar diffusional resistance to 
the solute. The results suggested that for these systems the initial porous structure of the 
matrix did not affect the propensity of the hydrated matrix to erode. Drug release from 
swellable matrix systems is thought to depend on the relative importance of tablet 
relaxation and drug diffusion rates (157). Within each HP-based tablet matrix drug 
diffusion rates are likely to be similar and it is the swelling of the matrix that dominates 
release behaviour. It appeared that any initial differences in tablet pore structure was 
outweighed by the extensive swelling of the system and that the rate of swelling was 
independent of initial tablet pore structure or bulk volume. It was thought that if matrix 
swelling dominated release behaviour then changes in release rates could be introduced by 
physically controlling matrix swelling. By coating one base and the lateral surface of 
tablets with an impermeable barrier the swelling of the matrix was restricted while the 
releasing surface area was maintained constant. Figure 4.8 shows that under conditions of 
restricted swelling release rates were faster in thinner (less porous) tablets. This was due 
to the longer diffusion pathway that existed in the thicker, more porous tablets. The high 
standard deviations observed could be due to be differences in tablet thickness within each 
set of tablets (3.62 ± 0.11mm, 5.20 ± 0.08mm).
Comparing figure 4.6, which shows the dissolution of benzamide from high and 
low porosity tablets under conditions of low agitation, with figure 4.5, which shows 
dissolution profiles at paddle speed 50rpm, it can be seen that the rate of release of
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benzamide was much slower under low agitation conditions. Thermodynamic conditions 
could effect either the rate of erosion of the matrix or the rate of water penetration and 
solute movement within the tablet. Since diffusion of the drug through the matrix is likely 
to be the main releasing mechanism for water-soluble drugs (6), then it proposed that the 
speed of agitation predominantly affected diffusitivity with the tablets rather than the rate 
of erosion of the outer hydrated layer.
The kinetics of drug release from swellable hydrophilic matrices have often been 
modeled mathematically (27,28,69). The mathematical analysis of release is complicated 
by the presence of moving boundaries: the diffusion front, the swelling from and the 
erosion front, therefore mathematical solutions to release kinetics are complex (20). An 
simple empirical equation, developed by Ritger and Peppas (23), can be used to describe 
the degree of Fickian and non-Fickian release behaviour of some swellable polymeric 
excipients. However, the method is only suitable for modeling systems that do not swell 
to more than 25% of their original volume. Since HP-based matrices swell extensively 
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Figure 4.4 Dissolution of benzamide under conditions of 
low agitation from TIMERxN tablets compacted to different 
thicknesses (n=3)
High thickness Low thickness
Tablet thickness ± S.D (mm) 5.17 ± 0.04 3.72 ± 0.04
Specific pore area (m2/g) 2.53 2.60
Median pore diameter (|L im ) 1.03 0.24
Porosity (%) 30.8 12.2
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Thickness ± S.D 
(mm)
T3K(2) 1.73 18.6 4.17 ± 0.12
T3J 1.60 15.3 4.12 ±0.03
T3E 1.42 11.8 4.12 ±0.05
T3L(2) 2.30 9.8 4.11 ±0.03
T3L(2) + PEG 2.87 4.8 4.25 ±0.07
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Figure 4.6 Dissolution of benzamide under conditions of low 
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Figure 4.7 Dissolution of benzamide from high and low 
porosity granules under conditions of low agitation (n=3)
G4A G4B
Specific pore area (m2/g) 0.390 0.163
Median pore diameter (jLim) 2.33 3.16
Porosity (%) 2.73 8.38
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Figure 4.8 Dissolution of benzamide from a single surface 
of TIMERxN tablets under conditions of low agitation (n=3)
Figure 4.9 shows the dissolution profiles of diclofenac sodium from tablets that 
had different geometrical shapes and therefore different initial bulk densities, bulk volumes 
and initial releasing surface areas (table 4.8). Although initial bulk characteristics were 
different, release rates were similar. A statistical comparison of the mean percentages 
released at each time point was made using Student’s t-test. This showed that there was 
no significant difference between the mean percentage released from 8mm cylindrical 
tablets and the mean percentage released from square tablets at each time point (p<0.05). 
The mean percentages released from 8mm tablets and caplets were not significantly 
different at the 2, 8, and lOhr time points (p<0.05) while the mean percentages released 
from square and caplet shaped tablets were not significantly different at the 2, 6, 8 and 
lOhr time points (p<0.05). Although some of the means were statistically different at a 
number of time points, overall the release profiles could not be considered practically 
different. Although a correlation between tablet shape and dissolution profile was not 
observed here, a relationship between shape and release profiles has been reported for 
other systems. Ford et al. (69) found that the root time release rates of promethazine HC1 
(a highly water-soluble drug) from HPMC K15M matrices was proportional to the initial
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surface area of the tablets. Release rates decreased as tablet surface area decreased. It is 
possible that observations of correlation or lack of correlation will depend on many 
parameters including the model drug selected, test conditions and the nature of the 
hydrophilic excipient.
Visual observations showed that each geometrical form swelled extensively 
producing tortuous swollen bodies. Since a large proportion of the dose was released 
while most of the matrix remained intact it appeared that release of diclofenac sodium was 
primarily controlled by diffusion through the swollen matrix. It is proposed that where a 
very tortuous matrix exists, as a result of high matrix viscosity and extensive swelling, 
then slight difference in the shape of the hydrated matrix becomes negligible. The 
diffusion path length becomes similar in each matrix and therefore, for models that are 
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Figure 4.9 Dissolution of diclofeanc sodium from tablets 
having different geometrical shapes (paddle speed 50rpm, n=3)
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Cylindrical Caplet Square
Volume (cm3) 0.387 0.327 0.279
Bulk density (g/cm3) 0.97 1.23 1.33
Tablet surface area (cm2) 2.93 3.63 2.08
Table 4.8 Volume, bulk density and tablet surface area of diclofenac sodium tablets 
compacted to different geometrical shapes
4.4.3 Effect o f tablet thickness on dissolution o f diclofenac sodium from Carbopol 
and Methocel matrices
Although release of diclofenac sodium and benzamide from HP-based matrices 
was independent of tablet pore structure, size and shape this situation has not always been 
observed in other hydrophilic matrix materials. Kawashima et al. (96) found that the 
sustained releasing action of low-substituted hydroxypropylcellulose (L-HPC) was 
determined by a function of internal pore size distribution and the swelling properties of 
the tablet. Van der Veen et al. (94) found that the release of theophylline from tablets 
containing 70% amylodextrin was dependent on the compaction pressure used to produce 
the tablets. Tablets compacted at a lower force had faster release rates. The results were 
attributed to difference in the rate of solvent penetration into the tablets. Korsmeyer et al. 
(92) found that the release of potassium chloride from hydroxypropylcellulose (HPC) 
matrices was found to vary inversely with tablet porosity and mean pore diameter. It was 
proposed that air entrapped within the matrix was acting as a transport barrier. Tablets 
with higher porosity had more entrapped air and thus released the drug at a slower rate. 
Rizk et al. (95) reported a scleroglucan/theophylline/lactose formulation that displayed a 
marked decrease in release rate with increasing tablet hardness. Perez-Marcos et al. (32) 
observed that an increase in the force used to compact a ffusemide/Carbopol formulation 
lead to an increase in of dissolution of the drug from the matrix. Drug release was 
thought to occur through erosion of the matrix and susceptibility to erosion was thought 
to change with tablet thickness. The result was correlated with a seven-fold decrease in 
pore radius. The work carried out by Perez-Marcos et al. (32) was re examined here to 
determine whether the observations made for Carbopol could be extended to HP-based 
material. When the formulation containing frusemide prepared according to Perez- 
Marcos et al. (32) was reproduced it was found that under the conditions reported by
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these authors the dissolution profiles were sensitive to changes in tablet thickness (figure 
4.10). When Carbopol was replaced with Methocel K15M, it was observed that again, 
tablets having different thicknesses released frusemide at different rates (figure 4.11). The 
difference between the profiles was less prominent than that observed with the Carbopol 
formulation. When Carbopol was replaced with HP-based material it was found that 
dissolution profiles were very variable because under the high agitation conditions 
employed, TIMERxN tablets did not remain stationary during the test. It was observed 
that formulations containing Carbopol and Methocel K15M did not swell to the same 
extent as HP-based tablets. Extensive swelling of HP-based material produced a large 
swollen mass that had sufficiently low density to become buoyant under the dissolution 
conditions. Figure 4.12 shows that when diclofenac sodium was used as a model drug in 
place of frusemide, then release rates ceased to be sensitive to tablet thickness. In this 
case very slow release rates were observed possibly due to an interaction between 
diclofenac sodium and Carbopol. When dissolution of the Carbopol/frusemide 
formulation was studied under more standard dissolution conditions, that is at a paddle 
speed of 50rpm rather than 150rpm, the release of drug from tablets was found to be 
independent of tablet thickness (figure 4.13). Overall, the sensitivity to compaction of the 
formulation used by Perez-Marcos et al. (32) was a function of a number of interacting 
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Figure 4.10 Dissolution of frusemide from Carbopol tablets 
compacted to different tablet thickness 
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Figure 4.11 Dissolution of frusemide from Methocel K15M 
tablets compacted to different tablet thicknessess 
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Figure 4.12 Dissolution of diclofenac sodium from Carbopol 
tablets compacted to different tablet thicknesses 
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Figure 4.13 Dissolution of frusemide from Carbopol 
tablets compacted to different tablet thicknessess 
(paddle speed 50rpm, n=3)
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4.4.4 Effect o f tablet thickness on dissolution profiles from tablets containing a low 
proportion o f HP.
Dissolution tests on tablets containing 5% HP compacted to four different tablet 
thickness showed that two very different release profiles were obtained (figure 4.14). In 
the case of tablets compacted to 7.40 ± 0.11mm rapid dissolution was observed leading to 
90% release in approximately 15min. In the case of tablets compacted to 5.34 ± 0.09mm 
and 6.17 ± 0.02mm, sustained release of diclofenac sodium was observed. The effect of 
tablet thickness on the release of drug from matrices containing low gum loading can be 
explained by percolation theory. Percolation theory was introduced into the 
pharmaceutical field when Leuenberger et a l (158) employed this theory in the 
characterisation of solid dosage forms. The theory supposes the existence of a regular 
lattice underlying the system In a binary mixture A/B, the sites of the lattice can be 
occupied by the component A or the component B. In random percolation models the 
occupation of the sites is random. A cluster is defined as a group of neighbour occupied 
sites in the lattice and the probability at which a cluster just percolates a system is called 
the percolation threshold. In HP-based matrices, HP-based granules can be considered as 
one component and the blend of diluent and drug can be considered a second component. 
When a tablet of low thickness (or low porosity) swells a network of gel-like material is 
formed which spans the tablet keeping it intact and sustaining the release of the drug. At 
higher tablet thickness swollen HP particles become isolated within the matrix and 
therefore the integrity of the matrix is lost leading to disintegration of the tablets and rapid 
drug release. The effect appears to be an “all or nothing” phenomena since no 
intermediate profiles were observed. Percolation theory has been used to explain the 
effect of drug loading (81,159) and polymer loading (160) on drug release from polymeric 
matrices. This work shows that the theory can also be used to explain the effect of tablet 
thickness (or compaction force) on the release controlling action of a tablet containing a 
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Figure 4.14 Dissolution of diclofenac sodium from tablets 
containing 5% HP (paddle speed 50rpm, n=3)
4.4.5 Comparison o f the release controlling action o f TIMERxN and BHP-based 
tablets
Figure 4.15 shows that the release profiles of benzamide from TIMERxN and 
BHP-based tablets were similar. In comparison, the rate of release of diclofenac sodium 
from TIMERxN tablets was much slower than from BHP-based tablets. Benzamide, 
being highly water-soluble, will have left the tablet matrix principally by a diffusion 
process. The fact that TIMERxN and BHP-based granules sustained the release to the 
same extent suggests that the diffusitivity of benzamide in theses two materials was 
similar. Being less water-soluble, the release of diclofenac sodium from the swollen 
material was likely to occur to some extent by attrition of the swollen material. Since 
TIMERxN sustained the release of diclofenac sodium longer than BHP-based tablets this 
suggests that matrices composed of TIMERxN were more resistant to erosion. This 
might possibly have been due to the presence of the tertiary components ethylcellulose 
and calcium sulphate in the TIMERxN matrix. Ethylcellulose is sometimes used as a 
binder in tablets where it reduces the rate of drug dissolution by virtue of its insoluble 
nature (161). The importance of calcium ions in the formation of firm gelatinous
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networks of polysaccharides has been documented (56,57). These may play a part in 
holding the matrix together and preventing attrition and matrix dissolution. It was 
observed that even after 24hr of agitation at 37°C a swollen body of TIMERxN still 
remained in the dissolution vessels and the dissolution medium remained clear. In 
contrast, after approximately 24hr of dissolution BHP-based tablets had completely 
eroded. It is also possible that diclofenac sodium interacted with one or more of the 















Figure 4.15 Comparison of the release controlling action of 
TIMERxN and BHP-based tablets (paddle speed 50rpm, n=5)
4.5 Conclusion
It appears than under certain conditions correlations between porosity, pore size 
distribution and release rates may be observed. However, for hydrophilic matrices that 
swell rapidly and extensively it seems likely that release rates will be generally be 
independent of the initial bulk physical characteristics of the matrix. The extensive 
swelling of HP-based matrix tablets meant that initial tablet porosity, pore size distribution
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and initial release surface area were not important in determining drug release rates for the 
formulations studied. The swelling characteristics of the matrix meant that even when the 
tablets had initially different geometrical shapes, the release profiles of a slightly water- 
soluble drug were similar.
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5. Functional interchangeability and pharmaceutical equivalence in HP-based 
tablet and capsule matrices: in vitro observations
5.1 Introduction
The rate of release of the model drugs benzamide and diclofenac sodium from HP- 
based tablets was found to be independent of the initial bulk characteristics of the dry 
tablet. A theory of porosity-independent release was postulated and tested using capsule 
matrices. Hard gelatin capsules containing uncompacted granules were considered 
analogous to tablets, the difference being that capsule matrices had a high interparticulate 
porosity. Assuming porosity-independent release then theoretically, capsules and tablets 
were expected to have equivalent rate controlling action. This was considered a novel 
concept since not only would the two dosage forms be equivalent in terms of release 
controlling action but they would also be equivalent in terms of formulation composition. 
The use of capsule matrices as an alternative to tablet matrices without formulation 
modification has not previously been reported. Capsule matrices have predominately been 
investigated as hydrodynamically balanced systems for prolonging gastric residence time 
(98,162). Only a limited number of studies have considered hydrophilic matrix capsules 
as simple hydrophilic matrix systems (14,31,70,99) and no studies have been reported that 
have compared the release controlling characteristics of swellable hydrophilic tablet with 
capsule matrices containing the same formulation.
5.2 Materials
Diltiazem HC1 (Lot No. 970611) was obtained from Seloc AG, SEFA Ltd., 
Shannon, Ireland). Propranolol HC1 (Lot No. 1067B193) was obtained from Industrie 
Chemiche Italiane, S.p.H. (Milan, Italy). Hard gelatin capsules, DBCAPS™ size A, were 
obtained from DAVCAPS (Capsugel, Belgium). Xanthan gum (Lot No. P5086), locust 
bean gum (Lot No. B21577), glucose (Lot No. CD6D29107) and TIMERxN (Lot No. 
NS664) were supplied by Penwest Pharmaceuticals Co., (Patterson, NY, USA). 
Diclofenac sodium (Lot No. 94-01342) was obtained from Heumann Pharma GmbH 
(Nurenberg, Germany). Benzamide (Lot No. 6366081) was obtained from Aldrich 
Chemical Co. (Loughborough, U.K.). Hydroxypropylmethylcellulose (Methocel K15M 
Premium EP, Lot No. KJ26012N01) was obtained from Colorcon (Kent, U.K). Acetone
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and magnesium stearate (Lot No. 30120362) were obtained from Fisons Scientific 
Equipment Ltd. (Loughborough, U.K.). lpm  cellulose nitrate filters were obtained from 
Whatman International Ltd., (Maidstone, U.K).
5.3 Methods
5.3.1 Characterisation o f diltiazem HCl and propranolol HCl
Diclofenac sodium, propranolol HCl, diltiazem HCl and benzamide were selected 
as model drugs. According to the USP solubility classification (65) diclofenac sodium can 
be described as being slightly water-soluble, benzamide and propranolol HCl as water- 
soluble and diltiazem HCl as freely water-soluble. The percentage solubility (w/v) of each 
drug in distilled water (pH 7.0) and the drug loadings used in this study are shown in table
5.1.
Model drug Solubility in water (%) Drug loading (%)
Diclofenac sodium 0.187* 5 and 7.5
Propranolol HCl 5* 20
Diltiazem HCl Freely soluble** 30
Benzamide 1.35** 3
*(154), **(153)
Table 5.1. Solubility and drug loading of model drugs
The chemical structures of propranolol HCl and diltiazem are shown in figures 5.1 










Figure 5.2 Molecular structure of diltiazem
5.3.2 Assay o f diltiazem HCl and propranolol HCl
Diltiazem HCl and propranolol HCl were assayed by UV detection at the tanax of 
each drug. The assay of diclofenac sodium and benzamide is described in section 4.3.2. 
Dilute solutions of propranolol HCl and diltiazem HCl were scanned between 200nm and 
350nm using a UV/VIS spectrophotometer (Lambda 3B, Perkin-Elmer, Beaconsfield, 
U.K.). The tanax were found to be 288nm for propranolol HCl and 236nm for diltiazem 
HCl. A stock solution of propranolol HCl (0.075%) was prepared by dissolving 375mg 
of propranolol HCl, accurately weighed, in 500ml of distilled water. Aliquots of the stock 
solution were diluted to produce a series of solutions having target concentrations of 
0.0015%, 0.0030%, 0.0045%, 0.0060% and 0.0075%. The absorbance of each solution 
was determined at 288nm using a UV/VIS spectrophotometer (Unicam 8625, Cambridge, 
U.K.) against a distilled water blank. Using the same stock solution a second series of 
dilutions was prepared and analysed in the same way. Using a fresh stock solution a third
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series of solutions were prepared and the UV absorbance determined. A stock solution of 
diltiazem HCl (0.025%) was prepared by dissolving 125mg of diltiazem HCl, accurately 
weighed, in 500ml of distilled water. Aliquots of the stock solution were diluted to 
produce a series of solutions having target concentrations of 0.0005%, 0.0010%, 
0.0015% and 0.0020%. A second set of dilutions was prepared from the same stock 
solution and a third set of dilutions was prepared from a fresh stock solution. The UV 
absorbance of the solutions at 236nm was determined against distilled water. 3 
calibration plots were constructed for each model drug and linear regressions were carried 
out using a computer graphics program (MicroCal Origin, MicroCal Scientific Inc., 
Northampton, MA, USA).
5.3.3 Sample preparation
Each model drug was distributed in one or more HP-based formulations, in 
powder and/or granule form. Diclofenac sodium was also incorporated into HPMC based 
granules. The gelatin bodies of size A hard gelatin capsules were filled to capacity with 
powder or granules, the fill weight used depending on the bulk density of each 
formulation. A similar weight of material was compacted into 5mm x 16mm caplet 
shaped tablets using a single-punch tablet press (Type F3, Manesty, Speke, Liverpool, 
U.K.). The geometry of the capsules and tablets meant that each dosage form had a 
similar shape and length prior to dissolution. Table 5.2 gives approximate volumes, initial 
surface areas and dimensions of size A gelatin capsules and caplet shaped tablets. The 
mean weight (n=5) of each batch of tablets and the mean weight (n=5) contained in each 
batch of capsules are given in table 5.3.
Capsule Caplet
Bulk volume (cm3) 0.97 0.44
Outer surface area (cm2) 5.77 3.91
Diameter (mm) 8 5
Length (mm) 18 16
Thickness (mm) - 5.5
Table 5.2 Bulk volume, surface area and dimensions of capsules and caplets
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5.3.3.1 Diclofenac sodium distributed intragranularly
XG (25%), LBG (25%), glucose (45%) and diclofenac sodium (5%) were blended 
for 5min in a high shear mixer (Cuisine Systeme Automatic 5000, Magimix, Surrey, 
U.K.). Total batch size was 300g. The blend was wet agglomerated with 21.6% distilled 
water and tray dried at 60°C in an oven (Model H-150, Size 2 Gallenkamp, 
Loughborough, U.K.) for 24hr giving material with an LOD <5%. The material was 
screened through a 0.63mm mesh using a mechanical granulator (Type MGL 4A, Frewitt, 
Switzerland). The granules were sieved for 30min (Endecotts Ltd., London, U.K.) 
through an I.S.O standard aperture diameter V2 sieve progression ranging from 710jim to 
63|Lim. The sieves were agitated using a Fritsch sieve shaker (Type 03-502, Fritsch, 
Germany). Quantities from each sieve fraction were selected in the following 
proportions: 500 to 710pm (2%), 355 to 500pm (4%), 250 to 355pm (26%), 180 to 
250pm (36%), 125 to 180pm (26%), 90 to 125pm (3%), 63 to 125pm (2%) and 0 to 
63pm (1%). Sieve fractions were recombined using turbula rotation (Type T2C, Glen 
Creston Ltd., Stanmore, Middlesex, U.K.) for 5 minutes at 30rpm giving particles with a 
theoretical median particle size of 182pm.
5.3.3.2 Diclofenac sodium distributed extragranularly
XG (25%), LBG (25%) and glucose (50%) were blended in a high shear mixer for 
5min. This gave a simple, non-granulated, HP-based blend. The true density of the blend 
determined by helium pycnometry (Accupyc 1330, Micromeritics, Norcross, USA) using 
the method described in section 2.3.1 was found to be 1.52g/cm3. The aerodynamic 
particle size distribution of the blend was measured using the method described in section
2.3.1 (Aerosizer, Amherst Instruments Inc., MA, USA). The D[4,3] was found to 59.6 ± 
5.6pm (n=3). Diclofenac sodium (7.5%) was distributed through the blend (92.5%) by 
geometric trituration.
A formulation containing diclofenac sodium distributed extragranularly in pre­
granulated HP-based material was also prepared. XG (25%), LBG (25%) and glucose 
(50%) were blended in a high shear mixer for 5min. The material was wet agglomerated 
with 15.9% distilled water, tray dried at 21°C for 48hr and hammer-milled (Type DFH 
48, Glen Creston Ltd., Stanmore, U.K.) using a 3mm screen. The sieve fraction less than 
180pm was collected (Endecotts Ltd., London, U.K.). The aerodynamic diameter of the 
granules (D[4,3]) was found to be 61.9pm ± 6.2pm, similar to the aerodynamic diameter 
of the simple HP-based dry blend. 92.5% of the pre-granulated material was blended with
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7.5% diclofenac sodium by geometric trituration. Both extragranular diclofenac sodium 
formulations contained the same proportion of drug and excipients and had similar 
particle sizes.
5.3.3.3 Propranolol HCl granules
XG (25%), LBG (25%), glucose (30%) and propranolol HCl (20%) were blended 
in a high shear mixer. The materials were wet agglomerated with 21% distilled water for 
5min then tray dried at 60°C in an oven for 24hr giving material with an LOD of less than 
5%. The material was passed through a 0.63mm screen using an oscillating granulator 
and size selected as described in section 5.3.3.1, to give granules with a theoretical 
median particle size of 182pm.
5.3.3.4 Diltiazem HCl dry blend
XG (25%), LBG (25%) and glucose (50%) were blended in a high shear mixer for 
5min. The simple dry blend of HP components was mixed, by geometric trituration, with 
diltiazem HCl in the ratio of 70% HP-based dry blend to 30% drug. The punch and die 
were lubricated with a suspension of 1.5% magnesium stearate in acetone prior to 
compaction of caplets.
5.3.3.5 Benzamide granules
XG (24.3%), LBG (24.3%), glucose (48.4%) and benzamide (3.0%) were blended 
for 5min using a high shear mixer. The dry blend was agglomerated using 17.8% distilled 
water, which was added over lmin. Total mixing time was 5min. The wet material was 
tray dried in an oven at 60°C for 24hr giving material with an LOD of less than 5%. The 
dry material was screened through a 0.63mm mesh using an oscillating granulator and size 
selected as described in section 5.3.3.1, giving granules with a theoretical median particle 
size of 182pm
5.3.3.6 Methocel K15M matrices
Methocel K15M is a grade of HPMC that has often been studied as a hydrophilic 
swellable excipient (82). It has a nominal apparent viscosity of 15000cp (163) and a mean 
aerodynamic diameter of 28.4 ± 0.5pm (determined using the method described in Section 
4.3.5). A formulation containing diclofenac sodium in a Methocel K15M matrix was 
prepared using a similar formulation and method used to produce the HP-based diclofenac
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sodium formulation. Diclofenac sodium, glucose and Methocel K15M were blended for 
5min in a high shear mixer. Batch size was 200g. The material was wet agglomerated 
with 33.3% distilled water for 5min. The material was tray dried for 24hr in an oven at 
60°C and passed through a 0.63mm screen using an oscillating granulator. The dry 
material was size selected as described in section 5.3.3.1, giving granules with a 
theoretical median particle size of 182jim.
5.3.3.7 Placebo granules and tablets
Placebo capsules and caplets were prepared for use in mechanical strength studies. 
XG (25%), LBG (25%) and glucose (50%) were dry blended in a high shear mixer for 
5min. The blend was wet agglomerated with 20.6% distilled water for 8min, dried at 
21°C for 48hr and hammer-milled (Type 14-586, Glen Creston Ltd., Stanmore, 
Middlesex, U.K.) using a 3mm screen. The granules were size selected as described in 






Diclofenac Na distributed intragranularly in 386.4 ±5.9 372.9 ±3.6
HP-based granules
Diclofenac Na distributed in simple HP-based 471.5 ±5.9 453.5 ± 12.8
dry blend
Diclofenac Na distributed in pre-granulated 477.3 ±19.1 469.7 ± 8.7
HP-based material
Propranolol HCl distributed intragranularly in 380.7 ±5.0 386.3 ±1.3
HP-based granules
Diltiazem HCl distributed in a simple HP- 431.4 ±14.0 433.8 ±4.6
based dry blend
Benzamide distributed intragranularly in HP- 396.9 ±9.2 399.5 ±2.8
based granules
Diclofenac Na distributed intragranularly in 251.0 ±4.7 252.3 ±0.8
Methocel K15M granules
Table 5.3 Weight of material constituting tablet and capsule matrices.
5.3.4 Dissolution testing
Dissolution of model drugs from matrices in 1000ml of distilled water heated to 
37°C ± 0.2°C was determined using a USP II dissolution apparatus (Type PTW S3C, 
Pharmatest Ltd., Gwent, U.K.) with paddles positioned 4cm above the point of curvature 
at the bottom of the vessel. Paddle speed was 50rpm or lOOrpm. The dosage forms to be 
analysed were supported in stainless steel wire cages (approximately 5cm x 2.5cm) to 
allow unrestricted swelling, ensure release from all surfaces and to prevent the capsules 
from floating. To assay drug release from HP-based matrices samples of dissolution 
medium were withdrawn at intervals using a syringe and filtered through ljim cellulose 
nitrate filters. An equal volume of distilled water heated to 37.0 ± 0.2°C was added to 
each dissolution vessel following sampling to maintain constant volume. The absorbance 
of the filtrate at the appropriate Amax was measured using an UV spectrophotometer 
(Unicam 8625, Cambridge, U.K.). Medium containing diltiazem HCl was diluted 1:5 with
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distilled water prior to filtration to bring the absorbance within the linear range of the 
calibration plot. The quantity of drug released at each time point was calculated taking 
into account the amount removed by sampling and the progressive dilution of the 
dissolution medium. Drug release was expressed as a percentage of the initial drug 
content while error bars represented the standard deviation from the mean. It was shown 
that no loss of UV absorbance occurred at the Amax of each model when solutions of 
diltiazem HCl, propranolol HCl, diclofenac sodium and benzamide were passed through 
cellulose filters. This suggested that the models did not adsorb on to the cellulose filters. 
The UV absorbance of approximately 373mg of a placebo formulation contained in a hard 
gelatin capsule, completely dispersed in water, was found to be less that 6% of the 
maximum drug absorbance after the medium was filtered through l|im  filters.
To follow the release of diclofenac sodium from Methocel K4M matrices samples 
were removed and analysed using the automated set up described in section 4.3.6.1. 
Automatic sampling was possible with these matrices as excipient interference could be 
minimised by passing the medium through the 20pm filters fitted for the automatic 
sampling method.
5.3.5 Determination o f content uniformity
The drug content of each diclofenac sodium formulation was determined. 
Accurately weighed samples (approximately lOOmg) were distributed in either 200ml or 
250ml of distilled water. The solutions were allowed to equilibrate for at least 6hr and 
sonicated (FS2006, Deacon Laboratories Ltd., U.K.) for 15min. Samples of the solution 
were filtered through 1pm cellulose nitrate filters and the UV absorption at 273nm was 
determined. The drug content of the diltiazem HCl formulation was determined by 
distributing approximately 70mg of powder, accurately weighed, in 500ml of distilled 
water. The samples were allowed to equilibrate for at least 6hr and filtered as described 
above. The UV absorbance at 236nm was determined. Six determinations were made on 
each batch of material and the mean drug content was calculated using the appropriate 
calibration data. The amount of drug release during dissolution was expressed as a 
percentage of the initial drug content. For the remainder of the formulations the drug 
released was expressed as a percentage of the theoretical drug content.
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5.3.6 Determination o f drug stability
The UV absorbance of solutions of diltiazem HCl and propranolol HCl maintained 
at 37.0 ± 0.2°C was measured at the tanax of each model drug at intervals over a 24hr 
period. The absorbance of a diltiazem HCl solution varied by + 5.2% over this period and 
the absorbance of a solution of propranolol HCl varied by up to + 4.3%. No loss of 
absorbance at the tanax occurred. This indicated that the model drugs would remain 
stable over the dissolution period.
5.3.7 Preparation o f reference tablets
Reference tablets were used to give confidence that the dissolution conditions 
used in each experiment were consistent (see section 4.3.4.4). Diltiazem HCl reference 
tablets were prepared by blending diltiazem HCl (3.75%) and TIMERxN (95.25%) by 
geometric trituration. Magnesium stearate was added as a lubricant and distributed by 
turbula rotation at 30rpm for 5min. The blend was compacted on a single-punch tablet 
press using 8mm flat-faced F tooling. The preparation of diclofenac sodium and 
benzamide reference tablets is described in section 4.3.4.4.
5.3.8 Determination o f the mechanical strength o f hydrated matrices
A measure of the mechanical strength of placebo swollen capsule and tablet 
matrices was obtained by measuring the work done as a probe penetrated the swollen 
material. Dosage forms to be tested were placed in 3.5cm x 2cm mesh baskets, which 
allowed both axial and radial swelling. The baskets were placed in dissolution vessels that 
contained 750ml of distilled water heated to 37.0 ± 0.2°C. The water was agitated using 
paddles, positioned 4cm above the bottom of the vessels, rotating at 50rpm. At each time 
point the basket was removed, drained and the swollen gel-like material was placed 
directly under a 6mm stainless-steel cylindrical probe attached to a texture analyser (TA- 
XT2 Texture Analyser, Stable Microsystems, Surrey, England) fitted with a 5kg load cell. 
The probe was lowered at a speed of lmm/s into the sample to a depth of 4mm. 
Measurement of force was triggered when the probe detected the surface of the material. 
The force generated was recorded over the period of movement of the probe and the 
work done was calculated as the area under the force (g)/distance (mm) plot. Six samples 
were tested at each time point using a fresh set of samples in each case.
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5.3.9 Imaging o f tablet and capsule swelling
Images were taken of hydrating capsule and tablet matrices prepared from granule 
batch G3B (see section 3.3.2). The granules were hand filled into a size A gelatin capsule 
(weight 460.7 ± 11.3mg) and compacted into a 5 x 16mm caplet shaped tablet (weight
467.7 ± 9.9mg). A flat-bottomed stainless steel vessel was filled to a depth of 4cm with 
distilled water. The vessel was heated with a hot plate (Model MR 3022, Heidolph, 
Germany) to 37°C ± 0.5°C and agitated using a magnetic flea rotating at 150rpm. The 
dosage forms to be imaged were anchored between two coils of a helical wire. This 
prevented the matrices from floating but put a minimum restriction on swelling. The 
dosage forms were imaged at pre-determined time intervals using a digital camera (DX-7, 
Fuji Photo Film Ltd., China) that was positioned directly above the vessel. A grid was 
used to provide a scale from which the dimensions of the swollen body could be 
determined. The images were processed using photoenhancer software (PictureWorks 
Technology Inc., Danville, USA).
5.4 Results and discussion
5.4.1 Calibration data
Tables 5.4 and 5.5 show calibration data for propranolol HCl and diltiazem HCl, 
respectively. Calibration plots, given in appendix 2, were found to be linear in the 
concentration range 0 to 0.075% for propranolol HCl and 0 to 0.020% for diltiazem HCl. 
Student’s t-tests showed that there were no significant differences between the calibration 
plots for each drug (p<0.05).
Calibration plot No.
1 2 3 M ean (n=3)
Intercept 0.0062 0.0122 0.0145 0.0109
Slope 178.44 177.92 182.17 179.51
Standard deviation 0.81 2.21 2.16 -
Regression (r2) 0.9999 0.9997 0.9997 -
Table 5.4 Calibration data for propranolol HCl
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Calibration plot No.
Mean (n=3)1 2 3
Intercept -0.0072 -0.0040 0.0014 -0.0006
Slope 520.80 513.43 507.42 513.88
Standard deviation 2.8 3.5 3.1 -
Regression (r2) 0.9999 0.9999 0.9999 -
Table 5.5 Calibration data for diltiazem HCl
5.4.2 Dissolution from HP-based tablet and capsule matrices
Figure 5.3 shows the release profiles of diclofenac sodium from capsule and tablet 
matrices that contained the drug distributed intragranularly. It can be seen that the release 
profiles obtained from capsules and tablets were very similar. Statistical analysis using 
Student’s t-test showed that the mean percentage released from capsule matrices was not 
significantly different from the mean percentage released from tablet matrices at the 2, 4, 
6 and lOhr time points (p<0.05). Although a statistical difference between the means 
existed at the 8hr time point this was not considered practically significant. Figures 5.4 
and 5.5 show the release of propranolol HCl from capsule and tablet matrices and the 
release of diltiazem HCl from capsule and tablet matrices, respectively. Despite the high 
water-solubility of the models, capsule and tablet matrices controlled the release to a 
similar degree. Statistical analysis of the mean percentages released at each time point 
using Student’s t-test showed that for tablets and capsules containing propranolol HCl the 
data was significantly different only at the 7hr time point (p<0.05). For diltiazem HCl 
statistical differences were calculated at the 1 and 3hr time points (p<0.05). Again, 
although statistically significant the differences were considered insignificant in practice. 
Although porosity independent release was predicted the results were interesting since it 
would have been conceivable that granules contained uncompacted in gelatin capsules 
would de-aggregate to some degree during the early stages of dissolution resulting in a 
burst release of drug. This was not observed with the capsule matrices studied.
It was also interesting to find that disintegration of the capsules did not occur 
when the degree of agitation in the dissolution medium was increased. Figure 5.6 shows 
that when the paddle speed was increased from 50 to lOOrpm, capsule and tablet matrices
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still controlled the release of diclofenac sodium to the same extent. Additionally, the 
release profiles obtained were very similar to the release profiles observed at 50rpm 
(figure 5.3). By increasing the paddle speed the hydrodynamic flow in the dissolution 
medium was increased. Paddle speed may also have affected the hydrodynamic stresses 
to which the dosage forms were subjected. However, the influence of paddle speed on 
hydrodynamic stress could not be quantified. An increase in paddle speed may not have 
caused a sufficient increase in hydrodynamic stress to affect the erosion of the matrices. 
Therefore, dissolution profiles remained similar. Alternatively, the fact that no differences 
in release profiles were observed when the paddle speed was increased was possibly due 
to the Theological properties of the swollen gel-like material formed in each case. 
Aqueous mixed solutions of XG and LBG are associated with high elastic moduli (50). In 
the context of dissolution from matrices this means that the matrices are likely to have a 
high resistance to erosion, as compared to purely viscous materials, which are likely to be 
washed away more quickly by the dissolution medium (39).
The absence of a burst release from capsule matrices was attributed to the 
hydration and Theological properties of HP-based material. When the capsules were 
placed in the dissolution vessel the gelatin shell slowly began to dissolve, gradually 
exposing the granules to the dissolution medium. The granules hydrated rapidly and 
began to swell, the rapid hydration probably being facilitated by the high proportion of 
glucose in the formulation and by the hydrophilic nature of the XG component. Swelling 
ensured that initially well separated particles came into contact. XG/LBG solutions are 
viscoelastic, which means that when the molecules come together they coalesce (50). 
This is in contrast to predominantly elastic solutions, which do not coalesce (39). It is 
this property that probably resulted in coalescence of the swollen particles producing a 
continuous viscoelastic matrix, which filled the interstices, maintaining the integrity of the 
capsule matrix. The digital images presented in figures 5.7 and 5.8 show that although 
hydrated capsule matrices appeared to be more diffuse than hydrated tablet matrices, 
hydrated capsules did not disintegrate and maintained an intact body over the six-hour 
period that the matrices were imaged. The gelatin shell modified the release profiles by 
allowing the polymer to gel prior to dissolution of the gelatin. The gelatin shell also 
appeared to be responsible for imparting a cylindrical shape to the powder plug.
Mechanistically, two distinctive processes, namely swelling and true dissolution, 
generally occur during the overall dissolution of polymers (164). Drug release occurs by 
a combination of diffusion through the swollen gel and erosion of the matrix (6). The
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independence of diclofenac sodium release rates on paddle speed indicated that the 
transfer of drug from the matrix into bulk solution due to dissolution of the actual matrix 
was less important than diffusion of the drug from the matrix. The fact that, for each 
formulation a large proportion of the dose was released while most of the matrix remained 
intact, also indicated that, under the test conditions employed, transfer of drug from the 
matrix was predominately a diffusion process. This observation is in agreement with that 
of Pharm and Lee (165) who found that the effect of HPMC dissolution on drug release 
was insignificant and the release kinetics were mostly regulated by a swelling-controlled 
diffusional process, particularly for higher viscosity grades of HMPC. Based on the 
findings described in chapter 4, where release from tablet matrices was found to be 
independent of initial matrix porosity, it is proposed that the propensity of the hydrated 
layer to erosion and the diffusitivity of drug in the hydrated layer was the same for both 
capsule and tablet matrices under the in vitro conditions evaluated. Therefore, the 
diffusional path length presented by both matrices must have been similar in order to 
account for the equivalent release profiles observed. This could be as a result of a similar 
degree of swelling by each matrix. Digital images of a hydrating caplet and capsule 
(figures 5.7 (a) to (h) and 5.8 (a) to (h)) show that both dosage forms swelled extensively 
and that capsules swelled to a slightly greater extent than tablets. For both capsules and 
tablets dimensional changes in length were more pronounced than changes in diameter, 
therefore both dosage forms maintained a cylindrical shape during hydration. After 5hr 
hydration the capsule matrix had swollen to approximately 104% of its original length 
while the tablet matrix had swollen to approximately 92% of its initial length. Although 
the dimensions of the swollen bodies were not identical at equivalent time points, it is 
possible that when the diffusion pathway caused by the tortuosity of the swollen gel-like 
material is long, then differences between the dimensions of the swollen material formed 
become negligible. This could account for the equivalent release profiles observed. 
Alternatively, it is possible that the slightly greater swelling observed in hydrated capsules 
matrices could be balanced by the looser porous network formed resulting in a overall 
diffusional path length similar to that of tablet matrices.
Although tablet and capsule dissolution profiles were equivalent for the model 
drug diclofenac sodium, propranolol H Q  and diltiazem HCl, figure 5.9 shows that the 
dissolution of benzamide from capsule matrices was faster than from tablet matrices. The 
difference was more pronounced at the first time point, at subsequent time points the 
differences between the percentage released from each dosage form decreased. It is
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possible that a slight burst release from these matrices became significant because of the 
overall low drug loading. Alternatively, for a low dose solute differences in the diffusion 
pathway presented by tablet and capsule dosage forms may become apparent. A third 
explanation for the differences may be related to the role played by the model drugs 
themselves in determining their own release rates. Examination of the release profiles for 
propranolol HCl (figure 5.4) and diltiazem HCl (figure 5.5) shows that after a period of 
time the rate of dissolution began to rapidly decrease. After 9hr dissolution only 
approximately 58% of propranolol HCl was released and after 1 lhr approximately 42% of 
diltiazem HCl was released. This suggested that some type of interaction, developing as 
hydration progressed, was taking place. The effect of drugs on the release controlling 
properties of hydrophilic matrices has been well documented and there are a number of 
ways in which drugs are known to interfere with dissolution rates. Interactions of drugs 
with polysaccharides can occur through adsorption of drugs to the excipients (166,167) 
and in some cases this has been shown to affect the dissolution of drugs from tablets 
(76,168). Adsorption is the preferential partitioning of a drug to a solid liquid interface as 
opposed to the bulk and probably occurs to some extent in all excipients. The primary 
mechanism of interaction is thought to be through weak Van der Waals’ attraction forces 
(169). This is known to occur between the amine groups of drug molecules and anionic 
regions of microcrystalline cellulose (167,170). Since XG is anionic and XG, LBG and 
glucose have many hydroxyl groups, the potential for hydrogen bonding with positively 
charged regions of drug molecules is high, especially when the polymer is highly hydrated. 
Hydrogen bonds however are weak and are unlikely to account for the interactions 
observed here. It has been shown that cationic drugs can adsorb onto the surface of MCC 
by an ion-exchange mechanism, due to the negatively charged MCC surface (170) and it 
is thought that cationic drugs can form complexes with sodium carboxymethylcellulose, 
an anionic hydrophilic material (76,171). It is possible that some type of covalent binding 
occurred between HP-based matrices and the cationic drugs, diltiazem HCl and 
propranolol HCl. Physicochemical interactions between the model drugs, benzamide and 
diclofenac sodium, and the excipients may also have occurred to a lesser extent. 
Although interactions can adversely effect dissolution they may also play a part in 
maintaining the integrity of the network. It was observed that after diltiazem HCl 
matrices had been exposed to the dissolution medium for a number of hours a solid, 
opaque mass had formed. After 24hr dissolution, a large proportion of the mass 
remained, indicating that a body was produced that had a high resistance to erosion. The
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presence of propranolol HCl in HPMC matrices has been shown to be important in 
maintaining the structure of the gel network (172). The presence of soluble solutes in the 
matrix can also affect the swelling and hydration of hydrophilic matrices (28). The 
presence of a very water-soluble drug has been shown to produce faster and more 
extensive swelling possibly due to osmotic effects (165). Talukdar and Ringet (28) found 
that the dissolution of caffeine from HPMC matrices was faster than the dissolution of 
indomethacin sodium despite indomethacin sodium being 10 times more soluble than 
caffeine. The results were attributed to the greater degree of swelling that occurred in the 
indomethacin sodium matrices, which emphasises the fact that swelling is a principle rate- 
limiting factor for drug release. In cellulose ethers, the presence of solute may lower the 
thermal gelation temperature, which can result in a higher than expected viscosity due to 
polymer-polymer interactions and can extend drug dissolution times (6,82). Since 
LBG/XG solutions do not exhibit the properties of thermal gelation (39) then the 
presence of strongly ionic drugs will not affect the gelation of the matrix in this way. 
High levels of strongly ionic salts can however, compete with for available water in the 
gel layer and cause polymer dehydration. This can cause precipitation of the gel, resulting 
in matrix failure and premature dissolution (6,87). This has not yet been reported for XG 
or HP matrices. The potential for interaction between drugs and HP-based materials has 
not been investigated extensively but this work shows that drug/excipient interactions 
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Figure 5.3 Dissolution of diclofenac sodium from capsule 
and tablet matrices containing the drug distributed 


















Figure 5.4 Dissolution of propranolol HCl from HP-based 
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Figure 5.5 Dissolution of diltiazem HCl from HP-based 
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Figure 5.6 Dissolution of diclofenac sodium from HP-based matrices 
containing the drug distributed intragranularly 
(paddle speed lOOprm, n=5)
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Figure 5.7 (a) t=0 Figure 5.8 (a) t=0
Figure 5.7 (b) t=10min Figure 5.8 (b) t=10min
Figure 5.8 (c) t=30minFigure 5.7 (c) t=30min
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Figure 5.7 (d) t=lhr Figure 5.8 (d) t=lhr
Figure 5.7 (e) t=2hr Figure 5.8 (e) t=2hr
Figure 5.7 (f) t=3hr Figure 5.8 (f) t=3hr
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Figure 5.7 (g) t=4hr Figure 5.8 (g) t=4hr
Figure 5.7 (h) t=5hr
Figure 5.7 (a) to (h) Digital images of 
of a hydrating capsule matrix
Figure 5.8 (h) t=5hr
Figure 5.8 (a) to (h) Digital images 
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Figure 5.9 Dissolution of benzamide from HP-based tablet 
and capsule matrices (paddle speed 50rpm, n=5)
In order to produce HP-based compacts that have the strength required for 
pharmaceutical processing it is necessary to granulate the components using a high shear 
mixer (37). To determine whether high shear agglomeration of HP components was 
necessary to obtain material possessing high release retarding properties the dissolution of 
diclofenac sodium from matrix tablets prepared from a simple dry blend of HP-based 
components was examined. Figure 5.10 shows that no difference in release controlling 
action was observed between matrices that had been prepared by wet agglomeration and 
matrices that had been prepared by simply dry blending the three components. The 
synergistic reaction that occurs between XG and LBG may develop as the matrix hydrates 
and high shear agglomeration of the components may not be necessary to obtain a 
formulation with high release retarding ability. Although this observation was made for 
matrices containing diclofenac sodium, matrices containing model drugs other than 
diclofenac sodium may behave differently. Figure 5.10 also shows that, when the 
formulation contained diclofenac sodium distributed extragranularly, equivalent capsule 
and tablet release rates were still observed. This demonstrated the rapid rate of swelling 
in these matrices, which prevented drug near the surface of the tablet or capsule being 
released at an initially rapid rate.
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Formulations containing diclofenac sodium distributed extragranularly contained 
HP-based material that had a median particle size of approximately 60|im while the 
formulation containing diclofenac sodium distributed intragranularly had a median particle 
size of 182pm. Both formulations were capable of sustaining the release of diclofenac 
sodium to the same degree for up to lOhr. This was interesting since Dhopeshwarker and 
Zatz (71) found that coarse sieve fractions of XG (74 to 177pm and 177 to 420pm) did 
not hydrate rapidly enough to sustain the release of acetominophen. In contrast, XG 
particles in the size range 40 to 70pm were found to sustain the release for more than 8hr. 
For HP-based formulations both coarse and fine particle sizes were found to provide 
sustained release of diclofenac sodium. This may be because of the presence of glucose in 
the formulation, which enhances wetting, thus ensuring that even coarser particles hydrate 
rapidly.
Simple monolithic swellable controlled release matrices are commonly associated 
with release rates that decrease with time, however, zero-order release kinetics have 
occasionally been reported (19). Release kinetics that approximated to zero-order for up 
to 70% drug release was observed from diclofenac sodium matrices that contained the 
drug incorporated extragranularly (r2 ranged from 0.976 to 0.996) (figure 5.10). This was 
in contrast to release profiles from matrices that contained diclofenac sodium dispersed 
intragranularly, where time-dependent release was observed. In swellable matrix systems 
the most important rate-limiting parameters controlling linear release kinetics are polymer 
relaxation, gel erosion, polymer dissolution and the maintenance of gel layer thickness (5). 
The mechanism of drug release and factors influencing the release process from theses 
systems are complex, debatable and still in progress (5,173). Baveja et a l (19) have 
proposed that zero-order drug release will be observed when the swelling and erosion 
fronts become synchronised thereby maintaining a gel-like layer of constant thickness. 
Colombo et a l (17) suggested that when a diffusion layer exists the dissolved drug layer 
thickness is the reference element for drug release. The difference in release of diclofenac 
sodium from the formulation were the drug was dispersed intragranularly and from the 
formulation with the drug dispersed extragranularly were possibly due to a number of 
factors including; a change in drug solubility as a result of wet granulation; differences 
between the degree of drug/polymer interaction in each formulation; differences in the 
contribution of the drug to swelling and hydration in each formulation. Section 4.4.2 
shows that the dissolution of benzamide from HP-based matrices followed zero-order 
kinetics. Although benzamide has a much higher aqueous solubility than diclofenac
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sodium the difference in release kinetics can not be attributed to solubility alone (76), 
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One of the important characteristics of soluble hydrophilic matrices is the 
dependence of the release on hydrodynamic conditions. Ideally, formulations would show 
a lack of dependence on dissolution conditions, however, this is not always be the case. It 
has been suggested that the influence of stirring rate is negligible for releases according to 
the square root of time, that is where the release is diffusion controlled rather than erosion 
controlled (173). This is thought to be the situation in well hydrated, high viscosity 
polymers (173). It has been shown that for matrices containing low viscosity swellable 
materials, or matrices containing a low proportion of polymer, increasing hydrodynamic 
stress by raising the speed of revolution in a USP II paddle apparatus can increase 
dissolution rates as a result of accelerated polymer dissolution (27,156). Although no
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difference in release of diclofenac sodium from HP-based matrices was observed when the 
paddle speed was increased to lOOrpm, differences in dissolution might be observed using 
other methods of in vitro dissolution testing. It is possible that under conditions were a 
different type of stress is applied e.g., rotating basket method, then differences in release 
profiles between tablet and capsule dosage forms may be observed.
5.4.3 Methocel K15M matrices
Figure 5.11 shows the release of diclofenac sodium from tablet and capsule 
matrices prepared using Methocel K15M as a hydrophilic swellable matrix excipient. The 
grade of HPMC chosen was a high viscosity grade that has frequently been studied as a 
controlled release excipient (17,82,165) because of its high release retarding properties. 
The K grades are the fastest to hydrate among the HPMC family because the products 
have a lower amount of hydrophobic methoxyl substitution and a higher amount of the 
hydrophilic hydroxypropyl substitution (163). It can seen from figure 5.11 that equivalent 
release profiles from capsule and caplet matrices were observed when Methocel K15M 
was used as the rate controlling material. The release controlling ability of different 
grades of HPMC, including lower viscosity and less rapidly hydrating material, in capsule 
and tablet form would be further area of study. It is anticipated that equivalent release 
profiles might not be observed with HPMC grades and other hydrophilic swellable 
excipients that hydrate more slowly and which swell less extensively.
Figure 5.11 shows the release of diclofenac sodium from HP-based tablets and 
from Methocel K15M based tablets. These formulations were similar in excipient 
composition (see table 5.4), particle size and were prepared in a similar way. The HP- 
based formulation was found to release diclofenac sodium at a much slower rate than the 
Methocel K15M based formulation. After 7hr dissolution 95% of diclofenac sodium had 
been released from Methocel K15M based matrices, in comparison, 92% of drug was 
released from HP-based matrices after lOhr dissolution. It has been reported that the 
release retarding ability of XG is higher than HPMC (30,71). Some of the possible 
reasons for the differences were investigated by Talukdar and Kinget (29), who found 
that; (a) the diffusitivity of indomethacin, indomethacin sodium and caffeine was higher in 
hydrated gels of XG than in hydrated gels of HPMC; (b) the equilibrium moisture content 
of XG powder was higher than that of Methocel K4M when the two materials were 
stored under identical controlled humidity conditions. This suggested that XG was more
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hydrophilic than HPMC; (c) the thickness of the outer layer of XG matrices was 
significantly higher than the thickness of the hydrated layer of a similar Methocel K4M 
matrix. It is possible that the differences observed between the release retarding 
properties of HMPC and HP-based matrices could be attributed to differences in 
hydrophilicity, extent of swelling and tortuosity of the swollen material. In combination, 
LBG, XG and glucose result in a material that has superior release controlling 
characteristics.
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Figure 5.12 Dissolution of diclofenac sodium from 
Methocel K15M and HP-based tablet matrices 
(paddles speed 50rpm, n=5)
HPMC formulation HP-based formulation
50% Methocel K15M 50% HP
45% glucose 45% glucose
5% diclofenac sodium 5% diclofenac sodium
Table 5.6 Formulation of Methocel K15M and HP-based diclofenac sodium matrices
5.4.4 Mechanical strength o f hydrated capsule and tablet matrices
The outer layer of hydrated polymer matrices controls drug release by determining 
diffusion and erosion rates. To some extent drug release must be controlled by the 
physical and mechanical properties of this layer. The mechanical strength of the 
gelatinous layer surrounding hydrophilic matrices is not routinely investigated in the 
formulation of swellable matrices, the viscosity of the gelatinous layer being more 
commonly used to characterise release-controlling properties. A measure of mechanical 
strength was obtained by measuring the force required to move a probe into the hydrated
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layer. Figure 5.13 shows the mechanical strength of swollen HP-based capsule and caplet 
matrices as a function of time. After 1 and 2 hr of swelling the gel-like material formed 
from the caplets had a much higher mechanical strength than the swollen body formed 
from the capsule matrices. At the subsequent time points the mechanical strength of the 
swollen material was similar in each case. This method of determining hydrated layer 
strength clearly differentiated between the two dosage forms. Although the propensity of 
the gels to true dissolution is certainly linked to the Theological properties of the materials 
it does not appear, at least in this instance, that the mechanical strength of the hydrated 
layer can be correlated to dissolution behaviour. Figures 5.14 and 5.15 show the 
penetrating force displacement curves for HP-based tablets and capsule matrices, 
respectively. The almost linear relationship between force and distance observed for both 
dosage forms was possibly due to the viscoelastic nature of the materials. As the probe 
penetrated the matrix the material flowed, like a viscous solution, around the indented 
probe. The absence of a sharp increase in force as the probe penetrated the core of the 
dosage form reflected the visual observation that the core had almost reached its glassy 













Figure 5.13 Mechanical strength of hyrated capsule and tablet 
matrices over a 6hr period
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Figure 5.14 Penetrating force vs displacements curves for 
caplet matrices
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Figure 5.15 Penetrating force vs displacement curves for 
capsule matrices
5.5 Conclusion
Capsule and tablet matrices based on HP were found to control the in vitro release 
of three model drugs at equivalent rates. The findings of this study were of relevance to a 
concept of dosage form interchangeability proposed by the standards development 
division of the USP Pharmacoepia. The standards division deals with maintaining existing 
standards and introducing new standards and proposed revisions are published for public 
review and comment in the pharmaceutical form (PF). Proposals that are believed to be of 
most interest to health care practitioners are abstracted from PF and published as a 
newsletter ‘standard issues for the health care practitioner’. In the January-February 
1997 issue (174), the dissolution and bio availability subcommittee of the standards 
division discussed the concept of functional interchangeability of solid oral dosage forms. 
The committee recommended that USP general notices and requirements include the 
following statement; ‘Unless otherwise stated in the individual monograph, tablets and 
capsules prepared with the same active substance and of the same release rate 
classification (e.g. prompt release) are considered to be functionally interchangeable’.
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This would mean that any specific USP solid oral dosage form could be dispensed 
regardless of whether it is formulated as a tablet or a capsule as long as three criteria are 
met:
(a) the articles contain the same active ingredient
(b) the articles contain the same amount of active ingredient
(c) the release characteristics are the same.
The practical implication of functionally interchangeability means that a 
practitioner could prescribe a medication in either capsule or tablet forms, depending on 
the patients needs and/or desires, as long as the two preparations contained the same drug 
in the same quantity and had equivalent release profiles. However, there would be no 
requirement for the tablets and capsules to contain the same excipients or for the 
formulations to be processed in the same way. Functional interchangeability could for 
example, exist between a hydrophilic matrix tablet and a capsule containing the drug 
formulated as controlled release pellets, even if the formulations contained different
excipients and were processed in different ways. Since tablet and capsule matrices based
on HP contained the same active ingredient, in the same quantity and had equivalent 
release profiles they could be considered functionally interchangeability. Additionally 
since they contained they same formulation, processed in the same way they could also be 
considered as pharmaceutically equivalent. Functionally interchangeability coupled with 
pharmaceutical equivalence is a concept that has not been reported until now.
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6. Investigation of the gastro intestinal transit of a placebo heterodisperse 
polysaccharide-based formulation in capsule and tablet form using gamma 
scintigraphy
6.1 Introduction
HP-based capsule and tablet matrices were found to have equivalent release 
controlling action under the in vitro dissolution conditions employed. However, it could 
not be concluded on the basis of this that the dosage forms would be bioequivalent. In 
order to determine the bioavailability of solid oral dosage forms it is essential that 
experiments are carried out in vivo. The ultimate test of an oral dosage form is the 
pharmacokinetics of drug release. However, by studying the transit of a dosage form in 
the gastrointestinal tract (GIT) an indication of the likelihood of the dosage form meeting 
in vivo pharmacokinetic objectives may be obtained (105). Scintigraphic imaging of 
radiolabelled controlled release dosage forms provides a non-invasive method of 
studying their GI transit.
The primary aim of the gamma scintigraphy study was to assess the degree to 
which HP-based capsule and tablet matrices maintained their integrity as they passed 
down the GIT. This was difficult to predict from in vitro studies because of two main 
reasons. Firstly, the physicochemical characteristics of the GIT were likely to differ 
substantially from the conditions that the dosage forms were exposed to during in vitro 
dissolution tests. Physiological conditions in the GIT such as hydrodynamic flow and 
mechanical destructive forces that arise from digestive actions (grinding and crushing of 
GI contents) are difficult to predict and are reported to be highly variable (103). GI 
hydrodynamic flow around dosage forms is thought to be slow (103) and, based on 
dissolution studies, it was concluded that the erosion and fragmentation of tablets and 
capsules was unlikely to be highly sensitive to the hydrodynamic flow conditions in the 
GIT. However, destructive forces were likely to be important in determining the degree 
to which capsule and tablet dosage forms maintained their integrity. The presence of 
food in the GI tract stimulates more intense mechanical agitation than exists in the fasted 
state. In order to present the greatest challenge to dosage forms studies may be carried 
out in the fed state since greater destruction of dosage forms has been found to occur in 
the fed state as compared to the fasted state (177). Secondly, it was difficult to predict 
how the pH conditions and ionic strength of the contents of the GIT would affect
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hydration and swelling of the matrices. Little is known about the effect of pH and ionic 
strength on hydration and swelling of HP-based matrices. Xanthan gum (XG) matrices 
are often regarded as being compatible with a wide range of salts, acids and bases 
(39,175) and the release of drugs from XG matrices has been found to be insensitive to 
changes in pH. Lu et al (175) found that pH had no effect on theophylline release from a 
xanthan gum matrix in both 0.1N HC1 and pH 6.8 phosphate buffer. The release of 
caffeine, a model whose solubility is independent of pH, was found to be similar in a 
range of phosphate buffers with pH between 5.8 and 7.4 (156). However, the rate of 
release was found to increase, as the ionic strength of the dissolution medium was 
increased (156). The presence of salts appeared to decrease the initial rate of hydration 
but once the tablet had hydrated the release rate in each solution was similar. Although 
dissolution studies under a range of pH conditions and ionic strengths may be of value in 
estimating the influence of these factors on the hydration and swelling of HP-based 
matrices it is possible that sensitivities observed in vitro could be of limited importance 
in vivo (60,104). This could be due to the transient characteristics of conditions in the 
GIT (60).
Since HP-based capsules and tablet dosage forms had initially different physical 
characteristics it was considered that this could result in differences between the GI 
transit of both dosage forms. Capsules had a lower bulk density than tablets, which 
could possibly affect the location of the dosage forms within the GIT. In a study 
comparing the GI transit of capsule formulations it was found that capsules with lower 
density remained in the fundus of the stomach whereas denser capsules sedimented to the 
more distal regions (179). However, capsule density has been shown to have only a 
minor effect on GI transit time (179). The presence of a gelatin shell could possibly 
influence the GI transit o f capsule dosage forms. When tablets or capsules are swallowed 
they may adhere to the oesophageal membrane thus delaying oesophageal transit (178). 
It has been shown that capsules are less likely to stick than tablets, and that the quantity 
of water taken with the dosage form can affect the passage of tablets but not of capsules 
(178). Differences between the bioadhesive nature of each dosage form could also affect 
GI transit. Although XG is not thought to have bioadhesive properties (100), the effect 
of a gelatin shell on bioadhesion is not known. The effect of bioadhesion is however, 
likely to be of limited importance as it has been shown that the gastric emptying of some 
potentially adhesive formulations did not differ greatly from that of control materials 
(176).
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The degree of destruction that capsules and tablets under go in the GIT is 
important since it is proposed that equivalent release profiles were observed in vitro 
because of similar diffusional path lengths existing within each swollen dosage form. 
Greater destruction of either dosage form presentation could increase the dissolution rate 
of a drug from the matrix by reduction of the diffusional path length. This is important 
since it is known that the bioavailability of many drugs is highly dependent on the rate of 
dissolution of the drug from the dosage form (182). From gamma scintigraphy studies 
the GI transit time of dosage forms and their position in the GIT may also be estimated. 
GI transit time and location is also important in relation to bioavailability since the 
absorption, and possibly the release, of drug from a controlled release formulation may 
depend in part on the location of the system within the GI tract (176) and/or GI transit 
time (176).
Gamma scintigraphy studies on hydrophilic matrix preparations have previously 
been carried out. Daly et al. (180) found good correlation between the in vitro and in 
vivo release of a non-absorbable water-soluble chelate labelled with technetium from 
HPMC matrices. Abrahamsson et al. (181) found that erosion of HM’s based on HPMC 
in the stomach and small intestine was similar to the erosion measured in vitro using a 
USP dissolution apparatus II with paddles rotating at 50rpm. The use of Gamma 
scintigraphy to compare and evaluate the integrity and fate of pharmaceutically 
equivalent hydrophilic capsule and tablets matrices in man, has not previously been 
reported.
6.2 Materials
TIMERxE (Lot No. NS1101), a formulation containing 25% xanthan gum, 25% 
locust bean gum and 50% glucose was provided by Penwest Pharmaceutical Co. The 
material received was of a suitable quality for clinical use. Hard gelatin capsules, 
DAVCAPS DB size A, Swedish orange, were obtained from Capsugel, Bomem, 
Belgium. The capsules were of a suitable quality for clinical use. Diclofenac sodium 
(Lot No. 94-01342) was obtained from Heumann Pharma GmbH (Nurenberg, Germany). 
The resin used for the in vitro and in vivo study was Amberlite CGI20, 100 to 200 mesh 
(Lot No. 344984/1), which was obtained from Fluka Chemika (Italy).
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6.3 Method
The integrity and fate of a placebo HP-based formulation presented in tablet and 
capsule form was evaluated in six healthy male volunteers using the non-invasive 
technique of gamma scintigraphy. The study was carried out in two parts and involved 
radio-labelling the tablets (first part) and capsules (second part) with (IMBq) 11'in bound 
to amberlite resin, which was then swallowed by the volunteers. Using a gamma camera, 
placed in front of the volunteer, the position of the dosage forms in the GIT was 
ascertained. Prior to the Gamma scintigraphy, dissolution tests were carried out on 
tablets and capsules prepared from blend of TTMERxE, diclofenac sodium and amberlite 
resin. This was to establish if equivalent release profiles from tablets and capsules were 
observed in the presence of amberlite resin.
6.3.1 In vitro validation
7.5% diclofenac sodium was blended with 92.5% TIMERxE by geometric 
trituration (blend 1). Total batch size was lOOg. 0.77% amberlite resin was incorporated 
into a proportion of the TIMERxE/diclofenac sodium blend by geometric trituration 
(blend 2). Each blend was filled into hard gelatin capsules giving a mean fill weight of 
529 ± 5mg (n=4, blend 1) and 526 ± 7mg (n=3, blend 2). Each blend was also 
compacted into 5 x 16mm caplet shaped tablets using a single punch tablet press (Type 
F3, Manesty, Speke, Liverpool, U.K.) with a strain gauge fitted to the top punch. 
Compaction force was approximately 15kN, mean tablet weight was 522 ± 14mg (n=3, 
blend 1) and 525 ± 1 lmg (n=3, blend 2). Dissolution studies were carried out in 1000ml 
of distilled water heated to 37°C ± 0.2°C using a USP II dissolution apparatus (Type 
8ST, GB Calerva Ltd., Dorset, U.K.) with paddles positioned 4cm above the point of 
curvature at the bottom of the vessel. Paddle speed was 50rpm. The dosage forms to be 
analysed were supported in stainless steel wire cages (approximately 3.5cm x 2.5cm), 
which allowed dissolution from all surfaces. Samples of dissolution medium (7.5ml) 
were manually removed at predetermined intervals and filtered through lpm  cellulose 
nitrate filters. UV absorbance at 274nm was determined using a diode array 
spectrophotometer (Type 8452A, Hewlett Packard, Palo Alto, CA). 7.5ml of distilled 
water, heated to approximately 37°C, was added after sampling to maintain constant 
volume. The absorbance of a solution of TIMERxE (500mg/l) was found to amount to 
4% of total absorbance after 100% dissolution.
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Gamma scintigraphy study
6.3.2.1 Preparation o f  radiolabelled tablets
lOOmg of amberlite resin CG-120 was weighed into a 10ml glass vial. The resin 
was washed 3 times with distilled water. As much water as possible was removed after 
washing using a Pasteur pipette. 0.3ml of an acidic solution of indium chloride (In111 
Mallinckrodt Medical B.V., Petten, Holland), having an activity of lllM B q, was added 
to the resin, mixed and incubated at room temperature for 15min. The resin was washed 
twice with distilled water to remove excess radioactivity. Excess water was removed 
using a Pasteur pipette. Before the dosage forms were prepared the resin was dried in an 
oven at 65°C for approximately 45min then ground in a pestle and mortar. TIMERxE 
was blended with approximately 1% w/w radiolabelled resin using a pestle and mortar. 
Tablet and capsule dosage forms were prepared using the procedure described in section
6.3.1. The radioactivity of tablets and capsules was measured (CompuGamma CS, 
Turku, Finland) to ensure that each dosage form contained approximately 1 MBq of 
activity at the time of administration.
6.3.2.2 Study protocol
The study was approved by the Liverpool John Moores University Ethics 
Committee, the Liverpool Research Ethics Committee (Liverpool Royal University 
Hospital) and the DoH Administration of Radioactive Substances Advisory Committee 
(ARSAC). The gamma camera, accessories and computers used were tested and 
validated by the Nuclear Medicine Department of the Royal Liverpool University 
Hospital prior to use.
The study was a two-way, cross-over study with a wash out period of 14 days. 
The weight, height and year of birth of the 6 healthy male volunteers are detailed in table
6.1. Subject inclusion and exclusion criteria are detailed in appendix IV. The volunteers 
underwent a medical check up at the Medical Centre, JMU, Byrom Street for general 
health, and blood and urine samples were tested for absence of drugs of abuse. The use of 
tobacco, alcohol, prescription and over-the-counter drugs were not permitted 48hr prior 
to or during the study.
The volunteers abstained from food and fluids after 2200hr on the day before the 
study. The dosage form was swallowed followed by 150ml of cool water. Gamma 
scintigraphy images were acquired using a Siemens Gamma Camera (Model 750). Both
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anterior and posterior images were recorded each over 180s. The position and movement 
of the dosage forms were noted using the Digital Operator Terminal (DOT) (Model 
3219), which gave a real time image of the dosage forms on screen. The behaviour of the 
dosage forms was demonstrated and recorded by the presence and release of 11'in. 
Before anterior imaging began an external anatomical marker (consisting of a tablet or a 
capsule, depending on the study, containing IMBq In-111, in a 2ml syringe) was held 2 
fingers above the sternum notch for about 15s. The marker was then removed without 
volunteers’ movement and imaging was continued for the 180s duration. After the last 
image, the camera was set up to record a dual isotope image in the energy levels suitable 
for In-111 and also Tc-99m. The volunteers were then given 150ml of orange juice 
containing 3MBq Tc-99m and a scan was carried out, which established the position of 
the stomach. The first image (Omin) was recorded 30s after ingestion of the dosage 
form. Subsequent images were recorded at 30min intervals for 7hr. A light breakfast 
was consumed after the 90min image along with tea or coffee. Lunch was consumed 
after the 270min image. After lunch there was no restriction on water uptake (water, 
juice or pop).
The qualitative image processing was carried out using ICON, a computer 
package developed by Siemens. Each acquired image was processed sequentially from 
time 0 to 420min by displaying them and drawing the outline of the stomach (from the 
Tc-99m image) and also taking into account the position of the external marker. Both 
anterior and posterior images were examined. The location of the radioactivity on the 
image was recorded and comments were make on the appearance of the source. The 
number of sources, if more than one, and the presence of traces of activity around the 
main source or in the vicinity of the source were related to the break down of the matrix 
and erosion of the outer layer of gel structure of the matrix, respectively. The movement 
of each source was separately noted from the DOT, real time images.
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Volunteer No. Year of birth Weight (Kg) Height (cm)
1 1976 76 182
2 1975 75 184
3 1977 62 164
4 1970 65 173
5 1968 75 180
6 1953 80 175
Table 6.1 Year of birth, weight and height of volunteers
6.4 Results and discussion
6.4.1 In vitro dissolution profiles
Figures 6.1 and 6.2 show that similar release profiles of diclofenac sodium from 
TIMERxE based capsule and tablet matrices were observed in formulations prepared 
without amberlite resin and with amberlite resin, respectively. Statistical analysis using 
Student’s t-test showed that there was no significant difference between the mean 
percentages released from tablet and capsule matrices at each time point. It was 
concluded that the presence of Amberlite resin was unlikely to cause differences between 
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Figure 6.1 Dissolution of diclofenac sodium from TIMERxE 
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Figure 6.2 Dissolution of diclofenac sodium from TIMERxE 
capsule and caplet matrices containing amberlite resin (n=3)
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6.4.2 Qualitative evaluation o f gamma scintigraphy images
A qualitative description of the size, location, number of centres of activity 
observed and degree of dispersion of radioactivity in each image is given in appendix V. 
A summary of the 6 observations made on capsules and tablets is given in tables 6.2 and 
6.3, respectively. Anterior images of the capsule and tablet administered to volunteer 
number 4, taken at time points 0, 30, 90, 180 and 390min are shown in appendix V.
The images taken 30s after ingestion of the dosage forms showed that both 
capsules and tablets remained intact after swallowing in all cases. In the majority of 
volunteers both dosage forms passed through the stomach within 30min, entering into the 
duodenum and small intestine. The images taken at 30min showed that the dosage 
forms had started to swell, indicating that rapid hydration of both capsules and tablets 
occurred in the GIT. This can be seen in the images presented in appendix V, were a 
central source is visible with some diffused activity around the perimeter of the source. 
It was noted that in all cases capsule matrices located at the upper part of the stomach 
compared to tablets, which settled in the lower part of the stomach. This is probably due 
to the lower bulk density of capsule matrices, which causes them to ‘float’ on the 
stomach contents. This confirms the findings of Muller-Lissner and Blum (179) who 
found that denser dosage forms sedimented to the more distal regions of the stomach 
while less dense dosage forms remained in the fundus of the stomach. Hydrodynamically 
balanced systems (HBS) are designed to ‘float’ in the stomach thereby increasing 
stomach residence time. It was observed here that the positioning of HP-based capsules 
did not increase stomach residence time relative to tablets and therefore HP-based 
capsule matrices are unlikely to be useful as HBS’s.
Images taken of dosage forms in the SI and in the colon, showed that at a number 
of time points the radioactivity was concentrated at more than one position, indicating 
that the dosage forms had separated into two or more fragments. The time at which the 
presence of more than one source was first noted was identified in each case and the 
mean time of fragmentation was calculated for tablets and capsules (table 6.4). It can be 
seen that capsules tended to separate into two or more fragments earlier than tablets, with 
capsules fragmenting approximately 75min after ingestion and tablets fragmenting 
approximately 190min after ingestion. The 90min image of the capsule in volunteer 4 
(appendix V) shows that the capsule separated into a smaller fragment and a larger 
fragment. However, in the 180min and 360min images the radiation appeared as a single
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source because the fragments regrouped at the ileocaecal junction after 150min (not 
shown). Regrouping of fragments at the ICJ and at other areas of the GIT could be due 
to the high viscoelasticity of HP-based components, which may promote coalescence of 
separated fragments. The images of the tablet administered to volunteer 4 show that at 
120min the tablet was observed as a large L-shaped source (not shown), which did not 
separate. Instead, fragmentation of the tablet occurred at 270min (not shown) but after 
300min a single source was visible due to regrouping of the fragments. Fragmentation of 
capsules and tablets was noted in all volunteers at various positions along the SI and 
colon. The earlier fragmentation of capsule matrices could be related to the lower 
mechanical strength of these matrices and/or the effect of the gelatin shell. It had been 
found that after lhr hydration at 37°C the force required to move a steel probe through a 
hydrated tablet was greater than 3 times the force required to move the probe through a 
hydrated capsule (see section 5.4.4). Digital images of hydrated matrices taken over a 
5hr period (Chapter 5, figures 5.7(a) to (h) and 5.8(a) to (h)) showed that capsule 
matrices formed a looser gel structure than tablet matrices when the dosage forms were 
allowed to swell without restriction. The more diffuse structure formed in capsule 
matrices was presumably due to the initial high porosity of these matrices.
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Table 6.2 Qualitative assessment of the in vivo behaviour of HP-based capsule matrices, summary of 6 observations
Time
(min)
Stomach Small intestine Ileocaecal junction Colon
0 Observed,
Intact
30 Swollen single unit
60 2 fragments, moving
90 1-2 fragments with dispersion*
120 1-2 fragments with dispersion and residues**
150 1-4 fragments with diffusion and erosion
180 1-2 fragments, residues and erosion, collecting at ICJ
210 Regrouping, generally appears as single unit, residues at ICJ
240 Spreading, erosion and residues
270 Mainly ICJ, ascending & transverse 
colon
300 Mostly in colon, dispersion and 
residues
330 Fragments still visible
360 Mostly lower ascending colon
390 More than 1 source, erosion and 
residues
420 As above
* Dispersion is evidence of erosion of the outer gel layer of the matrices
* * Residues form a back track of activity. This can be adhesion or remains of eroded polymer
Table 6.3 Qualitative assessment of the in vivo behaviour of HP-based tablet matrices, summary of 6 observations
Time
(min)
Stomach Small intestine Ileocaecal junction Colon
0 Observed,
intact
30 Single unit, swollen
60 Single fragments with swelling
90 Mainly single unit with erosion
120 Swollen, some intact, some with residues**. Mainly SI
150 Mainly SI. 1-2 fragments, dispersion*
180 Swollen, dispersing. Mainly SI
210 1-3 fragments with diffusion
240 1-2 fragments with diffusion
270 1-2 fragments with 
diffusion
300 Mainly colon, diffuse 
fragments
330 Mainly ascending colon, 1-2 
sources with dispersion
360 As above
390 As above, more dispersion
420 Central source still visible, 
more dispersion
* Residues form a back track of activity. This can be adhesion or remains of eroded polymer 
** Dispersion is evidence of erosion of the outer gel layer of the matrices
The mechanical stresses in the GIT could result in greater destruction of weaker gel 
structures and this may account for the earlier fragmentation of capsules. It was noted 
that capsules initially tended to separate into 2 fragments. This phenomenon may be 
partly due to the presence of a gelatin shell. The digital images of a hydrated capsule 
(figure 5.7 (a) to (h)) show that the gelatin shell dissolved firstly from either end of the 
capsule. At either end the capsule shell was one layer thick while in part of the centre 
two gelatin layers enclosed the granules. This meant that the gelatin shell at the centre 
dissolved more slowly and restricted swelling at the centre when swelling at both ends 
was unrestricted, resulting in the formation of a dumbbell structure. Figure 5.7 (d) shows 
the presence of the gelatin shell at the centre of the capsule after lhr hydration and the 
more swollen material at the ends. The dumbbell structure was more prominent after lhr 
hydration and this corresponded approximately to the time at which fragmentation was 
first noted in the GIT. It is possible that an area of low mechanical strength occurred 
between the well hydrated swollen material at the ends of the capsule and the less 
hydrated, less swollen material within the partly dissolved gelatin shell. This may have 
promoted separation of the ends of the capsule from the main body and may also explain 
why at later time points capsules tended to separate into 1-3 fragments while tablets 
separated into two fragments.
Time to fragmentation (min)
Tablets 190 ±77
Capsules 75 ±37
Table 6.4 Time at which fragmentation of the dosage forms was first noted (n=6)
Images taken of the dosage forms in the small intestine, and later the colon, show 
dispersed activity around the main bulk of activity in both capsule and tablet matrices. 
This is evidence slow erosion of the outer layer of the matrices. As the hydrated polymer 
matrix swells and erodes, In-111 is carried away from the main source and this is 
observed as dispersed radioactivity. Residues of activity behind the main source were 
also noted in both dosage forms. These were likely to be the remains of eroded material 
left behind as the main fragments moved along the GIT. Alternatively, this may have
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been material that had adhered to the mucosal lining. Without qualitative analysis of the 
images it is difficult to accurately estimate the degree of dispersion and diffusion around 
capsules and tablets matrices. Generally it appears that the degree of spreading and 
erosion was higher in the capsule matrices. In the images taken from volunteer 4 
(appendix V) it can be seen that the area of the main source was greater in the capsule 
matrix as compared to the tablet matrix. The images, which are of the same 
magnification, show that the length of the main source of the capsule matrix at 180 and 
390min was greater than that of the tablet matrix. Additionally, the radial spread of the 
swollen capsule was slightly greater than that of the tablets. The fact that the initial 
diameter of dry capsules was larger than that of tablets probably accounted in part for the 
differences in swollen diameter observed. The digital images of hydrated matrices 
(figures 5.7 (a) to (h) and figures 5.8 (a) to (h)) show that under in vitro testing 
conditions, where unrestricted swelling could occur, the length of swollen capsule 
matrices was greater than that of tablets at each time point. Similarly, the radial diameter 
of swollen capsules was greater than that of swollen tablets under in vitro conditions. 
This is important because although capsule matrices swelled more than tablets in vitro, 
equivalent release profiles were still observed. It was proposed that this was because (a) 
small differences in the degree of swelling between capsules and tablets became 
negligible when the overall tortuosity of the matrices was very large or (b) the looser 
porous network formed in capsule matrices compensated for the higher degree of 
swelling in these matrices causing the overall diffusional path length to be similar. It is 
therefore possible that capsule matrices and tablet matrices may have similar release 
controlling action in the GIT despite capsules spreading more than tablets. However, 
differences in the time and extent of fragmentation between capsule and tablets may 
largely affect dissolution because fragmentation will substantially decrease the 
diffusional path length and therefore increase dissolution.
Gamma scintigraphy images taken of the dosage forms in the lower part of the SI, 
the ascending and transverse colon, showed that both tablets and capsules maintained a 
degree of integrity through out GI transit. The 390min of the capsule administered to 
volunteer No.4 (appendix V) shows that the cylindrical shape of the capsule was still 
well defined. It was clear that coalescence of hydrated granules had occurred producing 
a continuous matrix that maintained the shape of the capsule in which the granules were 
initially contained. The image showed diffused radiation and residues that were left 
behind as the dosage form moved up the ascending colon. The final images, taken
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420min after ingestion, showed that in all cases were a tablet had been administered a 
main source was still visible. When a capsule had been administered, a single source 
was still visible in 5 cases. The images in appendix V show that after 390min in the GIT 
the cylindrical shape of the capsule dosage form in volunteer no. 4 was still clearly 
visible and a concentrated source of radioactivity could be seen. Although capsules 
tended to fragment earlier than tablets the dosage forms appeared to undergo more 
similar degrees of fragmentation further down the GIT. This could be because the 
mechanical stresses further along the GI tract were less aggressive. Alternatively, the 
observations could again be related to the mechanical strength of the matrices. It had 
been found that the mechanical strength of hydrated matrices became more similar as 
hydration progressed (section 5.4.4). After 2 hours, hydrated capsules had half the 
mechanical strength of tablet matrices, while after 3 and 4 hours hydration the strength of 
both matrices was similar. It is possible that the propensity of the dosage forms to 
destruction was similar after a number of hour’s hydration since the mechanical strengths 
were similar. Additionally, it had been found that after 2hr hydration the gelatin shell 
enclosing the capsules had dissolved and more uniform swelling of the matrix had 
occurred (figure 5.7 (e)). Uniform swelling of material comprising the capsule may have 
provided more resistance to fragmentation and destruction as compared to the more 
uneven swelling observed in the earlier stages of hydration.
The mean time for capsules and tablets to reach the small intestine, ileocaecal 
junction and colon was calculated (table 6.5). This showed that the GI transit times of 
tablets and capsules were roughly similar. Capsules appeared to have slightly more 
variable GI transit times than tablets. The degree of integrity that each dosage form 
maintained as it passed through the GI tract varied between volunteers (appendix V). For 
example, in volunteer No. 1 the capsule formulation remained in the small intestine and 
existed mainly as a single source with diffusion around it for up to 420min. In contrast, 
when the capsule formulation was administered to volunteer No. 6, extensive swelling 
and erosion occurred after 90min, spreading to the transverse colon by 270min. 
Generally, the degree of variation between subjects appeared to be higher for the capsule 
formulation than the tablet formulation. This could be due to the wide variation in 
gastric motility that can exist between individuals and the resultant effect of mechanical 
agitation on destruction of capsule dosage forms.
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Mean gastro-intestinal transit time ± S.D (min)
Tablets Capsules
Stomach 0.5 ± 0 0.5 ± 0
Small intestine 40 ±15 30 ± 0
Ileocaecal junction 182 ±47 215 ± 106
Colon 255 ± 65 250 ± 96
Table 6.5 Mean gastro-intestinal transit time of tablet sand capsules (n=6)
From the gamma scintigraphy results a number of clear observations could be 
made concerning the GI transit of pharmaceutically equivalent HP-based tablets and 
capsules; (a) capsule matrices fragmented earlier than capsule matrices; (b) more 
spreading of activity was noted in capsule matrices; (c) the GI transit time of both 
dosage forms was similar. Quantitative evaluation of the images would be required to 
more accurately assess the extent of swelling/dispersion and erosion. The degree to 
which the differences in fragmentation and erosion will affect bioavailability from each 
matrix will depend upon the drug under consideration. The fundamental parameters 
controlling bioavailability are dissolution of the drug and its gastrointestinal permeability 
(182). Drugs selected for extended release products should have good gastrointestinal 
permeability and an extended site of absorption (183). Four physiological factors have 
been identified that can also affect the release and absorption of a drug from an extended 
release product (183). Firstly, the residence times at each GI site. There is increasing 
evidence that the absorption of many drugs is not confined to the small intestine and 
significant absorption may occur in the colon (183). Colonic residence times are 
substantially larger than those in the small intestine and this may result in substantial 
absorption. Secondly, the effective permeability coefficient. Drugs are considered to be 
optimally absorbed from the upper part of the small intestine. Indirect evidence suggests 
that permeability decreases with distance down the GIT. Thirdly, pH/buffer capacity of 
the intestinal fluid. Substantial hydrogen ion changes occur with distance down the GI 
tract. There is an initial rise in pH on exiting the stomach, with pH continuing to rise 
down the small intestine until the caecum is reached at which point a drop in the order of 
1 unit appears to occur. The pH then rises gradually down the colon. These pH changes
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can have dramatic effects on ionisable drugs altering the proportion of ionised to 
nonionised and hence solubility and permeability. Acidic drugs will tend to have lower 
solubilities high up the GIT, with solubility increasing down the GIT. With increased 
ionisation intestinal permeability should fall. In contrast, bases will loose solubility with 
transit down the GIT, but become more permeable. Fourthly, the potential for drug 
degradation at different sites. Many drugs are metabolised in the colon and this may 
reduce the amount available for absorption. All of above factors may affect the rate and 
extent of absorption of a drug from an extended release product. Amidon et al (182) 
established a biopharmaceutical classification for drugs taking into account that 
gastropermeability and solubility were fundamental in determining bioavailability. The 
aim of the classification was to assist in correlating in vitro drug product dissolution and 
in vivo bioavailability for IR products. The classes were defined as: Case 1. High 
solubility-high permeability drugs. Case 2. Low-solubility-high permeability drugs. 
Case 3. High solubility-low permeability drugs. Case 4. Low solubility-low 
permeability drugs. A modified biopharmaceutical classification for ER drugs has also 
been proposed, which does not consider drugs having low gastropermeability since these 
are unlikely to be formulated as ER products (183):
Class I Solubility high and independent of site
(a) permeability-high and independent of site
(b) permeability dependent on site-narrow absorption window
Class II Solubility low and independent of site
(a) permeability high and independent of site
(b) permeability dependent on site-narrow absorption window
Class V Variable solubility and permeability
This classification may be useful when attempting to assess on the basis of 
gamma scintigraphy results whether two dosage forms are likely to be bioequivalent. 
Drug products can be considered bioequivalent when the rate and extent of absorption of 
the therapeutic moiety from each product does not differ significantly when the same 
molar dose of the therapeutic moiety is administered under similar experimental 
conditions (184). Considering that HP-based capsule matrices under go fragmentation 
and possibly erosion earlier that tablet matrices then it is possible that for drugs that have
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a high solubility and are absorbed in the upper part of the GIT that bioavailability from 
capsule and tablet matrices may not be comparable. However, because fragments tend to 
regroup forming single units then it is possible that bioavailability from capsules and 
tablets may be more similar in the lower part of the GIT. Therefore, if a drug was 
primarily absorbed in the lower part of the small intestine and/or colon then it is more 
likely that bioequivalence would be observed. Unfortunately, information on regional 
variations in drug permeability along the GIT is limited. Additionally, the pH and ionic 
strength of the GIT contents are often variable and difficult to measure making it difficult 
to predict the extent of drug ionisation. Therefore, for drugs that do not have a high 
water-soiubility and high gastrointestinal permeability it may still be necessary to carry 
out in vivo pharmacokinetic studies in order to establish if capsule and tablet matrices are 
bioequivalent. Drugs that are marketed as ER products represent a small subgroup of 
those that are administered orally to man. Of these compounds 63% may be chemically 
classified as weak bases, the majority of which are incorporated in salt form (183). As 
weak bases lose solubility as they pass down the GIT absorption becomes more 
dissolution/release-controlled (183). So for the majority of drugs that have been 
marketed as ER products an increase in dissolution rate would probably increase 
bioavailability.
The USP II dissolution apparatus with paddles rotating at 50rpm and lOOrpm did 
not identify any differences between the in vitro erosion and fragmentation of capsules 
and tablets. By testing the dosage forms under conditions of greater mechanical stresses 
then differences that have been observed in vivo may become apparent in vitro. A 
suitable apparatus may be the USP IE (Biodis) apparatus, which employs a reciprocating 
basket. Dissolution in media having a range of ionic strength and pH’s may also help to 
discriminate between the dosage form presentations. If dissolution conditions are found 
which mimic more closely how the dosage forms fragment and erode in the GIT then in 
vitro dissolution profiles of capsules and tablets under these conditions can be obtained. 
If similar release profiles from pharmaceutical equivalent capsules and tablets under 
these conditions were observed then this would support the argument that capsules and 
tablets could potentially be functionally interchangeable.
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7.0 Conclusions and  fu rth e r w ork
The in vitro dissolution profiles of model drugs from hydrophilic matrix tablets 
based on HP were found to be independent of the initial bulk physical characteristics of 
the tablets. This is a useful characteristic of HP-based tablets, as small changes in 
processing conditions are unlikely to affect the in vitro and possibly in vivo dissolution 
behaviour of the product. Thus, tablet matrices based on HP are robust formulations.
Functional interchangeability of pharmaceutically equivalent tablet and capsule 
matrices containing diclofenac sodium, diltiazem HC1 and propranolol HC1 was 
established in vitro, using a USP II rotating paddle method. The high release controlling 
action of capsule matrices containing loose, uncompacted granules was considered due to 
the rapid hydration of HP-based material and the tendency of hydrated particles to 
coalesce, forming a continues viscous elastic network that had a high resistance to 
erosion. Functional interchangeability was attributed to similar diffusional path lengths 
existing within hydrated tablet and capsule matrices, despite more extensive swelling of 
capsule matrices.
Clear images of the transit of pharmaceutically equivalent tablet and capsule 
matrices based on HP through the GIT of 6 male volunteers were obtained using the 
technique of gamma scintigraphy. The images showed that capsule matrices fragmented 
earlier in the GIT than tablet matrices and that the spreading of capsule matrices was 
more extensive as compared to tablets. However, regrouping of the fragments meant that 
capsules still maintained a high degree of integrity after 7hr in the GIT. The results 
suggested that further in vitro dissolution testing using more aggressive testing 
conditions may help to predict whether capsules and tablets are likely to be functionally 
interchangeable in vivo. The USP EH apparatus should be evaluated as a dissolution test 
method. This employs a reciprocating basket, which is likely to subject the dosage forms 
to higher mechanical stresses. Additionally, swelling, hydration and drug release from 
capsule and tablet matrices in media having different pH values and ionic strengths 
requires investigation. Statistical analysis of the gamma scintigraphy is also required in 
order to effectively compare the spreading, fragmentation and erosion of HP-based 
capsules and tablets. Quantification of the degree of swelling in vitro would be useful for 
comparative purposes.
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It was found that HP-based material had a greater release controlling action than 
Methocel K15M, when the two materials were used in equivalent amounts. Mechanical 
strength studies had also shown that matrices based on HP had a greater resistance to a 
penetrating probe than matrices based on Methocel K15M. Therefore, it might be 
expected that under similar in vivo conditions, capsules matrices based on cellulose 
ethers such as Methocel K15M may under go a higher of destruction in the GIT as 
compared to HP-based capsules. An evaluation of the release sustaining action of 
capsule matrices formulated using different grades of cellulose ethers and other 
commonly used hydrophilic excipients would be of interest. An assessment could then 
be made of the effectiveness of HP, relative to other hydrophilic excipients, in 
formulating hydrophilic capsule matrices. The levels of hydrophilic carrier required to 
ensure that a coherent swollen body is formed could also be assessed along with the 
effect of capsule size and capsule fill weight on the dissolution of model drugs from 
capsule matrices.
A clear difference in mechanical strength of capsule and tablet matrices based on 
HP was observed using the penetrating probe method described. The mechanical 
strength of hydrated matrices may correlate with the degree of destruction that the dosage 
forms encounter in the GIT. This could be further investigated. Alternative methods of 
assessing the mechanical and physical characteristics of hydrated matrices could be also 
evaluated.
Although the pore structure of HP-based matrices was easily quantified using 
mercury porosimetry no correlation was observed between tablet pore structure and 
release controlling action. However, the pore structure of tablets may be related to other 
physical characteristics of tablets such as hardness and friability. Similarly, the porous 
structure of granules may influence the physical properties of granules. Further 
evaluation of the effect of granule and tablet pore structure on the mechanical properties 
of these materials would be interesting.
The interaction between drugs and HP is an area that would warrant further 
investigation. The degree to which drugs are involved in maintaining a strong 
hydrophilic network in HP-based matrices is not known. The investigations carried out 
here indicated a potential interaction between propranolol HC1 and diltiazem HC1 with
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HP. It is possible that this also would be observed with other cationic drugs and possibly 
anionic and non-ionic materials. These interactions may largely determine the rate of 
release of the drug from the matrix.
A clear difference in the release controlling action of TEMERxN and BHP-based 
material has been observed. To fully explain these differences further studies to 
investigate the effect of the tertiary components ethylcellulose and calcium sulphate on 
release controlling action is required. Additional investigation into the effect of wet and 
alcoholic granulation on dissolution profiles may be useful in understanding the 
differences in release controlling action observed. A further area of investigation would 
involve a study of the effect of tertiary components on interactions between drugs and HP 
matrix components.
This work also suggested that wet granulation of TIMERxN components was not 
necessary to obtain a material that had a high release controlling action. However, this 
observation was made with one drug substance only and further studies using a range of 
drug entities would be necessary to evaluate the release characteristics of matrices 
containing a simple dry blend of HP components.
Dissolution studies showed that granules contained, uncompacted in hard gelatin 
capsules produced a dosage form that had a high release controlling action in vitro. The 
gamma scintigraphy study showed that capsule matrices maintained a high degree of 
integrity as they passed through the GIT. This suggests that capsule matrices may also 
have a high release sustaining action in vivo. Additionally, the dosage form is simple to 
produce, can be processed using standard powder processing and encapsulation 
equipment and has a high capacity to incorporate active principles. An in vivo study to 
determine the pharmacokinetics of drug release from these matrices would be useful to 
assess the potential of capsule matrices as simple controlled release dosage forms.
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Appendix I







Total intrusion volume (ml/g) 414000 0.55 ± 0.03 0.521
207000 0.51 ±0.03 0.483
Median pore diameter (pm) 414000 0.0075 ± 0.0005 0.0072
207000 0.0076 ± 0.0005 0.0073
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Appendix II
Yates method for calculating magnitude of factors and interactions
iI
Y ield I n in
y<D y(D + ya (y a )+ y a ) + (yb+yab) [(y<i)+ya) + (yb + yab)] +  
[(yc + yac) +  (ybc + yabc)]
ya yb + yab (yc +  yac) +  (ybc + yabc) [ (y a -y o ))  + (yab-yb)] +  
[(yac -  yc) + (yabc -  ybc)]
yb yc + yac * 1 Q* + ? 1 g, [(yb + y a b )-(y o )+ y a )]  + 
[(ybc + yabc) -  (yc +yac)]
yab ybc ■+■ yabc (y>c -  yc) +  (yabc -  ybc) [ (y a b -y b )- (y a -y ( i> )]  + 
[(yabc -  ybc) -  (yac -  yc)]
yc ya - y o ) (yb +  y a b )- (y o )+ y a ) [(yc +  yac) +  (ybc + yabc)] 
- [ ( y o )+ y a )  + (yb + yab)]
yac yab -  yb (ybc +  yabc) -  (yc + yac) [(yac -  yc) + (yabc -  ybc)] 
- [ ( y a - y c i ) )  +  (yab-yb)]
ybc p o 1 ( y a b - y b ) - ( y a -y < i) ) [(ybc + yabc) -  (yc +yac)]
- [ (y b  + y a b )- (y ( i)+ y a)]
yabc yabc ybc (yabc -  ybc) -  (yac -  yc) [(yabc -  ybc) -  (yac -  yc)] 
-  [ ( y a b - y b ) - ( y a - y o i ) ]
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Calibration plots o f  frusemide in pH 5.8 phosphate buffer at 271nm
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Written and witnessed informed consent to participate in the trial given voluntarily 
Healthy males between the ages of 18 and 45years
No clinically significant abnormal findings on the physical examination and medical 
history
No clinically significant abnormal laboratory values 
Negative urine screen for alcohol and drugs of abuse
Body weight not more than 15% above or below the ideal weight for height an frame 
Normal blood pressure measured after resting supine for 3min. Normal range 100 to 
140mmHg systolic and 50 to 90mmHg diastolic 
Normal heart rate in the range 50 to 90bpm
Able to communicate with the investigator and to comply with the requirements of the 
entire study
Subject exclusion criteria:
Participation in another trial within the past four weeks prior to or during the trial 
History of alcohol or drug abuse within the last two years
History of allergic or adverse response to any of the polysaccharides used in this study
Any condition or disease, which in the opinion of the clinical investigator, would place
the subject at undue risk, or interfere with the ability of the subject to complete the study
Abnormal diet, or substantial changes in eating habits in the past 30 days
Difficulty in swallowing capsules or tablets
Use of any alcoholic beverages within 48 hr of study initiation
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Volunteer No. : 1
Tablet formulation
Appendix V





60 Intact, swollen, bigger
90 Two sources
120 Two sources
150 Two segments with 
dispersion in the image





210 Dispersion in the image, 
one unit











300 Clear image of 
dispersion of 
the tablets in 
the ascending 
colon, still 2 
segments
330 As above
360 Still 2 pieces 
moving up in 
the ascending 
colon












Time Stomach Small intestine Ileocaecal
Junction
Colon Remarks





60 2 separate units, moving
90 One fragment intact 
second diffusing out
120 Static but diffusing, 2 
fragments
150 Static, 2 fragments with 
diffusion
180 2 loose fragments
210 Regrouping of fragments 
with diffusion radiating 
around it
240 As above except more 
diffusion
270 No movement, as above
300 Appears as a single source with diffusion 
around it
330 As above
360 As above with more diffusion of 
radiation










60 Swollen, intact, much 
sharper view from 
posterior
90 Intact, swollen
120 Swollen further, intact
150 As above
180 As above but slowly 
diffusing Could all 
be in ICJ210 Traces of diffusion, 
intact
240 As above










330 Moving up the 
as a single unit
360 Single diffused 
unit moving up 
AC
390 Tablet moving 
upwards in the 
AC leaving 
residues
420 Bolus of 
activity halfway 
up ascending 













30 Moving single 
with swelling and 
residues








movement of a 
single unit
150 3 distinct 












210 Regrouping of 2 fragments 
in ACJ/ASC colon
240 Residues at 
ICJ
One fragment in AJC colon 
a clear 2nd fragment in the 
transverse colon
270 Residues at 
ICJ
Residues at ICJ one 
fragment ASC and second at 
transverse colon







360 As above with more 
dispersion and residues 
visible
390 As above
420 More evidence of dispersion 
of both fragments
Volunteer No.: 3 
Tablet formulation
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Time Stomach Small intestine Ileocaecal Junction Colon Remarks
0 Observed
30 Observed, small 
swelling
60 Intact with swelling
90 Intact with swelling
120 As above with larger 
image (swelling)
150 Swelling with some 
dispersion but still 
intact
180 Evidence of more 
dispersion of tablet
Moving into ICJ
210 2 distinct segments 
well apart, 1 appears 
in ICJ/AC colon, the 
second in transverse 
colon








300 Diffused segment of tablet observed 
over the area




330 Extensive diffusion includes transverse colon
360 Main bolus 













30 Single unit, seen as 2 due 
to moving
60 Still single piece but 
moving, swelling
90 Single unit with movement
120 Single unit with some 
diffusion and swelling
150 3-4 fragments with residues
180 Regrouped and single unit 
image
210 Single unit with diffusion 
around it
240 Still in SI Traces in AC 




ahead of the 
second




down on left 
side of 
image
300 Anterior: low intensity image 
Posterior: high intensity image, 3 
fragments
330 As above
















30 Swelling, single unit
60 Single unit moved right 
down compared to 
marker
90 Single unit with 
residues around it
120 Large unit with 
residues around it
150 Single unit with 
residues
Possibly at ICJ
180 As above with trail of 
residues at the base of 
activity
210 As above with more 
diffusion around
240 2 fragments with 
diffusion around 
them




300 Appears as a 
single unit with 
some erosion
330 The main single 
unit moving up 
the AC with 
residues behind
360 In the AC with 
erosion, seen as 
a single unit
390 Moving up the 
AC









30 Single unit veiy low 
position in abdomen
60 2 fragments with 
movement
90 Main unit still intact 
but erosion and 
residues observed





150 Collecting as a 
single unit at the 
ICJ with 







240 Moving up the 
AC as an 
eroded mass 
with 2 main 
fragments
270 As above
300 All at the lower 
end of the AC 
with sign of 
erosion around 
















30 Still in stomach, 
swollen
60 Moving unit. 
Single tablet
Swollen




In fact is 
only one 
unit
150 Single unit with 
residues
Possibly at ICJ
180 As above more 
diffusion210
240 As above with 
more erosion
270 As above
300 Moving as two 
fragments in the 
AC
330 Two clear 
fragments in 
AC with no 
movement
360 Extensive 
erosion of the 





390 As above with 
more erosion









30 Moved down with 
swelling, single unit
60 2 clear fragments
90 Observed as a single 
unit (regrouping or 
superimposing)*
120 Single unit with 
residues
150 Single unit with 
extensive erosion
180 Collection at ICJ with 
a single unit with 
residues around it
210 As above, some 
movement
240 As above with 
erosion and residues 
around it
270 Stationary still one 
central source with 
residue around it
300 At the lower 
end of the AC 
appears as one 
up to 360 min 



















30 Movement, single 
unit
60 Single unit with 
slight erosion
90 Single unit with 
more erosion
120 Movement as single unit into ICJ
150 Erosion in AC, 
seen as a long 
extended source
180 3 fragments 
along the AC 
colon





regrouped into 2 
fragments
270 As above with no 
movement

















30 Main unit with some erosion in the 
stomach and small intestine
60 Still the main fragment in the stomach 
with residues spread to right and left 
segments of SI
90 Very little residues 
in stomach
Main unit and 
extensive spreading 
in the SI
120 Spreading of 
activity around SI
150 As above and collecting at the ICJ
180 Spread of 
activity without 
evidence of a 
single fragment 
in the AC
210 All in the AC
240 AC as a mass
270 Upper part of AC 
and start of 
transverse colon
300 Spread of activity from AC to 
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